recent
year
routin
use
highsensit
alloantibodi
detect
assay
clarifi
posttranspl
detect
serum
donorspecif
antihla
antibodi
sdsa
main
caus
lead
tissu
damag
renal
transplant
failur
howev
actual
graftdamag
potenti
sdsa
yet
complet
clarifi
proport
patient
develop
sdsa
show
relev
graft
damag
even
longterm
followup
furthermor
recent
data
obtain
adult
kidney
graft
recipi
indic
dsa
graft
home
consid
promis
biomark
antibodymedi
graft
lesion
wors
graft
outcom
analyz
graft
biopsi
specimen
posttranspl
sera
patient
suspect
graft
reject
graft
reject
defin
sudden
persist
serum
creatinin
increas
exclus
major
caus
infect
dehydr
signific
proteinuria
develop
posttranspl
detect
dn
sdsa
patient
sera
studi
luminex
standard
test
three
paediatr
patient
one
adult
consid
two
first
transplant
two
retranspl
one
two
patient
enrol
first
transplant
receiv
kidney
live
donor
pretranspl
serum
antibodi
screen
neg
patient
posit
two
pra
one
retranspl
patient
receiv
kidney
hla
b
dr
mismatch
one
repeat
mismatch
first
donor
two
retranspl
patient
show
evid
dsa
posttranspl
sera
contrari
detect
presenc
dsa
biopsi
specimen
patient
receiv
kidney
live
donor
show
evid
dsa
sera
biopsi
specimen
second
patient
first
transplant
develop
de
novo
posttranspl
sdsa
antibodi
detect
graft
biopsi
specimen
kidney
graft
success
two
patient
first
transplant
oneyear
followup
contrari
two
retranspl
patient
explant
sever
humor
reject
soon
transplant
preliminari
data
show
presenc
intragraft
dsa
unfavor
prognost
factor
earli
transplant
outcom
even
absenc
sdsa
singlecent
variant
gene
identifi
snap
shot
method
level
fc
receptor
engag
express
assess
flow
cytometri
analysi
alloantibodyinduc
regul
observ
within
peripher
blood
natur
killer
nk
effector
cell
expos
allogen
target
cell
presenc
donor
specif
antibodi
dsa
thirtynin
recipi
develop
clad
eight
restrict
allograft
syndrom
bronchiol
obliteran
syndrom
median
surviv
month
dsa
detect
case
case
bound
dsa
respect
dsa
associ
lower
surviv
p
higher
occurr
clad
p
independ
bind
polymorph
impact
function
outcom
allograft
interestingli
contrast
previou
find
kidney
heart
transplant
set
dsamedi
engag
low
whatev
mfi
intens
bind
function
outcom
data
indic
polymorph
major
impact
clad
occurr
overal
surviv
ltxr
suggest
ltx
set
specif
mechan
dsa
depend
pathogen
fulli
explain
complement
ligat
fc
fragment
dsa
may
play
develop
clad
result
prompt
studi
larger
cohort
ltxr
kidney
transplant
repres
best
care
patient
sever
irrevers
renal
failur
provid
treatment
opportun
dialysi
sicili
overal
patient
await
transplant
septemb
divid
three
region
transplant
center
ct
policlinico
catania
ismett
arna
civico
number
patient
wait
list
highrisk
immunolog
profil
posit
pra
well
nation
averag
vs
around
consid
hyperimmun
pra
caus
growth
list
extens
wait
time
patient
includ
nation
hyperimmun
program
pni
criteria
furthermor
crossov
program
till
poorli
use
accord
nation
guidelin
issu
nation
transplant
center
cnt
region
transplant
center
crt
assign
kidney
taken
region
select
recipi
singl
region
list
mean
group
patient
wait
list
regardless
chosen
ct
sublist
allow
select
recipi
region
octob
effect
date
singl
region
list
kidney
assign
accord
specif
shift
ct
author
choos
group
patient
select
criteria
determin
differ
access
care
less
patient
protect
singl
region
list
howev
criteria
appli
center
made
possibl
guarante
better
preliminari
assess
hyperimmun
patient
guarante
patient
fairer
access
organ
alloc
opinion
repres
necessari
basi
activ
hyperregion
region
protocol
less
restrict
access
criteria
compar
nation
protocol
share
region
ct
exhaust
vascular
bed
imposs
perform
periton
dialysi
unfortun
crossmatch
perform
cadaver
donor
avail
sicili
result
posit
patient
exclud
worsen
clinic
condit
patient
perform
seri
immunoadsorpt
treatment
obtain
favor
opinion
inclus
onto
nationwid
hyperimmun
programm
nhp
avail
kidney
itali
primarili
propos
highli
sensit
patient
panel
reactiv
antibodi
final
novemb
neg
cdcxm
obtain
despit
patient
show
two
dsa
mfi
respect
transplant
perform
time
transplant
fcxm
neg
four
posttranspl
sera
show
pra
hla
class
dsa
disappear
biopsi
perform
two
month
transplant
ident
one
perform
time
transplant
damag
due
humor
reject
detect
cytotox
damag
probabl
due
pharmacolog
treatment
everi
clinic
evalu
prematur
case
repres
posit
outcom
applic
singl
region
list
omiss
prospect
crossmatch
xm
deceas
donor
kidney
recipi
neg
hla
antibodi
ab
standard
practic
numer
center
unit
mani
sensit
patient
also
proceed
transplant
tx
without
prospect
xm
day
tx
ab
sampl
test
singl
antigen
bead
virtual
xm
review
perform
senior
h
scientist
result
current
hla
ab
statu
gener
donor
xm
materi
avail
approach
support
clinic
staff
reduc
cold
ischemia
time
cit
assess
xm
omiss
risk
investig
incid
earli
amr
histolog
evid
microcircul
inflamm
stain
within
month
tx
year
graft
loss
attribut
reject
three
renal
tx
cohort
transplant
januari
novemb
patient
neg
hla
ab
proceed
without
xm
group
patient
posit
hla
ab
proceed
without
xm
group
patient
prospect
xm
group
overal
patient
receiv
tx
absenc
prospect
xm
median
cit
compar
xm
patient
incid
amr
group
group
group
p
two
amr
case
group
retrospect
neg
flow
xm
one
three
amr
case
group
known
hla
donor
specif
ab
dsa
time
tx
differ
graft
loss
three
group
graft
lost
reject
high
rate
omiss
prospect
xm
achiev
well
character
sensit
patient
date
ab
screen
result
without
increas
risk
amr
donor
hla
type
hla
ab
definit
continu
improv
patient
identifi
hla
dsa
requir
prospect
xm
assess
risk
center
deceas
donor
kidney
tx
proceed
without
prospect
xm
complement
fix
antihlaantibodi
ab
serum
transplant
tx
recipi
neg
impact
graft
surviv
littl
known
influenc
noncompl
fix
iga
ab
isotyp
previous
report
high
preval
iga
ab
serum
kidney
retx
patient
lead
us
investig
donor
specif
effect
iga
isotyp
graft
surviv
kidney
retx
candid
retrospect
multicent
cohort
select
importantli
time
first
dialysi
tx
ttd
measur
month
mo
use
precis
endpoint
marker
loss
graft
function
iggand
iga
ab
investig
posttx
sera
use
luminex
microbeadbas
screeningand
subsequ
specificationassay
sera
test
posit
iga
igg
ab
interestingli
presenc
iga
highli
link
presenc
igg
odd
ratio
p
expect
stratif
igaand
igg
statu
reveal
highest
median
graft
surviv
igaigg
doubl
neg
patient
ttd
mo
patient
test
posit
either
iga
igg
ab
display
intermedi
graft
surviv
ttd
mo
mo
respect
wherea
doubl
posit
patient
significantli
reduc
median
graft
surviv
compar
subgroup
ttd
mo
p
importantli
presenc
donor
specif
iga
igadsa
serum
correl
signific
wors
outcom
ttd
mo
compar
total
cohort
ttd
mo
p
well
compar
iga
posit
patient
without
show
igadsa
ttd
mo
presenc
serum
anti
hlaiga
ab
conjunct
antihla
igg
ab
mark
highrisk
subgroup
kidney
retx
candid
reduc
graft
surviv
notabl
detriment
impact
igadsa
among
total
antihla
iga
may
indic
novel
function
contribut
antihla
iga
ab
graft
failur
rituximab
commonli
prescrib
abo
hlaincompat
kidney
transplant
use
transplant
interfer
b
lymphocyt
complementdepend
crossmatch
cdcxm
fac
crossmatch
fcxm
give
fals
posit
result
render
interpret
imposs
present
adapt
cdc
fcxm
order
abolish
effect
b
lymphocyt
incub
patient
sera
antirituximab
mous
monoclon
antibodi
clone
abnova
ar
mab
easi
effici
rel
inexpens
method
elimin
rituximab
interfer
cdc
fac
xm
first
determin
smallest
quantiti
ar
mab
need
five
patient
without
class
ii
hla
antibodi
chosen
receiv
rituximab
day
xm
cdcxm
four
differ
ar
mab
concentr
fcxm
test
gl
gl
gl
gl
ar
mab
incub
patient
serum
minut
room
temperatur
classic
cross
match
done
patient
sera
contain
rituximab
sera
block
ar
mab
concentr
test
cdc
fcxm
sera
patient
desensit
rituximab
abo
hla
incompat
confirm
result
concentr
ar
mab
abolish
fals
posit
result
cdc
fac
xm
expect
neg
xm
found
neg
patient
without
anti
hla
antibodi
concentr
ar
mab
dilut
serum
cancel
expect
posit
result
cdc
fac
xm
remain
posit
sera
donor
specif
hla
antibodi
improv
definit
antihla
pattern
luminexassay
implement
clear
success
permit
develop
highlysensit
patient
alloc
donorpair
exchang
program
improv
access
transplant
howev
incid
nonhla
antibodi
highlysensit
patient
unclear
aim
work
assess
concomit
presenc
serum
antihla
nonhla
antibodi
highlysensit
patient
total
highlysensit
patient
await
kidney
transplant
studi
antihla
antibodi
profil
confirm
serum
singl
antigen
one
lambda
reaction
nonhla
antigen
labscreen
autoantibodi
class
ii
one
lambda
perform
upon
antihla
analysi
patient
panel
reactiv
antigen
moreov
present
concomit
antihla
nonhla
reaction
within
autoantigen
test
frequent
reaction
nonhla
antiglutathion
transferas
antictermin
fragment
perlecan
patient
includ
studi
incid
nonhla
antibodi
patient
wait
list
larg
unexplor
concomit
antihla
nonhla
antibodi
reaction
highlysensit
patient
extrem
high
sever
case
vascular
reject
kidney
transplant
describ
despit
neg
virtual
crossmatch
test
hla
antigen
screen
nonhla
antibodi
highlysensit
patient
could
allow
us
identifi
patient
increas
risk
vascular
reject
kidney
transplant
live
donat
donor
recipi
besid
abo
incompat
presenc
hla
antibodi
andor
presenc
posit
crossmatch
differ
methodolog
develop
overcom
immunolog
barrier
match
highli
increas
number
patient
endstag
renal
diseas
saudi
arabia
current
rang
patient
per
million
per
annum
hospit
king
faisal
specialist
hospit
jeddah
therefor
success
establish
desensit
aboi
renal
transplant
program
recent
also
start
use
kidney
exchang
program
kep
herebi
report
experi
overcom
immunolog
hurdl
use
kep
use
extens
computer
donor
exchang
program
high
grade
flexibl
perform
differ
option
includ
simpl
twopair
exchang
complic
domino
exchang
chain
donat
recipi
will
donor
high
titer
hla
antibodi
andor
strong
posit
cross
match
includ
program
hla
type
perform
use
one
lambda
sequenc
specif
oligonucleotid
revers
sequenc
specif
primer
ssorssp
hla
antibodi
identif
singl
antigen
class
iii
b
cell
igg
xm
perform
facscanto
ii
flow
cytomet
cutoff
posit
xm
determin
base
normal
human
studi
twenti
patient
transplant
success
use
kep
within
period
month
consid
total
number
transplant
kidney
time
mean
creat
largest
center
renal
transplant
saudi
arabia
till
abl
increas
number
transplant
organ
significantli
continu
extend
optim
histocompat
servic
hospit
experi
demonstr
high
effici
donor
exchang
program
overcom
immunolog
barrier
renal
transplant
program
provid
case
also
altern
invas
costli
desensit
protocol
effort
thought
go
extend
success
program
includ
diseas
donor
also
match
increas
demand
renal
transplant
rtx
hospit
besid
invas
technolog
like
desensit
aboi
rtx
also
establish
noninvas
strategi
like
kidney
pair
exchang
kpe
result
increas
rtx
reduct
wait
list
time
howev
avoid
immunolog
complic
relat
hla
incompat
invas
noninvas
procedur
must
support
outstand
hla
laboratori
reduct
immunolog
obstacl
evalu
residu
risk
requir
knowledg
special
skill
natur
immunolog
mechan
involv
hlaantibodi
support
critic
respons
staff
still
success
use
cdc
test
besid
advanc
technolog
like
flow
cytometri
crossmatch
luminex
platform
detect
antibodi
test
report
two
kpe
case
use
cdc
addit
test
along
flow
crossmatch
assay
first
case
femal
patient
multipl
nondsa
high
titer
dsa
mfi
mfi
mfi
neg
tcell
flow
crossmatch
posit
bcell
flow
crossmatch
fxm
mc
evalu
clinic
relev
dsa
crossmatch
result
perform
cdc
assay
b
cell
clearli
neg
acquisit
result
along
abovement
laboratori
find
sinc
multisensit
patient
suitabl
donor
henc
took
cumul
decis
perform
rtx
donat
organ
function
immedi
without
sign
reject
three
month
transplant
patient
normal
renal
retent
paramet
second
kpe
case
old
male
patient
multipl
nondsa
dsa
mfi
mfi
mfi
b
mfi
mfi
strong
posit
tcell
flow
crossmatch
fxm
mc
strong
posit
bcell
flow
crossmatch
fxm
mc
cdc
assay
b
cell
show
strong
reaction
even
serum
dilut
abl
initi
desensit
procedur
case
still
pend
wait
list
two
case
demonstr
cdc
could
support
enhanc
decis
evalu
immunolog
risk
patient
kpe
set
proinflammatori
cytokin
produc
activ
cell
receptor
present
differ
cell
type
specif
express
cell
spleen
kidney
protein
mediat
inflammatori
respons
follow
activ
cell
associ
certain
inflammatori
diseas
transplant
reject
reaction
present
studi
aim
assess
relationship
polymorph
within
gene
code
receptor
well
serum
level
cytokin
dialyz
patient
purpos
patient
control
genotyp
allel
use
lightsnip
assay
level
patient
serum
sampl
assess
elisa
observ
patient
frequent
present
g
allel
polymorph
compar
control
p
furthermor
presenc
g
allel
associ
higher
serum
level
pgml
signific
differ
observ
analyz
polymorph
express
encod
gene
signific
differ
distribut
genotyp
dialyz
patient
control
compar
result
show
patient
await
kidney
transplant
healthi
control
differ
respect
distribut
genet
variant
polymorph
correl
protein
express
known
act
potent
immuneregulatori
cytokin
block
cell
activ
consid
potenti
target
specif
less
toxic
immunosuppress
control
alloimmun
respons
long
term
solid
organ
transplant
sot
yet
recent
studi
reveal
also
proinflammatori
function
play
critic
role
develop
effector
immun
respons
set
main
function
sot
remain
yet
unclear
import
character
role
differ
clinic
circumst
oper
toler
also
amongst
comorbid
opportunist
infect
oi
aim
studi
assess
concentr
supernat
stimul
whole
peripher
blood
wpb
cohort
sot
recipi
sotr
correl
primari
studi
outcom
occurr
oi
thirti
liver
ltr
kidney
ktr
transplant
recipi
well
healthi
volunt
hc
recruit
prospect
monitor
one
year
immunolog
servic
univers
clinic
virgen
de
la
arrixaca
hospit
murcia
southeast
spain
enzymelink
immun
assay
elisa
carri
calcul
concentr
wpb
cultur
concanavalin
cona
hour
prior
transplant
sotr
show
higher
concentr
compar
hc
stratif
analysi
show
significantli
higher
patient
oi
within
first
six
month
follow
transplant
ngml
ltr
ngml
ktr
shown
accur
cutoff
valu
stratifi
sotr
high
risk
oi
regress
model
confirm
biomark
main
recipi
risk
factor
develop
oi
data
show
quantif
could
provid
valuabl
inform
occurr
opportunist
infect
liver
kidney
transplant
recipi
antigen
bead
assay
assign
antibodi
allel
level
becom
necessari
hla
type
potenti
solid
organ
recipi
done
high
resolut
howev
develop
countri
easi
access
afford
high
resolut
type
still
remain
challeng
background
aim
studi
intermedi
resolut
type
result
compar
high
resolut
type
result
luminex
base
test
hla
type
use
institut
offer
intermedi
level
resolut
summar
like
allel
base
particular
probe
hit
pattern
high
resolut
type
result
avail
group
sampl
test
laboratori
sent
registri
oversea
extern
qualiti
assur
sampl
receiv
threeyear
period
sampl
intermedi
highresolut
data
use
studi
highresolut
type
compar
probabl
allel
assign
per
intermedi
resolut
kit
concord
assess
hlaa
b
loci
sampl
test
overal
concord
sampl
concord
rate
locu
wise
hlaa
loci
b
locu
respect
dispar
seen
one
sampl
b
locu
dispar
note
hlab
intermedi
resolut
kit
first
probabl
assign
b
concord
greater
larger
number
sampl
need
studi
howev
develop
countri
high
resolut
type
becom
easili
access
afford
use
intermedi
resolut
type
might
offer
interim
feasibl
solut
anastasiya
mihaylova
petiya
yankova
anzhela
antonova
nevena
gesheva
valentina
atanasova
milena
ivanovashivarova
elissaveta
naumova
univers
hospit
alexandrovska
medic
univers
sofia
bulgaria
univers
hospit
alexandrovska
sofia
bulgaria
correspond
mihaylovaap
abvbg
import
pretranspl
crossmatch
test
final
confirm
compat
donor
recipi
proper
decis
make
undoubt
regular
assess
sensit
statu
recipi
wait
list
import
prerequisit
assess
probabl
positiveneg
crossmatch
virtual
xm
howev
unexpect
posit
prospect
crossmatch
may
observ
clinic
signific
question
studi
aim
discuss
unanticip
flow
cytometri
crossmatch
fcxm
result
observ
transplant
practic
total
fcxm
perform
januari
novemb
potenti
deceas
live
donor
kidney
transplant
evalu
standard
threecolor
fcxm
perform
hla
antibodi
screen
identifi
beadbas
assay
luminex
andor
flowpra
nineteen
test
patient
fcxm
posit
three
patient
tcell
bcell
five
tcell
bcell
tcell
bcell
fcxm
analys
show
tcell
bcell
fcxm
due
donor
specif
alloantibodi
dsa
base
autofcxm
result
alloantibodi
test
tcell
bcell
patient
autoimmun
reactiv
detect
six
posit
autofcxm
dsa
found
remain
five
patient
hla
class
dsa
detect
patient
tcell
bcell
fcxm
mainli
hlab
donor
mm
antigen
thu
less
half
unexpect
prospect
posit
fcxm
may
attribut
hla
dsa
accord
polici
posit
fcxm
andor
b
contraind
transplant
therefor
reason
unanticip
posit
crossmatch
elucid
transplant
ensur
effici
organ
alloc
optim
patient
outcom
immunogen
hla
antigen
relat
molecular
differ
immun
respond
antigen
probabl
also
individu
abil
mount
humor
respons
differ
may
relat
gener
dr
restrict
tcell
epitop
comput
algorithm
hlamatchmak
use
determin
hla
match
base
number
expos
molecular
mismatch
form
eplet
aim
work
analyz
incid
hla
antibodi
function
number
nonselfpeptid
could
theoret
gener
immun
antigen
independ
locat
molecul
theoret
affin
respond
measur
percentil
rank
studi
perform
two
context
pregnancyinduc
immun
kidney
transplant
number
affin
nonselfpeptid
determin
use
internet
resourc
wwwiedborg
coupl
inhous
algorithm
addit
number
eplet
determin
allogen
hla
use
hlamatchmak
mismatch
hla
antigen
classifi
immunogen
nonimmunogen
depend
whether
antibodi
could
detect
everpregn
group
comparison
immunogen
nonimmunogen
alloantigen
show
highli
signific
differ
number
nonselfpeptid
p
number
eplet
p
immun
transplant
group
signific
differ
number
nonselfpeptid
p
signific
number
eplet
p
shown
group
lower
percentil
rank
valu
associ
develop
hla
antibodi
conclus
data
suggest
likelihood
develop
hla
antibodi
increas
greater
differ
molecular
level
includ
expos
nonexpos
residu
could
form
tcell
epitop
virtual
crossmatch
vxm
refer
comparison
antihla
antibodi
recipi
defin
luminex
singl
antigen
lsa
bead
test
hla
donor
provid
reason
predict
result
actual
crossmatch
axm
perform
use
complementdepend
cytotox
cdc
method
without
addit
dithiothreitol
dtt
aim
studi
analyz
correl
neg
vxm
axm
perform
three
year
period
cadav
donor
kidney
transplant
programm
carri
vxm
donor
hla
molecul
patient
show
lsadetect
antibodi
normal
mean
fluoresc
intens
mfi
hlaa
b
hlac
consid
unaccept
antigen
cadav
donor
patient
type
hlaa
b
dr
dqb
pcr
sequencespecif
primer
method
eurotranspl
alloc
system
xm
list
produc
select
potenti
kidney
transplant
recipi
includ
patient
predict
neg
result
axm
basi
neg
vxm
axm
perform
kidney
alloc
procedur
cadav
donor
total
perform
cdc
cdc
cdcdtt
axm
posit
axm
obtain
sera
sampl
patient
patient
alway
histor
pra
total
patient
posit
axm
one
cadaver
donor
analysi
posit
axm
reveal
possibl
reason
axm
posit
mostli
due
presenc
igm
antibodi
nonhla
antibodi
also
unreport
transfus
lead
nondetect
unaccept
antigen
prior
offer
overal
neg
vxm
show
correl
cdc
xm
show
high
sensit
predict
donorrecipi
immunolog
compat
solid
organ
transplant
presenc
donor
specif
antibodi
dsa
direct
hla
antigen
recipi
indic
shorter
graft
surviv
howev
clinic
signific
vari
accord
sensit
cytotox
test
less
sensit
bead
array
test
higher
clinic
impact
flowcytometr
crossmatch
studi
case
solid
organ
transplant
use
bead
array
techniqu
detect
hla
specif
antibodi
mean
fluoresc
intens
mfi
consid
posit
also
perform
flow
cytometr
crossmatch
use
pronas
treat
b
lymphocyt
signal
detect
perform
linear
mode
fluoresc
shift
six
deem
posit
order
correl
mfi
bead
array
test
posit
fac
crossmatch
receiv
oper
characterist
roc
curv
analys
perform
auc
area
curv
valu
observ
compar
dsa
posit
defin
sum
mfi
class
class
ii
antibodi
fac
posit
defin
posit
andor
b
cell
crossmatch
valu
indic
good
accuraci
test
use
curv
found
optim
threshold
mfi
conting
tabl
construct
threshold
analyz
fisher
exact
test
p
test
true
neg
true
posit
test
fals
neg
dsa
posit
fac
neg
fals
posit
dsa
neg
fac
posit
fals
posit
case
weak
posit
fac
crossmatch
higher
cutoff
could
elimin
fals
neg
case
could
due
lower
express
level
allel
due
limit
bead
array
test
found
evid
possibl
low
express
allel
case
conclus
found
good
correl
mfi
bead
array
test
outcom
fac
crossmatch
relev
posit
complementdepend
lymphocytotox
crossmatch
cdcxm
hyper
acut
reject
kidney
transplant
known
year
introduct
sensit
technolog
luminex
provid
altern
method
hla
donor
specif
antibodi
dsa
detect
may
interest
know
level
fluoresc
correspond
posit
cdcxm
especi
case
cardiac
transplant
decis
accept
organ
immun
recipi
delay
work
aim
establish
antihla
dsa
fluoresc
intens
mfi
level
correspond
posit
cdcxm
use
total
sera
posit
virtual
xm
hla
class
molecul
dsai
sera
posit
virtual
xm
hla
class
ii
molecul
dsaii
criteria
consid
dsai
andor
dsaii
posit
patient
serum
mfi
valu
least
one
class
b
c
andor
class
ii
molecul
donor
cdcxm
b
cell
perform
dsai
dsaii
sera
respect
mannwhitney
test
use
compar
median
distribut
mfi
median
valu
posit
neg
cdcxm
statist
signific
differ
case
antihla
class
antibodi
median
valu
neg
posit
cdcxmt
respect
p
regard
class
ii
antibodi
mfi
median
valu
neg
posit
cdcxmb
respect
p
likelihood
posit
cdcxm
case
dsa
mfi
valu
conclus
although
sampl
size
small
data
suggest
mfi
valu
greater
predict
posit
cdcxm
presenc
dsa
kidney
recipi
strongli
associ
hyperacut
acceler
acut
reject
product
de
novo
posttranspl
dsa
kidney
recipi
often
indic
antibodi
mediat
reject
amr
ampl
clinic
data
support
import
hladsa
monitor
risk
assess
recipi
preand
posttranspl
aim
studi
evalu
develop
alloantibodi
kidney
transplant
patient
year
univers
hospit
parma
studi
conduct
consecut
patient
mean
age
male
transplant
kidney
cadaver
donor
mean
age
inclus
restrict
topati
first
kidney
transplant
hla
pretranspl
alloantibodi
antibodi
develop
monitor
conduct
use
bead
array
technolog
data
collect
baselin
one
three
six
month
posttranspl
annual
five
year
posttranspl
percentag
patient
de
novo
dsa
class
ii
relat
number
mismatch
dr
locu
statist
signific
differ
patient
mismatch
none
one
mismatch
dr
locu
three
year
patient
two
mismatch
hladr
develop
dsa
class
ii
antigen
patient
one
mismatch
develop
dsa
class
ii
antigen
correl
class
mismatch
develop
specif
class
dsa
statist
signific
perhap
owe
limit
number
patient
despit
low
sampl
size
data
confirm
mismatch
class
ii
loci
repres
major
antigen
stimul
reflect
dsa
product
reduc
longterm
transplant
surviv
highli
sensit
patient
wait
mani
year
offer
transplant
due
mani
unaccept
antigen
list
uk
transplant
previou
work
center
shown
cumul
antibodi
detect
mfi
use
luminex
singl
antigen
bead
correl
neg
flow
cytometr
cdc
crossmatch
therefor
instig
monthli
multidisciplin
team
meet
discuss
highli
sensit
long
wait
patient
deselect
antigen
less
mfi
whilst
median
calcul
reaction
frequenc
crf
fell
median
number
list
unaccept
antigen
halv
use
new
uk
transplant
match
tool
result
predict
increas
median
number
potenti
tier
donor
donor
past
two
year
transplant
hospit
cohort
highli
sensit
patient
number
patient
wait
longer
day
transplant
reduc
seven
transplant
live
donor
previous
exclud
due
unaccept
antigen
pretranspl
crossmatch
neg
case
outcom
good
median
month
creatinin
role
antihladp
dqa
antibodi
renal
graft
poorli
understood
long
time
howev
introduct
solid
phase
assay
allow
identif
better
understand
clinic
import
kidney
transplant
studi
describ
incid
antidp
dqa
antibodi
cohort
male
femal
patient
transplant
januari
decemb
univers
hospit
parma
mean
age
transplant
year
preand
posttranspl
sera
identifi
use
luminex
singl
antigen
lsa
luminex
singl
antigen
class
ii
one
lambda
antidp
dqa
antibodi
detect
patient
posttranspl
sera
patient
antibodi
loci
transplant
three
retranspl
wherea
develop
de
novo
within
followup
period
nine
patient
previou
pregnanc
blood
transfus
among
posttranspl
antibodi
detect
antidp
specif
show
mean
fluoresc
intens
mfi
level
less
posit
cutoff
aibt
guid
line
antidqa
specif
also
reach
mfi
valu
greater
summari
shown
antidp
dqa
antibodi
common
primari
renal
transplant
commonli
accompani
antibodi
make
impact
graft
surviv
hard
determin
moreov
type
hladp
dqa
antigen
still
routin
perform
difficult
classifi
antidp
antibodi
donorspecif
therefor
current
avail
lsa
panel
antidp
dqa
antibodi
detect
cover
small
number
identifi
allel
futur
studi
extend
followup
warrant
character
role
antibodi
flow
cytometri
crossmatch
fcxm
vs
flowdsaxm
techniqu
use
detect
cdc
vs
flow
cytometri
solid
phase
new
flowdsaxm
techniqu
combin
sensit
classic
fcxm
specif
singl
antigen
bead
assay
allow
better
correl
crossmatch
result
patient
hla
class
ii
sensit
detect
solid
phase
assay
perform
compar
analysi
fcxm
flowdsaxm
result
test
sera
hla
class
posit
seven
hla
class
ii
posit
hla
class
ii
posit
five
differ
lymphocyt
popul
type
hla
class
ii
loci
high
resolut
pcrssp
sso
techniqu
standard
fcxm
techniqu
allow
detect
iggantibodi
specif
b
lymphocyt
flowdsaxm
consist
incub
lymphocyt
serum
perform
three
differ
captur
bead
hla
b
c
bead
hla
iia
dq
bead
hla
iib
dr
dq
dp
bead
ad
lastli
lysisstain
buffer
use
solubil
hla
molecul
label
antibodi
bound
flowdsaxm
fcxm
show
strong
concord
nine
pra
neg
sera
antihla
class
posit
sera
flowdsaxm
partial
discord
one
seven
antihla
class
ii
posit
sera
fcxm
b
cell
show
weak
posit
flowdsaxm
hla
iib
show
result
near
cutoff
moreov
flowdsaxm
sensit
fcxm
show
higher
valu
posit
especi
presenc
antihla
class
dsa
gave
specif
result
discrimin
hla
class
andor
ii
dsa
contrari
fcxm
gave
b
posit
result
presenc
hla
class
class
ii
dsa
conclus
flowdsaxm
allow
better
interpret
crossmatch
result
could
repres
crossmatch
new
millennium
clinic
impact
antihla
antibodi
liver
transplant
lt
set
unclear
although
recent
studi
describ
increas
diagnosi
antibodymedi
damag
popul
aim
studi
correl
develop
de
novo
donorspecif
antihla
antibodi
dndsa
lt
immunosuppress
well
graft
outcom
total
liver
transplant
patient
male
period
patient
exclud
due
earli
graft
loss
month
includ
analysi
patient
screen
luminex
antihla
antibodi
month
year
year
lt
hla
type
perform
donor
recipi
pair
de
novo
antibodi
emerg
patient
liver
dysfunct
graft
loss
two
year
posttransplant
versu
de
novo
neg
patient
fifteen
posit
patient
dndsa
four
class
class
ii
graft
dysfunct
fibrosi
versu
neg
patient
concern
immunosuppress
regimen
patient
receiv
mtori
mainten
therapi
dndsa
dndsa
class
ii
patient
receiv
mtori
moreov
less
hla
compat
patient
match
dndsa
compat
patient
match
less
compat
patient
dndsa
graft
dysfunct
compat
patient
neg
dndsa
graft
dysfunct
conclus
preliminari
result
ongo
studi
show
de
novo
antihla
antibodi
seem
affect
liver
graft
outcom
hla
compat
well
immunosuppress
seem
effect
dndsa
emerg
howev
differ
yet
statist
signific
allel
hlab
null
allel
januari
herebi
report
identif
novel
hlab
null
variant
potenti
kidney
transplant
recipi
denmark
use
next
gener
sequenc
ng
luminex
lum
platform
permit
detect
hla
antibodi
detect
complementdepend
lymphocytotox
cdc
clinic
signific
antibodi
complet
understood
aim
studi
evalu
whether
presenc
pretranspl
lumdetect
hla
antibodi
associ
develop
allograft
failur
singlecent
cohort
studi
consecut
kidney
recipi
transplant
kidney
transplant
center
deceas
donor
januari
decemb
enrol
pretranspl
plasma
sampl
retrospect
analyz
presenc
lumdetect
antibodi
patient
follow
year
censor
allograft
failur
death
end
followup
whichev
came
first
surviv
analys
perform
assess
risk
allograft
failur
lum
detect
lumdetect
antibodi
found
subject
lumposit
subsequ
develop
allograft
failur
surviv
rate
confid
interv
wherea
among
without
antibodi
return
dialysi
surviv
rate
last
decad
observ
remark
progress
clinic
outcom
renal
transplant
patient
develop
novel
effect
immunosuppress
agent
despit
advanc
graft
dysfunctionreject
reduc
graft
surviv
remain
major
burden
clinician
well
patient
one
major
reason
problem
format
antihladq
donor
specif
antibodi
dsa
present
studi
done
evalu
incid
antidq
antibodi
role
renal
transplant
reject
hla
antibodi
ab
screen
posit
patient
assess
singl
antigen
bead
sab
assay
determin
specif
hla
type
perform
donor
determin
dsa
initi
hlaa
b
dr
type
perform
donor
patient
howev
donor
antihladq
antihlac
antibodi
hlac
hladq
type
perform
determin
dsa
patient
patient
develop
antidq
dsa
present
associ
hla
class
ii
antibodi
seven
patient
alon
eight
patient
common
antidq
antibodi
follow
studi
suggest
high
incid
antidq
dsa
antibodi
renal
transplant
recipi
singl
antigen
bead
test
donor
type
hladq
includ
routin
investig
workup
solid
organ
transplant
claudia
lehmann
ramona
landgraf
ilia
doxiadi
transfus
medicin
hlalaboratori
leipzig
germani
correspond
clehmann
medizinunileipzigd
antibodi
screen
specif
regard
prerequisit
patient
organ
stem
cell
transplant
platelet
substitut
center
perform
test
use
gener
singl
antigen
assay
one
lambda
usa
present
report
show
data
year
total
sera
test
start
gener
assay
sera
class
posit
class
ii
mica
posit
respect
posit
sera
enter
singl
antigen
assay
addit
mhc
class
mhc
class
ii
neg
result
lead
us
reconsid
cutoff
valu
gener
assay
futur
test
use
remain
sera
ask
question
whether
differ
loci
mhc
hlaa
b
c
dp
differenti
immunogen
everi
defin
specif
calcul
singl
hit
sum
hit
show
often
antibodi
toward
given
locu
observ
present
analysi
solid
organ
transplant
patient
sera
class
class
ii
class
ii
recogn
differ
specif
total
hit
hlaa
hlab
hlac
hladp
respect
stem
cell
transplant
patient
includ
platelet
substitut
patient
total
hit
count
hlaa
hlab
hlac
preliminari
data
present
clearli
suggest
hla
loci
induc
antibodi
respons
hlab
hlaa
hlac
hladp
test
loci
includ
result
although
observ
rather
small
number
patient
suggest
alloc
procedur
besid
known
loci
hlaa
b
well
hladp
use
serum
sampl
transplant
recipi
regularli
screen
igg
hla
antibodi
due
clinic
relev
transplant
outcom
howev
isotyp
hla
antibodi
iga
may
also
contribut
alloimmun
respons
yet
properli
valid
method
iga
hla
antibodi
detect
avail
therefor
aim
modifi
optim
commonli
use
luminex
singl
antigen
bead
sab
assay
reliabl
iga
hla
antibodi
detect
valid
recombin
iga
hlaspecif
human
monoclon
antibodi
mab
well
appli
igg
deplet
serum
sampl
replac
standard
luminex
sab
igg
secondari
antibodi
optim
concentr
secondari
antibodi
verifi
specif
assay
use
igg
isotyp
variant
hlaspecif
human
mab
recogn
specif
found
isotyp
mab
ident
igg
isotyp
furthermor
found
crossreact
secondari
antibodi
igg
isotyp
mab
vice
versa
mix
experi
use
iga
igg
mab
show
igg
dosedepend
interf
iga
detect
therefor
develop
igg
deplet
protocol
use
protein
g
column
elimin
igg
competit
next
valid
modifi
sab
small
set
serum
sampl
igg
deplet
serum
sampl
individu
without
histori
alloantigen
exposur
show
iga
isotyp
hla
antibodi
iga
isotyp
hlaspecif
antibodi
detect
two
eight
serum
sampl
individu
histori
alloantigen
exposur
preliminari
result
show
current
modifi
sab
assay
use
screen
serum
sampl
hlaspecif
iga
antibodi
may
facilit
studi
aim
deciph
clinic
relev
iga
hla
antibodi
solid
organ
transplant
gwendalin
guidicelli
mami
ralazamahaleo
charlen
bouthemi
thoa
nong
jarhow
lee
jeanluc
taupin
jonathan
visentin
centr
hospitali
universitair
de
bordeaux
bordeaux
franc
one
lambda
inc
canoga
park
ca
unit
state
america
correspond
jonathanvisentin
chubordeauxfr
studi
attempt
predict
tlymphocyt
flow
cytometri
crossmatch
tfcxm
result
mean
fluoresc
intens
mfi
singl
antigen
flow
bead
safb
assay
conduct
descript
high
frequenc
class
antidenatur
antibodi
antidhla
previous
describ
antidhla
hlac
particularli
frequent
antin
hlac
antibodi
provid
random
tfcxm
result
yet
number
tfcxm
perform
small
reassess
tfcxm
predict
presenc
antihlac
mfi
classic
safb
ibead
safb
larg
devoid
dhla
surfac
use
sera
patient
cell
organ
donor
total
tfcxm
perform
sera
select
react
one
cw
donor
antigen
classic
safb
fourteen
among
exist
hlac
antigen
specif
test
twentyf
among
tfcxm
posit
fifteen
among
tfcxm
studi
antidhla
defin
ibead
mfi
none
induc
posit
tfcxm
correl
classic
safb
mfi
tfcxm
ratio
low
higher
ibead
mfi
roc
auc
tfxcm
predict
safb
mfi
optim
threshold
classic
safb
mfi
tfcxm
predict
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
roc
auc
significantli
higher
ibead
mfi
p
roc
auc
comparison
optim
threshold
ibead
mfi
sensit
specif
ppv
npv
conclus
ibead
mfi
accur
predict
tfcxm
result
antihlac
antibodi
favor
resurg
ibead
product
assay
prove
effici
elimin
antidhla
highli
preval
among
antihlac
antibodi
sensit
luminex
technolog
use
detect
identif
antihla
antibodi
detect
perform
use
pool
antigen
provid
inform
presenc
antibodi
identif
specif
achiev
singl
antigen
bead
assay
sab
slovenian
transplant
program
perform
antibodi
detect
use
cdc
luminex
assay
twice
year
addit
identif
alway
perform
sab
labscreen
singl
antigen
one
lambda
determin
patient
immunolog
statu
combin
hisher
clinic
data
test
result
well
known
luminex
base
antibodi
detect
assay
less
sensit
sab
assay
order
compar
assay
influenc
result
patient
immunolog
statu
implement
labscreen
mix
assay
one
lambda
antihla
antibodi
detect
total
sera
test
antihla
antibodi
sab
determin
antibodi
posit
mfi
sab
ratio
compar
result
serum
found
result
obtain
sab
concord
discrep
found
mainli
case
posit
sab
neg
case
immunolog
statu
patient
would
affect
sinc
sab
basi
final
decis
statu
would
perform
neg
sera
turn
posit
sab
immunolog
statu
would
affect
sinc
patient
would
test
sab
import
sensit
could
overlook
base
find
chang
strategi
test
patient
enter
wait
list
kidney
transplant
addit
sab
assay
axl
tam
receptor
tyrosin
kinas
express
macrophag
monocyt
dendrit
cell
natur
killer
cell
axl
modul
immun
respons
prevent
activ
antigenpres
cell
downregul
proinflammatori
cytokin
upregul
suppressor
cytokin
signal
soc
previous
report
mix
lymphocyt
reaction
mlr
postkidney
transplant
ktx
display
downregul
other
addit
aspir
biopsi
cultur
supernat
sn
seven
day
postktx
report
observ
axl
donorrecipi
rd
thirdparti
recipi
rt
combin
mlr
done
six
month
posttranspl
stabl
half
well
without
sn
sn
end
mlr
cytospin
stain
axl
immunoperoxidas
use
antihuman
axl
antibodi
r
result
shown
rd
rt
combin
mlr
display
posit
stimul
index
si
neg
si
cpm
decreas
least
compar
well
supplement
sn
call
downregul
patient
first
cadav
ktx
csammfpr
treatment
rd
rt
eleven
show
posit
si
neg
si
addit
sn
axl
express
quartil
rd
rt
respect
stimul
inhibit
mlr
respect
find
show
trend
higher
express
axl
rt
compar
rd
inhibit
mlr
surmis
particip
axl
modul
immun
respons
previous
show
signific
differ
soc
express
end
mlr
ktx
specul
axl
may
behind
observ
studi
encompass
reject
case
differ
treatment
potenti
signific
iga
nephropathi
igan
glomerulari
diseas
caus
endstag
renal
diseas
esrd
cosmc
molecular
chaperon
glycosyl
togeth
inadequ
galactosyl
lead
galactosedefici
studi
aim
demonstr
relationship
cosmc
gene
promot
methyl
cosmc
mrna
level
patient
nt
treatment
diagnos
igan
biopsi
first
degre
healthi
rel
patient
healthi
control
includ
studi
blymphocyt
cultur
three
differ
group
dna
methyl
modifi
agent
group
blank
group
ii
group
iii
aza
cosmc
gene
dna
methyl
express
level
studi
use
rtpcr
level
serum
cell
cultur
supernat
studi
use
elisa
serum
level
igan
patient
detect
significantli
higher
p
compar
healthi
rel
control
cosmc
promot
dna
methyl
rate
significantli
p
igan
patient
compar
healthi
rel
control
cosmc
mrna
level
igan
patient
found
significantli
lower
compar
healthi
rel
control
p
cosmc
methyl
level
p
decreas
cosmc
mrna
level
p
increas
significantli
group
iii
increas
cosmc
dna
methyl
level
limit
cosmc
mrna
level
significantli
decreas
group
ii
find
support
hypermethyl
cosmc
gene
promot
region
associ
low
cosmc
mrna
express
level
believ
find
inform
pathogenesi
diseas
iga
nephropathi
igan
frequent
primari
glomerular
diseas
import
caus
endstag
renal
diseas
esrd
studi
aim
investig
diagnost
valu
marker
progress
iga
nephropathi
longterm
clinic
cours
igan
patient
retrospect
evalu
initi
serum
level
oxford
classif
igan
clinic
data
subject
statist
analysi
estim
glomerular
filtrat
rate
egfr
sex
bodi
mass
laboratori
test
ie
proteinuria
serum
creatinin
treatment
serum
galactos
level
patient
sera
measur
use
elisa
assay
immunobiolog
laboratori
ibl
co
renal
biopsi
score
accord
oxford
mest
score
system
experienc
pathologist
primari
outcom
defin
esrd
need
dialysi
egfr
patient
calcul
ckdepi
formula
fortyfour
patient
mean
age
year
examin
eleven
patient
reach
esrd
followup
period
initi
serum
level
significantli
lower
patient
esrd
also
mest
score
significantli
higher
patient
esrd
surviv
analysi
iga
deposit
segment
sclerosi
tubular
atrophi
found
signific
predictor
primari
outcom
p
p
respect
serum
level
mest
score
may
use
predict
progress
iga
nephropathi
overt
proteinuria
may
caus
lower
serum
concentr
patient
end
stage
renal
diseas
mani
kidney
recipi
need
one
kidney
transplant
lifetim
patient
often
develop
antihla
antibodi
lose
graft
investig
effect
donorspecif
hla
antibodi
dsa
retranspl
patient
retx
versu
patient
transplant
first
time
firsttx
dutch
procar
consortium
studi
graft
surviv
firsttx
retx
patient
without
hla
antibodi
compar
vs
patient
hla
antibodi
donorspecif
ndsa
graft
surviv
lower
retx
compar
firsttx
vs
also
case
patient
dsa
graft
surviv
firsttx
vs
retx
effect
might
hla
antibodi
independ
may
also
caus
previou
transplant
induc
differ
hla
antibodi
investig
whether
higher
level
immun
might
drive
graft
surviv
differ
ndsa
dsa
group
analyz
differ
percentag
panel
reactiv
antibodi
pra
time
transplant
current
pra
histor
highest
level
transplant
high
pra
firsttx
retx
found
pra
consider
higher
retx
dsa
detect
singl
antigen
bead
sab
assay
pretranspl
serum
rel
number
transplant
current
pra
equal
transplant
cdc
crossmatch
panel
donor
neg
yet
sab
assay
pick
hla
antibodi
consider
higher
firsttx
exclud
transplant
current
pra
reduc
differ
immun
level
firsttx
retx
found
remain
differ
graft
surviv
firsttx
retx
ndsa
posit
transplant
greatli
reduc
differ
dsa
posit
transplant
conclus
cohort
relat
retransplant
graft
surviv
seem
predominantli
depend
presenc
pretranspl
hla
antibodi
ndsa
dsa
therefor
one
consid
includ
variabl
retransplant
multivari
model
studi
effect
hla
antibodi
long
term
graft
surviv
like
mask
part
studi
effect
adrienn
seitz
katherin
mounsey
ruth
foster
pamela
hugh
richard
baker
brendan
clark
leed
teach
hospit
nh
trust
leed
unit
kingdom
great
britain
correspond
umacl
leedsacuk
hla
donor
specif
antibodi
dsa
associ
acut
reject
decreas
graft
surviv
uk
nation
deceas
donor
alloc
algorithm
current
take
hladp
sensit
account
alloc
kidney
present
center
recent
experi
hladp
incompat
offer
outcom
patient
includ
studi
hladp
dsa
alon
identifi
within
six
month
time
offer
sampl
hladp
specif
mfi
valu
consid
posit
crossmatch
clinic
outcom
data
compar
control
group
includ
recipi
sampl
contain
nondonorrelev
hladp
antibodi
recipi
identifi
follow
median
day
seventeen
receiv
dp
incompat
transplant
dpdsa
group
plan
augment
immunosuppress
plasma
exchang
major
patient
receiv
deceas
donor
graft
retranspl
addit
possess
hladp
antibodi
highli
sensit
patient
calcul
reaction
frequenc
flow
cytometr
fcxm
cdc
tcell
crossmatch
result
neg
case
five
patient
dpdsa
cohort
gener
bcell
posit
fcxm
result
associ
hladp
mfi
level
observ
bfcxm
neg
vs
bfcxm
posit
estim
reject
free
surviv
reduc
dpdsa
cohort
compar
control
vs
graft
surviv
group
within
followup
period
two
graft
lost
dpdsa
cohort
interestingli
repres
two
three
patient
receiv
fulli
hla
match
graft
hlaa
b
c
dr
dq
neither
mfi
level
crossmatch
result
abl
riskstratifi
patient
could
reflect
variabl
hladp
express
donor
tissu
vigil
requir
transplant
across
barrier
develop
new
fcxm
assay
distinguish
harm
complementactiv
noncompl
activ
antibodi
use
donor
cell
recipi
sera
new
fcxm
assay
led
success
heart
kidney
transplant
adult
paediatr
case
pbmc
isol
donor
sampl
incub
pretranspl
sera
eight
heart
ten
kidney
recipi
appropri
control
cell
incub
lyophil
custom
cocktail
antibodi
specif
recogn
variou
igg
subtyp
bound
cell
follow
fcxm
analysi
test
carri
sera
heart
transplant
case
studi
posit
crossmatch
due
antibodi
noncompl
activ
correl
result
two
case
posit
probabl
due
prozon
effect
hlaspecif
igm
antibodi
case
posit
surviv
posttranspl
pgd
reject
two
case
document
amr
continu
normal
graft
function
almost
complet
agreement
igg
subtyp
assay
assay
result
case
studi
posit
fcxm
due
presenc
noncompl
activ
igg
antibodi
one
case
show
presenc
antibodi
neg
probabl
result
denatur
antibodi
new
fcxm
assay
also
help
two
paediatr
kidney
recipi
reject
episod
report
preliminari
result
demonstr
new
assay
facilit
safe
transplant
even
presenc
contraind
standard
posit
fcxm
assay
shown
highli
accur
detect
igg
subtyp
caus
posit
flow
crossmatch
clinic
implement
igg
subtyp
assay
would
great
impact
increas
number
success
transplant
carri
especi
sensit
recipi
kidney
transplant
donor
recipi
match
abo
compat
hla
sinc
januari
laboratori
within
scandiatranspl
perform
hla
type
hlaa
b
c
addit
hla
match
donorspecif
hla
antibodi
dsa
taken
account
match
donor
recipi
dsa
high
intens
associ
high
risk
antibodymedi
reject
amr
impair
longterm
allograft
surviv
consequ
dsa
fulli
understood
suggest
equal
nearli
equal
import
aim
studi
quantifi
preval
antibodi
among
patient
wait
list
kidney
transplant
western
part
denmark
patient
activ
wait
list
kidney
transplant
western
part
denmark
septemb
includ
recent
luminex
analysi
reexamin
antibodi
patient
antibodi
frequent
found
among
patient
wait
list
patient
antibodi
antibodi
among
patient
wait
first
transplant
antibodi
frequent
antibodi
antibodi
wherea
antibodi
among
patient
wait
repeat
transplant
frequenc
antibodi
compar
presenc
respect
show
antibodi
frequent
found
patient
wait
list
kidney
transplant
suggest
antibodi
includ
immunolog
risk
assess
prior
transplant
calcul
panelreact
antibodi
cpra
accur
measur
definit
candid
immun
transplant
base
upon
unaccept
hla
antigen
patient
sensit
cpra
comput
hla
allel
haplotyp
frequenc
pool
possibl
donor
repres
percentag
donor
express
one
antigen
unaccept
given
transplant
candid
aim
studi
compar
cpra
valu
obtain
hla
frequenc
portugues
donor
valu
obtain
cpra
calcul
intern
establish
sourc
randomli
gener
hlaa
b
unaccept
antigen
simul
cohort
transplant
candid
respect
antigen
patient
comput
portugues
pt
cpra
valu
use
formula
develop
zachari
braun
base
hla
allel
haplotyp
frequenc
unrel
bone
marrow
donor
result
obtain
compar
cpra
valu
defin
canadian
transplant
registri
ctr
unit
network
organ
share
uno
eurotranspl
et
calcul
calcul
also
classifi
cpra
low
sensit
sensit
highli
sensit
spearman
rho
test
use
compar
result
calcul
assess
correl
cohen
kappa
coeffici
use
access
agreement
categor
valu
valu
obtain
cpra
pt
calcul
highli
correl
cpra
obtain
one
three
calcul
categor
cpra
valu
calcul
substanti
agreement
obtain
pt
et
kappa
pt
uno
kappa
moder
agreement
obtain
pt
ctr
valu
kappa
cpra
give
us
probabl
transplant
candid
posit
crossmatch
next
avail
donor
transplant
reliabl
cpra
valu
depend
donor
pool
calcul
crucial
highli
sensit
patient
classifi
genotyp
frequenc
use
cpra
comput
frequenc
known
scrutin
assur
correct
measur
candid
sensit
must
correspond
far
possibl
futur
organ
donor
hlag
gene
stand
natur
immunosuppress
patient
go
transplant
low
express
associ
graft
reject
singl
nucleotid
polymorph
affect
mrna
stabil
promot
inhibit
molecul
express
studi
focus
sequenc
hlag
regard
polymorph
kidney
transplant
patient
year
posttranspl
reject
episod
haplotyp
genotyp
allel
frequenc
snp
compar
detect
associ
risk
kidney
allograft
reject
eleven
haplotyp
describ
literatur
observ
present
studi
haplotyp
show
associ
kidney
graft
outcom
howev
genotyp
snp
character
protect
factor
develop
reject
heterozyg
genotyp
posit
consid
risk
factor
accord
fischer
exact
test
multivari
analysi
also
high
valu
pra
higher
shown
risk
factor
agreement
result
other
clinic
studi
heterozyg
genotyp
posit
snp
risk
factor
detect
fischer
exact
test
evidenc
multivari
analysi
addit
observ
strong
linkag
disequilibrium
r
exist
worth
note
differ
studi
consid
risk
factor
preeclampsia
develop
risk
factor
autoimmun
diseas
present
linkag
disequilibrium
associ
observ
kidney
transplant
outcom
better
investig
order
clarifi
suggest
doubl
effect
polymorph
updown
regul
hlag
express
protectorrisk
factor
report
case
patient
experienc
antibodi
mediat
reject
abmr
two
month
second
kidney
transplant
kt
patient
transplant
chronic
glomerulopathi
kidney
malform
first
transplant
lost
due
chronic
allograft
reject
patient
develop
hlac
antibodi
ab
antihlac
c
c
c
c
c
c
c
epitop
dsa
c
transplantectomi
perform
patient
receiv
second
kidney
transplant
deceas
donor
c
incompat
antithymocyt
globulin
use
induct
therapi
immunosuppress
regimen
contain
tacrolimu
mycophenol
mofetil
steroid
three
cure
intraven
immunoglobulin
ivig
renal
allograft
biopsi
made
two
month
acut
renal
dysfunct
show
neg
acut
humor
reject
abmr
accord
banff
classif
despit
treatment
rituximab
ivig
steroid
featur
persist
two
subsequ
biopsi
perform
three
ten
month
later
find
antihla
dsa
serum
sdsa
neither
antimica
decid
search
intragraft
ab
elut
perform
elukit
ii
elut
specif
detect
use
singl
antigen
luminex
kit
one
lambda
final
wash
supernat
test
control
effici
wash
hla
ab
detect
intragraft
antihla
antibodi
detect
two
biopsi
perform
month
month
kt
result
elut
show
posit
hlac
matchmak
analysi
show
hlac
share
eplet
allel
c
c
c
hlac
high
resolut
type
donor
reveal
presenc
c
allel
test
sa
kit
clinic
observ
illustr
use
search
hla
intragraft
ab
case
abmr
without
detect
sdsa
risk
assess
patient
retransplant
knowledg
hla
type
previou
organ
donor
crucial
howev
complet
partial
unknown
mainli
due
hla
type
techniqu
appli
time
transplant
clinic
signific
detect
hla
antibodi
well
risk
repeat
incompat
new
donor
determin
definit
without
complet
type
initi
donor
histor
sampl
deceas
donor
avail
clearli
benefici
hla
type
determin
graft
biopsi
materi
howev
complic
fact
graft
biopsi
contain
donor
tissu
infiltr
lymphocyt
patient
thu
hla
type
deduc
biopsi
materi
repres
donor
recipi
aim
investig
whether
hla
type
perform
biopsi
materi
would
allow
hla
type
previou
donor
thu
enabl
better
pretranspl
risk
assess
initi
test
mixtur
dna
known
hla
type
use
linkag
qpcr
kit
suretyp
softwar
abl
detect
expect
allel
next
test
two
allograft
biopsi
cardiac
transplant
patient
biopsi
renal
transplant
patient
transplant
perform
year
ago
abl
detect
two
nine
hla
allel
donor
origin
conclud
possibl
determin
multipl
donor
hla
type
differ
patient
type
expect
found
correl
graft
age
number
detect
allel
test
enabl
us
detect
donor
specif
antibodi
furthermor
defin
unaccept
mismatch
believ
feasibl
method
use
routin
must
stress
possibl
mismatch
found
de
novo
donorspecif
antibodi
dndsa
detect
posttranspl
independ
risk
factor
late
graft
failur
gf
develop
respons
hla
mismatch
mm
howev
individu
mm
differ
effect
gf
kidney
transplant
kt
aim
work
determin
associ
mm
use
hlamatchmak
hlamm
predict
indirectli
recogn
hla
epitop
pirch
ii
develop
dndsa
kt
live
donor
ldkt
total
ldkt
perform
hospit
santo
hsa
livingrel
donor
lrd
live
unrel
donor
lurd
includ
studi
hlaa
b
dr
low
resolut
type
perform
donorrecipi
pair
high
resolut
determin
hlaa
b
pirch
ii
version
score
determin
epitop
mm
load
epmm
assign
hlamm
version
dsa
assess
longitudin
maximum
followup
year
singleantigen
bead
sab
assay
patient
develop
dndsa
frequent
retranspl
higher
pirch
ii
retransplant
younger
recipi
age
higher
pirch
ii
per
unit
increas
independ
predictor
dndsa
multivari
cox
analysi
epmm
per
unit
increas
antigen
hla
mm
per
unit
increas
consid
epmm
pirch
ii
tercil
cumul
incid
dndsa
epmm
logrank
pirch
ii
logrank
respect
highest
tercil
epmm
pirch
independ
predictor
dndsa
studi
show
eplet
mismatch
load
pirch
ii
score
predictor
dndsa
may
contribut
signific
improv
hla
match
allow
identif
low
high
risk
hla
mismatch
kidney
transplant
presenc
donor
specif
antihla
antibodi
dsa
major
risk
factor
poor
graft
outcom
kidney
transplant
recipi
desensit
protocol
develop
order
overcom
immunolog
barrier
rabin
medic
center
israel
implement
program
desensit
highlysensit
posit
dsa
neg
nihcdc
cross
match
live
donor
recipi
longterm
outcom
highlysensit
kidney
transplant
recipi
treat
ivig
plasmapheresi
without
rituximab
ad
mfi
compar
nonsensit
livingdonor
recipi
transplant
year
center
thirtysix
highlysensit
recipi
nonsensit
live
donor
recipi
includ
mean
followup
month
deathcensor
graft
failur
occur
six
recipi
highlysensit
group
recipi
nonsensit
group
tenyear
deathcensor
graft
surviv
rate
versu
differ
patient
surviv
highlysensit
group
graft
failur
dsa
persist
transplant
significantli
associ
presenc
class
ii
antigen
ci
associ
found
class
antigen
peak
dsa
level
three
five
recipi
dsa
hla
lost
graft
compar
dsa
antigen
twenti
highlysensit
patient
remain
aliv
lose
graft
dsa
end
followup
period
long
term
deathcensor
graft
surviv
highlysensit
recipi
less
favor
compar
nonsensit
recipi
although
cohort
better
previous
report
howev
dsa
rebound
longterm
graft
outcom
excel
dsa
class
ii
especi
associ
signific
risk
graft
failur
dsa
persist
conclud
ad
rituximab
desensit
therapi
highrisk
recipi
may
offer
benefit
david
pinelli
muralidhar
gopalakrishnan
anat
r
tambur
northwestern
univers
chicago
il
unit
state
america
correspond
atambur
northwesternedu
tempor
model
igg
subclass
switch
support
sequenti
igg
convers
howev
divers
previous
stimul
b
cell
known
shape
respons
differ
direct
recent
studi
suggest
differ
subclass
igg
possess
vari
capac
caus
graft
injuri
igg
subclass
switch
dynam
process
perform
preliminari
exploratori
studi
adult
pediatr
recipi
pancrea
investig
kinet
rel
magnitud
donorspecif
antibodi
dsa
igg
subclass
compar
total
igg
time
serial
posttranspl
sampl
test
total
igg
subclass
use
class
ii
luminex
sab
patient
total
igg
dsa
mfi
time
point
test
receiv
treatment
activ
amr
total
igg
antibodi
ab
compar
detect
reagent
hla
ab
specif
interestingli
patient
ab
direct
target
posit
singl
serum
sampl
patient
mfi
valu
posit
total
igg
bead
higher
compar
seen
reagent
howev
two
patient
show
much
higher
mfi
valu
reagent
total
igg
patient
notic
subclass
bind
least
one
serum
sampl
mfi
vari
dramat
time
gener
follow
similar
pattern
increasedecreas
correspond
specif
total
igg
assay
notabl
see
class
switch
time
although
comprehens
studi
among
ten
patient
test
time
activ
amr
biopsi
two
dsa
three
dsa
summari
mfi
igg
subclass
fluctuat
time
seem
correspond
clinic
statu
patient
ab
may
posit
complic
analysi
clinic
studi
suspect
reagent
current
avail
readi
clinic
use
advis
signific
caution
interpret
result
especi
obtain
singl
time
point
sevim
kandur
hakan
guz
glu
modul
immun
bkv
recent
studi
show
hla
antigen
within
major
histocompat
complex
mhc
may
play
role
respons
viral
infect
may
influenc
cours
bkv
infect
identif
hla
alter
cours
infect
facilit
risk
stratif
custom
preemptiv
intervent
strategi
aim
present
studi
determin
hla
antigen
associ
bk
viremia
kidney
transplant
retrospect
singlecent
studi
look
associ
recipi
origin
bkv
renal
transplant
hla
antigen
patient
follow
univers
transplant
centr
analyz
hla
antigen
associ
kidney
transplant
patient
bkv
nephropathi
control
group
unaffect
transplant
recipi
tacrolimusbas
immunosuppress
hla
analyz
pcrsso
method
use
luminex
technolog
result
show
signific
differ
patient
control
group
mean
frequenc
hla
locu
howev
hlaa
significantli
less
frequent
patient
control
group
although
patient
number
limit
suggest
kidney
transplant
recipi
carri
hla
allel
group
carri
hlaa
risk
bkv
infect
random
studi
larger
sampl
size
increas
knowledg
issu
kidney
transplant
pivot
prevent
human
leukocyt
antigen
hla
donor
specif
antibodi
dsa
format
trigger
immunogen
epitop
present
mismatch
hla
optim
donor
theoret
select
avoid
epitop
mismatch
implement
epitop
match
essenti
defin
relev
epitop
mismatch
recipi
donor
therefor
aim
develop
valid
tool
defin
amino
acid
mismatch
donor
hla
tool
use
defin
immunogen
hla
mismatch
larg
number
recipientdonor
pair
develop
comput
algorithm
contain
hla
amino
acid
aa
sequenc
ipdimgthla
databas
theoret
antibodyverifi
eplet
aa
posit
type
hla
epitop
registri
hla
input
prefer
second
field
type
hla
sequenc
recipi
compar
mismatch
hla
allel
donor
defin
number
aa
mismatch
addit
physiochem
properti
aa
mismatch
defin
correl
dsa
format
detect
luminex
singl
antigen
transplant
defin
immunogen
epitop
tool
approach
epvix
cambridg
aa
mm
score
use
analyz
first
kidney
transplant
recipientdonor
pair
part
ihiw
epitop
compon
compar
result
approach
similar
number
mismatch
observ
hla
class
class
ii
found
increas
number
aa
mismatch
result
higher
probabl
dsa
format
newli
develop
comput
algorithm
use
defin
hla
aa
mismatch
larg
number
recipientdonor
pair
kind
popul
select
optim
donor
kidney
transplant
advantag
tool
hla
allel
includ
rare
allel
analyz
pregnanc
excel
model
studi
antibodi
respons
hla
mismatch
antibodi
induc
patern
allel
unborn
child
time
interv
absenc
immunosuppress
drug
hla
type
mother
child
one
readili
determin
repertoir
mismatch
eplet
studi
done
first
pregnanc
case
immedi
deliveri
serum
test
igmtyp
iggtyp
hla
class
antibodi
evalu
epletassoci
pattern
antibodi
reactiv
analysi
effect
eplet
load
pircheii
number
antibodi
respons
show
gener
correl
often
enough
low
level
statist
signific
find
prompt
new
interpret
role
eplet
load
pircheii
number
studi
also
provid
data
immunogen
mismatch
eplet
determin
consider
differ
frequenc
specif
antibodi
format
inform
eplet
immunogen
could
appli
new
system
eplet
load
mismatch
hla
allel
sinc
implement
luminex
antihla
test
improv
definit
antihla
pattern
clear
howev
sever
caveat
taken
account
fals
posit
neg
result
due
technic
issu
denatur
molecul
crossreact
lack
cutoff
consensu
wide
interand
intraassay
variabl
prozon
effect
interfer
complement
may
appear
sought
improv
definit
antihla
result
luminex
assay
serum
individu
newli
list
kidney
transplant
institut
solid
organ
transplant
patient
follow
posttranspl
within
one
year
test
antihla
antibodi
singl
antigen
sab
screen
one
lambda
acid
treatment
bead
identifi
reaction
denaturedhla
dhla
nativehla
nhla
molecul
complementdepend
cytotox
cdc
flow
cytometri
crossmatch
fcxm
confirm
dhla
nhla
reaction
perform
patient
seven
list
transplant
specif
reaction
screen
neg
sab
posit
result
found
mfi
specif
reaction
significantli
increas
sab
vs
screen
vs
p
acid
treatment
bead
reaction
dhla
identifi
moreov
neg
result
cdc
fcxm
confirm
nonnhla
specif
reaction
perform
sab
nonsensit
patient
wait
list
identifi
reaction
dhla
molecul
without
relev
crossmatch
acid
treatment
bead
allow
identif
dhla
perform
improv
accuraci
antihla
antibodi
assign
solid
organ
transplant
presenc
dsa
confirm
nhla
reaction
asymptomat
patient
luminex
platform
emerg
favor
technolog
detect
hla
antibodi
addit
cdc
crossmatch
xm
still
gold
standard
luminex
dsa
crossmatch
introduc
india
prognost
marker
graft
surviv
detect
antibodi
miss
cdc
xm
antibodi
mediat
reject
amr
still
issu
concern
transplant
tx
patient
cdc
neg
xm
aim
present
studi
evalu
impact
pretranspl
dsa
detect
luminex
crossmatch
clinic
outcom
renal
graft
period
one
year
recipi
underw
renal
transplant
sir
ganga
ram
hospit
pretranspl
sera
renal
tx
recipi
neg
cdc
crossmatch
assess
dsa
luminex
platform
use
lifecod
dsa
kit
immucor
serum
sampl
dsa
hlaclass
ii
mfi
mean
fluoresc
intens
valu
consid
posit
result
correl
clinic
outcom
renal
allograft
dsa
found
recipi
eleven
dsa
posit
patient
three
patient
develop
acut
graft
reject
three
patient
posit
stain
biopsi
mfi
valu
dsa
luminex
platform
found
remain
eight
dsa
posit
patient
show
reject
stabl
graft
function
mfi
valu
dsa
patient
rang
dsa
neg
patient
also
stabl
graft
function
one
year
follow
amr
frequent
dsa
posit
group
less
amr
dsa
neg
group
versu
present
studi
evalu
import
luminex
dsa
crossmatch
test
detect
donor
specif
hla
antibodi
cdc
crossmatch
higher
incid
amr
patient
pretranspl
dsa
despit
neg
cdc
crossmatch
present
studi
clearli
establish
luminex
dsa
crossmatch
help
predict
posttranspl
graft
outcom
reject
dsa
mfi
valu
consid
evalu
singl
bead
assay
sab
luminex
advanc
dna
base
technolog
led
switch
serolog
type
high
resolut
dna
type
method
dna
sequenc
techniqu
assign
antigen
hlab
allel
group
presenc
antibodi
defin
serolog
split
patient
urg
identif
serolog
split
donor
hla
antigen
presenc
donor
specif
antibodi
import
contraind
kidney
transplant
b
allel
without
assign
serolog
type
hla
dictionari
henc
aim
facilit
assign
b
allel
specif
serolog
subtyp
identifi
specif
nucleotid
motif
subtyp
base
singl
nucleotid
polymorph
snp
purpos
obtain
fulllength
sequenc
b
allel
ipdimgthla
databas
extend
genom
sequenc
anoth
allel
group
specif
hemizyg
sanger
sequenc
b
allel
defin
serolog
specif
align
clustal
omega
align
lead
identif
specif
nucleotid
motif
split
antigen
differ
snp
intron
exon
b
allel
predict
power
nucleotid
valid
data
set
b
allel
assign
serolog
type
hla
dictionari
concord
moreov
predict
serolog
subtyp
two
new
b
allel
confirm
serolog
type
panel
b
allel
unknownunidentifi
serolog
specif
predict
b
serolog
equival
allel
reveal
inconclus
nucleotid
pattern
split
identifi
posit
fast
reliabl
method
enabl
predict
serolog
equival
import
case
donor
specif
antibodi
present
prevent
kidney
transplant
reject
human
leukocyt
antigen
hla
match
practic
usabl
heart
lung
transplant
alloc
effect
donorrecipi
hla
match
outcom
remain
rel
unexplor
thorac
transplant
object
studi
investig
effect
donorrecipi
hla
match
graft
surviv
heart
lung
transplant
retrospect
analysi
perform
data
obtain
centro
regional
trapianti
registri
piemont
itali
overal
cohort
heart
lung
transplant
perform
transplant
center
torino
kaplanmei
model
use
assess
influenc
graft
loss
among
hla
match
group
paramet
age
era
transplant
purpos
multivari
cox
regress
analysi
continu
variabl
transplant
year
age
divid
creat
categor
variabl
earli
transplant
era
graft
perform
period
versu
late
transplant
era
addit
analysi
graft
surviv
perform
match
individu
hlaa
b
locu
greater
degre
hla
donorrecipi
match
occur
randomli
thorac
transplant
associ
improv
graft
surviv
especi
earli
era
within
one
year
date
transplant
heart
transplant
earli
era
differ
pharmacokinet
mycophenol
acid
mpa
among
individu
mpa
primarili
metabol
uridin
diphosphateglucuronosyltransferas
ugt
import
ugt
glucuronid
mpa
aim
studi
explain
mpa
pharmacokinet
polymorph
turkish
renal
transplant
patient
patient
renal
transplant
includ
studi
genotyp
perform
use
pcrrflp
concentr
mpa
determin
clone
enzym
donor
immunoassay
cedia
blood
sampl
taken
renal
transplant
patient
take
g
mpa
daili
least
three
month
histori
transplant
patient
monitor
acut
reject
graft
function
studi
period
genotyp
frequenc
among
patient
respect
found
frequenc
heterozyg
homozyg
observ
patient
patient
eight
heterozyg
polymorph
singl
nucleotid
polymorph
hardi
weinberg
equilibrium
one
month
level
mpa
significantli
lower
carrier
carrier
p
ratio
blood
concentr
dose
mpa
daytim
less
genotyp
group
genotyp
group
ratio
significantli
differ
p
also
associ
found
polymorph
acut
reject
p
result
demonstr
correl
polymorph
mpa
pharmacokinet
among
renal
transplant
patient
ugt
polymorph
partli
respons
interindividu
differ
among
renal
transplant
patient
although
patient
accept
mpa
plasma
level
aim
present
studi
investig
role
lymphocytotox
tcell
bcell
crossmatch
xm
result
liver
transplant
outcom
retrospect
cohort
data
obtain
singl
transplant
center
itali
analyz
orthotrop
liver
transplant
consecut
perform
deceas
donor
della
salut
e
della
scienza
di
torino
univers
hospit
whether
posit
crossmatch
relev
liver
graft
outcom
controversi
studi
report
presenc
pretranspl
posit
result
prognost
factor
focu
impact
crossmatch
result
accord
first
retranspl
outcom
especi
earli
followup
within
three
month
crossmatch
prospect
perform
test
andor
b
cell
mainli
recipi
sera
time
transplant
complement
depend
long
incub
cytotox
test
kaplanmei
product
limit
method
cox
regress
analysi
use
assess
graft
surviv
signific
determin
log
rank
test
cox
test
appropri
result
show
statist
signific
impact
graft
surviv
first
transplant
recipi
tbcell
posit
crossmatch
three
month
tcell
neg
xm
tbcell
posit
xm
year
tcell
neg
xm
tbcell
posit
xm
effect
evid
retranspl
outcom
effect
concern
bcell
posit
xm
anti
hla
class
preexist
antibodi
relev
impact
liver
graft
outcom
although
less
extent
respect
solid
organ
transplant
aida
turganbekova
zhando
burkitbaev
saniya
abdrakhmanova
indira
ramilyeva
dana
baimukasheva
zhazira
saduaka
perizat
zhunu
republ
scientif
product
center
transfusiolog
astana
kazakhstan
correspond
draida
mailru
detect
donorspecif
antibodi
dsa
risk
factor
transplant
reject
therefor
earli
diagnosi
dsa
may
affect
result
transplant
engraft
monitor
preexist
antibodi
carri
elisa
method
one
lambda
inc
flow
cytometri
use
luminex
technolog
one
lambda
kit
donor
patient
type
perform
use
pcrssp
method
low
resolut
loci
hlaa
b
prortan
mdp
gmbh
compat
test
transplant
carri
basi
lymphocytotox
test
cdccrossmatch
sampl
neg
posttransplant
monitor
perform
use
singl
antigen
bead
assay
luminex
one
lambda
inc
technolog
posit
result
show
mfi
mean
floresc
intens
monitor
preexist
posttranspl
leukocyt
antibodi
perform
patient
underw
heart
transplant
result
show
patient
preexist
antibodi
seven
patient
antibodi
direct
class
antigen
one
patient
class
ii
antigen
one
patient
high
level
sensit
antigen
class
ii
posttransplant
monitor
show
follow
result
patient
neg
result
five
patient
class
antibodi
two
patient
class
ii
three
patient
antibodi
class
ii
antigen
one
patient
identifi
donorspecif
antibodi
dsa
complet
detect
dsa
class
ii
possibl
due
incomplet
hla
genotyp
donor
low
type
resolut
base
result
studi
govern
consid
possibl
chang
protocol
donor
survey
includ
necessari
type
necessari
loci
high
resolut
subsequ
diagnost
dsa
heighten
sensit
assay
detect
antihla
antibodi
greatli
improv
renal
allograft
outcom
though
reduc
antibodi
mediat
reject
continu
challeng
nonhla
antibodi
antiangiotensin
receptor
antimica
antiendotheli
cell
antibodi
shown
impact
latter
known
induc
viral
infect
india
outbreak
viral
infect
known
occur
season
investig
two
cluster
acut
antibodi
mediat
reject
ten
patient
last
year
studi
perform
aim
test
pretranspl
serum
antiendotheli
cell
antiangiotensin
receptor
antibodi
renal
transplant
last
develop
acut
antibodi
mediat
reject
ten
occur
two
cluster
four
ten
patient
transplant
august
six
transplant
novemb
decemb
control
five
patient
transplant
time
period
reject
patient
control
neg
donor
specif
antihla
antibodi
complement
depend
cytotox
flow
cytometr
crossmatch
luminex
base
singl
antigen
bead
assay
antibodi
angiotensin
receptor
test
use
eia
kit
one
lambda
neg
patient
control
antiendotheli
antibodi
test
use
euroimmun
kit
titer
plane
techniqu
nine
ten
patient
strongli
posit
indic
presenc
antiendotheli
cell
antibodi
one
patient
neg
show
posit
reaction
posttranspl
serum
five
control
neg
borderlin
posit
one
strongli
posit
data
though
limit
small
patient
number
suggest
tropic
develop
countri
like
india
antiendotheli
antibodi
consid
possibl
culprit
cluster
unexplain
acut
antibodi
mediat
renal
transplant
reject
whether
etiolog
viral
need
investig
specif
nonhla
antibodi
direct
angiotensin
ii
type
receptor
type
receptor
antietar
vascular
cell
respons
antibodi
mediat
reject
absenc
donor
specif
antihla
antibodi
aim
determin
presenc
nonhla
antibodi
pretranspl
posttranspl
sera
particip
acut
humor
reject
relat
donor
specif
antihla
antibodi
presenc
antietar
antibodi
evalu
store
serum
sampl
consecut
recipi
kidney
pretranspl
first
month
posttransplant
studi
antibodi
evalu
elisa
concentr
larger
uml
antietar
consid
posit
determin
presenc
hla
antibodi
includ
studi
routin
perform
luminex
technolog
level
nonhla
antibodi
andor
antietar
posit
studi
patient
perform
test
posit
patient
antibodi
antietar
total
patient
presenc
nonhla
antibodi
pretranspl
sera
averag
level
posit
nonhla
antibodi
found
equal
uml
antietar
uml
latter
equal
uml
antietar
uml
posttranspl
sera
graft
loss
mediat
acut
humor
reject
first
year
posttransplant
detect
eight
patient
posit
result
nonhla
antibodi
although
four
show
donor
specif
antihla
antibodi
chronic
humor
reject
found
one
patient
acut
cellular
reject
anoth
patient
presenc
detect
two
mention
posit
patient
high
correl
level
nonhla
antibodi
reduc
kidney
function
first
month
transplant
found
especi
presenc
donor
specif
antihla
antibodi
antietar
antibodi
use
evalu
risk
allograft
loss
uromodulin
umod
urinari
protein
secret
epitheli
cell
thick
ascend
limb
henl
loop
play
critic
role
prevent
urinari
tract
infect
mainten
osmot
pressur
electrolyt
homeostasi
umod
usual
precipit
urinari
tract
due
acid
ph
make
measur
urin
sampl
challeng
although
concentr
plasma
lower
elisa
assay
guarante
precis
estim
umod
concentr
correl
well
renal
function
work
correl
umod
serum
level
singl
nucleotid
polymorph
snp
locat
promot
region
gene
lead
g
substitut
cohort
cadaver
kidney
donor
cohort
allel
frequenc
g
allel
line
report
literatur
result
indic
gg
carrier
mean
umod
plasmat
level
ngml
umod
level
gt
carrier
ngml
tt
ngml
result
indic
dose
depend
relationship
presenc
g
allel
umod
serum
level
furthermor
recipi
gt
kidney
character
shorter
graft
surviv
compar
gg
followup
year
specif
one
year
surviv
gg
graft
compar
gt
year
surviv
gg
vs
gt
graft
recipi
tt
homozyg
kidney
exclud
analysi
low
number
result
show
influenc
plasmat
urinari
umod
level
potenti
identifi
heterozyg
graft
less
perform
subset
kidney
lead
long
run
decreas
graft
surviv
conclus
work
confirm
dosedepend
relationship
presenc
allel
lower
umod
serum
level
turn
associ
reduc
kidney
function
studi
tell
whether
ad
serum
umod
test
perform
evalu
kidney
donor
may
add
pretranspl
diagnost
power
antibodymedi
reject
abmr
common
caus
kidney
allograft
failur
renal
transplant
recipi
preexist
donorspecif
antibodi
dsa
patient
develop
de
novo
dsa
transplant
risk
abmr
therefor
hla
antibodi
monitor
transplant
well
may
help
identifi
patient
risk
graft
loss
hla
antibodi
screen
kidney
transplant
routin
test
day
transplant
one
month
decemb
start
perform
posttransplant
monitor
hla
antibodi
month
retrospect
analysi
includ
hla
antibodi
screen
result
patient
transplant
decemb
februari
patient
sera
test
cdc
luminex
immucor
techniqu
transplant
patient
neg
six
cdc
andor
lum
posit
among
neg
patient
remain
neg
four
becam
posit
transplant
one
patient
class
ii
dsa
detect
three
month
transplant
nine
month
later
graft
loss
anoth
patient
class
ii
nondsa
detect
six
month
transplant
without
sign
graft
dysfunct
class
iii
nondsa
detect
two
patient
month
transplant
associ
transitori
graft
dysfunct
among
pretranspl
immun
patient
one
develop
class
ii
dsa
three
month
transplant
along
graft
dysfunct
adjust
immunosuppress
therapi
success
result
suggest
develop
de
novo
dsa
nondsa
may
detriment
effect
graft
function
kidney
transplant
reliabl
conclus
posttransl
monitor
need
continu
includ
larger
number
patient
angeliki
g
vittoraki
maria
darema
dimitra
skoumi
maria
apostolaki
ioanni
boko
alexandra
siorenta
georgio
zavvo
john
n
boleti
aliki
g
iniotaki
immunolog
depart
nation
tissu
type
center
gener
hospit
athen
g
gennimata
athen
greec
transplant
unit
laikon
hospit
athen
greec
correspond
yahoocom
antihla
donor
specif
antibodi
dsa
abo
incompat
aboi
major
immunolog
barrier
success
kidney
transplant
pair
kidney
donat
pkd
program
enabl
kidney
transplant
candid
incompat
live
donor
join
registri
incompat
pair
order
find
suitabl
donor
pkd
program
greec
start
laikon
transplant
unit
support
nation
tissu
type
center
present
result
first
four
transplant
total
patient
either
one
two
live
donor
regist
program
patient
donor
type
hlaa
b
c
pcrsso
antihla
antibodi
defin
luminex
singl
antigen
bead
analysi
one
lambda
nine
patient
preform
dsa
hlai
posit
actual
cdc
andor
tb
flow
crossmatch
six
patient
aboi
intend
donor
pair
record
excelbas
databas
compar
pairwis
allversusal
fashion
accord
abo
compat
absenc
dsa
four
pair
identifi
match
hlai
aboi
twoway
exchang
program
one
two
hlai
patient
highli
sensit
cdc
tb
flow
crossmatch
select
pair
neg
twoway
exchang
transplant
perform
day
consequ
without
undesir
event
one
recipi
day
transplant
experienc
acut
cellular
reject
episod
accord
banff
classif
success
treat
corticosteroid
six
month
posttransplant
four
recipi
serum
creatinin
mgdl
respect
donor
normal
renal
function
result
confirm
kpd
program
help
overcom
immunolog
barrier
renal
transplant
increas
access
transplant
especi
hla
sensit
patient
incorpor
nation
transplant
program
nephrologist
reli
mfi
iggtyp
donor
specif
antibodi
dsa
identif
test
assess
risk
graft
loss
humor
reject
howev
heterogen
pathogen
follow
first
dsa
research
studi
renal
transplant
patient
patient
humor
reject
biopsi
banff
score
g
cpt
g
cpt
patient
without
reject
dsa
includ
genprob
test
measur
abil
dsa
fix
biopsi
day
serum
humor
reject
group
dsa
identifi
patient
seven
class
class
ii
mostli
antihladq
univari
analysi
dfg
time
renal
biopsi
found
invers
associ
graft
loss
p
presenc
dsa
fix
p
number
dsa
fix
p
mfi
strongest
dsa
p
sum
mfi
dsa
fix
p
found
posit
associ
graft
loss
signific
associ
found
presenc
dsa
strongest
dsa
mfi
sum
dsa
mfi
number
dsa
graft
loss
either
genprob
ingen
igg
assay
banff
cg
score
found
posit
correl
graft
loss
p
score
found
significantli
associ
graft
loss
close
threshold
p
multivari
analysi
gfr
time
biopsi
identifi
independ
risk
factor
graft
loss
p
subgroup
patient
genprob
dsa
acut
reject
cg
equal
score
multivari
analysi
gfr
time
biopsi
presenc
dsa
found
risk
independ
graft
loss
p
p
good
correl
genprob
mfi
result
r
agreement
two
test
good
icc
ci
test
would
provid
addit
prognost
inform
singl
antigen
igg
type
test
would
combin
dfg
time
diagnosi
acut
previou
gene
express
microarray
studi
preimplant
biopsi
pib
kidney
deceas
donor
genechip
human
gene
st
array
affymetrix
geo
access
number
show
higher
express
hla
class
ii
gene
case
present
poor
egfr
graft
function
gf
posttx
present
studi
aim
investig
relationship
express
pib
gf
b
valid
differ
cohort
realtim
pcr
rtpcr
associ
high
express
pib
poor
gf
c
investig
relationship
snp
allel
express
pib
investig
relationship
presenc
donor
high
express
allel
g
gf
tx
one
two
mismatch
mm
rtpcr
perform
taqman
assay
appli
biosystem
type
done
pcrsso
one
lambda
allel
determin
taqman
assay
high
express
pib
microarray
studi
associ
poor
gf
p
associ
high
express
pib
poor
gf
confirm
differ
cohort
case
poor
case
good
gf
p
pib
donor
homozyg
high
express
snp
allel
present
higher
express
level
compar
pib
donor
homozyg
low
express
allel
p
signific
differ
observ
proport
case
poor
gf
transplant
high
low
express
allel
mm
antigen
associ
increas
express
pib
poor
graft
function
despit
associ
allel
high
express
pib
presenc
allel
mismatch
allel
associ
poor
gf
mean
fluoresc
intens
mfi
valu
luminexbas
hla
antibodi
assay
use
determin
rel
strength
hla
antibodi
howev
mfi
valu
inaccur
especi
patient
serum
contain
heterophil
antibodi
present
normal
blood
donor
heterophil
antibodi
shown
caus
falseposit
result
luminexbas
immunoassay
use
anim
protein
bovin
serum
albumin
casein
block
reactiv
site
bead
howev
protein
provid
potenti
sourc
assay
interfer
falseposit
result
result
heterophil
antibodi
bind
aim
studi
determin
whether
fetal
bovin
serum
fb
would
effect
reliabl
way
reduc
heterophil
antibodi
interfer
luminexbas
hla
antibodi
assay
toward
test
select
sera
contain
heterophil
antibodi
mean
labscreen
singl
antigen
assay
one
lambda
inc
sera
pretreat
fb
normal
human
serum
nh
mfi
valu
compar
one
untreat
sampl
addit
sampl
without
heterophil
antibodi
contain
welldefin
hla
antibodi
profil
also
pretreat
fb
mfi
valu
compar
one
untreat
sampl
show
herein
pretreat
fb
elimin
heterophil
antibodi
interfer
mfi
sever
hla
class
hla
class
ii
specif
contrari
nh
show
effect
heterophil
antibodi
interfer
sampl
moreov
fb
effect
hla
antibodi
profil
sera
display
welldefin
hla
antibodi
specif
result
studi
indic
fbstreatment
costeffect
simpl
procedur
elimin
heterophil
antibodi
interfer
luminexbas
hla
antibodi
assay
interfer
lead
signific
disadvantag
select
patient
display
heterophil
antibodi
interfer
serum
pretreat
fb
would
prevent
patient
inappropri
exclud
receiv
organ
due
falseposit
virtual
crossmatch
result
aim
studi
distribut
killer
cell
immunoglobulinlik
receptor
kir
nk
cell
human
leukocyt
antigen
hla
match
unrel
donorrecipi
pair
receiv
hematopoiet
stem
cell
transplant
hsct
sequencedbas
type
sbt
use
type
hla
genotyp
donorrecipi
pair
sequencespecificprim
polymeras
chain
reaction
ssppcr
select
kir
type
hlamatch
unrel
donorrecipi
pair
kir
genotyp
found
hlamatch
unrel
donorrecipi
pair
distribut
frequenc
genotyp
show
signific
differ
donor
recipi
kir
haplotyp
distribut
frequenc
aa
ab
bb
respect
eleven
case
kirhla
mismatch
identifi
account
signific
differ
distribut
frequenc
kir
gene
donor
recipi
found
hlamatch
unrel
donorrecipi
pair
rate
kirhla
mismatch
low
loss
heterozygos
loh
caus
erron
homozygos
human
leukocyt
antigen
hla
type
pretranspl
patient
hematolog
malign
woman
diagnos
stage
iv
lung
cancer
april
thu
receiv
concurr
chemoradiotherapi
lobectomi
surgeri
peripher
blood
blastosi
discov
regular
followup
care
may
refer
hematolog
depart
nation
taiwan
univers
hospit
bone
marrow
bm
studi
patient
diagnos
acut
myelomonocyt
leukemia
express
cytoplasm
mpo
cytogenet
studi
reveal
normal
karyotyp
mutant
gene
detect
level
peripher
blast
cell
hla
sequencebas
type
sbt
reveal
homozygos
three
hla
class
loci
heterozygos
loci
receiv
chemotherapi
hla
type
reconfirm
blood
leukocyt
count
kul
neutrophil
blast
mutant
level
bm
homozygos
hla
class
loci
still
report
howev
hla
type
result
parent
indic
inde
lost
matern
allel
hlaa
b
c
loci
use
hla
sbt
group
specif
primer
matern
allel
final
demonstr
patient
heterozygos
hla
class
loci
case
matern
allel
hla
class
loci
detect
blood
sampl
high
realli
low
blast
cell
suggest
loh
affect
leukocyt
includ
blast
neutrophil
erron
homozygos
result
due
loh
would
caus
erron
histocompat
could
result
fatal
consequ
hla
laboratori
awar
hla
homozygos
result
patient
undergo
hematopoiet
stem
cell
transplant
homozygos
hla
loci
report
proven
famili
studi
rayna
ivanova
derin
pascal
loiseau
kahina
amokran
sophi
caillat
zucman
aphp
saint
loui
pari
franc
correspond
raynaivanovaderin
aphpfr
import
grow
activ
hla
type
dna
extract
respect
sampl
day
introduc
autom
dna
purif
use
qiasymphoni
system
dna
midi
kit
qiagen
qualiti
valid
studi
found
two
minor
problem
extract
dna
spectrophotometr
analysi
show
deviat
ratio
measur
suggest
organ
salt
solvent
contamin
acceler
age
test
accord
biomatrica
protocol
show
dna
degrad
import
compar
purif
method
fujifilm
dna
purif
system
labturbo
compact
system
problem
later
solv
qiagen
observ
effect
differ
pcrbase
hla
type
techniqu
use
laboratori
pcrssp
pcrsso
howev
consequ
dna
degrad
longterm
storag
remain
open
issu
moreov
sinc
store
dna
sampl
per
manufactur
instruct
regular
qualiti
control
requir
end
test
nine
dna
sampl
extract
store
check
qualiti
integr
use
sever
criteria
monitor
dna
degrad
agaros
gel
electrophoresi
pcrbase
hla
type
pcrsso
luminex
technolog
acceler
age
result
compar
use
dna
sampl
extract
quickgen
system
fujifilm
observ
dna
degrad
agaros
gel
electrophoresi
impact
pcrbase
amplif
hla
type
dna
purif
method
differ
observ
lower
acceler
age
use
fujifilm
dna
extract
conclus
qualiti
dna
sampl
extract
fulli
autom
qiasymphoni
purif
system
remain
correct
year
storag
affect
dna
integr
stabil
repeat
studi
requir
next
year
monitor
dna
qualiti
time
acut
graftversushost
diseas
agvhd
lead
caus
morbid
transplantrel
mortal
postallogen
hematopoiet
stem
cell
transplant
ahsct
sever
inflammatori
complic
involv
tcell
activ
play
crucial
role
pathogenesi
modul
immun
system
play
import
role
regul
inflammatori
innat
immun
respons
import
neg
regul
cell
nuclear
factor
kappa
beta
nfkb
transcript
factor
inflammatori
process
regul
express
turn
regul
nfkb
activ
neg
feedback
loop
involv
adapt
molecul
dysregul
nfkb
activ
associ
inflammatori
disord
autoimmun
diseas
present
studi
analyz
potenti
associ
polymorph
g
c
insdel
attg
risk
agvhd
genotyp
polymorph
perform
hlamatch
relat
donor
use
polymeras
chain
reactionrestrict
fragment
length
polymorph
pcrrflp
patient
receiv
myeloabl
condit
regimen
busulfan
cyclophosphamid
cyclosporin
methotrex
gvhd
prophylaxi
incid
agvhd
grade
iiiv
whole
cohort
find
signific
associ
nfkb
polymorph
agvhd
p
combin
genotyp
analysi
gene
show
signific
associ
agvhd
p
preliminari
data
support
associ
molecul
agvhd
research
need
outlin
possibl
mechan
nfkb
underli
inflammatori
reaction
agvhd
includ
studi
larger
cohort
inclus
molecul
involv
pathway
combin
immunodefici
due
dedic
cytokinesi
protein
defici
form
b
cell
immunodefici
character
recurr
cutan
sinopulmonari
viral
infect
suscept
cancer
laboratori
find
includ
elev
ige
level
serum
eosinophilia
cell
lymphopenia
reduc
cell
function
report
patient
also
nk
b
cell
lymphopenia
igg
level
may
elev
specif
antibodi
respons
impair
igm
iga
level
may
reduc
immunodefici
syndrom
refer
autosom
recess
hyper
ige
syndrom
arhi
consid
rare
form
hie
therefor
present
three
case
immunodefici
syndrom
receiv
hlaident
sibl
donor
bone
marrow
transplant
bmt
first
year
second
year
case
sibl
parent
first
cousin
three
case
recurr
pulmonari
infect
erythemat
eczemat
rash
whole
bodi
hepatosplenomegali
furthermor
first
case
bilater
chronic
supur
otiti
mass
left
auricular
third
femal
patient
year
also
clitor
veget
mass
immunolog
investig
three
case
reveal
mean
absolut
neutrophil
count
mm
mean
absolut
lymphocyt
count
mean
absolut
eosinophil
count
mean
igg
level
mgdl
iga
level
mgdl
igm
level
mgdl
ige
level
iuml
lymphocyt
subset
case
analyz
use
flow
cytometri
determin
percentag
cd
posit
cell
patient
abnorm
low
count
absolut
count
therapeut
measur
includ
antivir
antibacteri
prophylaxi
immunoglobulin
replac
allogen
bmt
auricular
clitor
mass
abmt
regress
spontan
followup
clinic
conclud
earli
bmt
strongli
consid
potenti
cur
therapi
immunodefici
syndrom
describ
case
male
patient
hematolog
malign
transplant
peripher
blood
stem
cell
femal
donor
laboratori
posttranspl
chimer
monitor
short
tandem
repeat
str
analysi
use
powerplex
fusion
kit
loci
amelogenin
promega
occasion
identifili
kit
loci
amelogenin
life
thecnolog
pretranspl
patient
studi
identifi
absenc
ame
allel
three
dna
patient
sampl
collect
three
differ
pretranspl
period
two
extract
peripher
blood
one
buccal
cell
ame
loss
absenc
femal
donor
make
locu
inform
chimer
quantit
extend
studi
chromosom
method
cytogenet
chromosom
microdelet
analysi
b
c
region
str
powerplex
system
promega
coamplif
malespecif
str
loci
cytogenet
analysi
show
normal
xy
karyotyp
mitos
fluoresc
pcr
devys
kit
demonstr
absenc
azfa
azfb
azfc
microdelet
powerplex
analysi
evidenc
delet
follow
marker
marker
lie
short
arm
chromosom
analyz
marker
examin
differ
method
observ
larg
delet
span
least
mb
region
nearest
marker
conserv
telomer
centromer
respect
delet
studi
allow
us
obtain
inform
delet
local
chromosom
work
highlight
import
use
differ
avail
method
collabor
extern
laboratori
order
solv
difficult
case
mani
solid
tumor
character
loss
decreas
express
hla
antigen
surfac
tumor
cell
due
complet
partial
delet
hla
gene
one
chromosom
lymphoprolif
diseas
chang
hla
antigen
express
less
common
man
diagnos
ptclno
stage
iv
involv
lymph
node
spleen
bone
marrow
leukem
attend
nation
research
center
hematolog
moscow
two
cours
induct
chemotherapi
partial
respons
achiev
size
lymph
node
decreas
howev
persist
residu
tumor
clone
peripher
blood
bone
marrow
note
therefor
transplant
allogen
hematopoiet
cell
suggest
firstlin
therapi
regimen
search
match
unrel
donor
initi
haplotypespecif
sequenc
hla
gene
dna
obtain
patient
blood
cell
reveal
heterogen
ct
posit
codon
hlaa
allel
exon
chromatogram
second
allel
hlaa
clearli
homogen
thu
obtain
data
indic
presenc
allel
hlaa
locu
patient
g
dna
sequenc
anoth
blood
sampl
two
homogen
chromatogram
allel
obtain
addit
analysi
hlaa
gene
dna
obtain
patient
lymph
node
biopsi
perform
result
unambigu
answer
present
case
third
addit
hlaa
allel
identifi
probabl
result
mutat
tumor
cell
nucleotid
replac
c
indic
posit
result
format
stop
codon
loss
express
hlaa
gene
tumor
cell
due
possibl
influenc
tumor
clone
result
hla
type
care
taken
perform
hlatyp
tumorfre
sampl
human
major
histocompat
complex
mhc
lie
within
short
arm
chromosom
respons
product
human
leukocyt
antigen
hla
hla
gene
polymorph
gene
human
genom
encod
allel
variant
laboratori
involv
hla
tissu
type
patient
rel
volunt
donor
italian
bone
marrow
regist
dna
extract
edta
blood
sampl
use
autom
system
maxwel
promega
pcrsbt
perform
use
sbtexceller
gendx
protran
hlab
hlab
high
resolut
type
rel
potenti
donor
found
sequenc
larg
homolog
b
mutat
posit
c
instead
g
mutat
result
code
chang
arginin
prolin
exon
codon
cgc
ccc
repeat
sequenc
isol
second
allel
analyz
sbtengin
could
nt
studi
parent
due
unavail
describ
mutat
uniqu
observ
hlaa
b
c
allel
hlab
allel
submit
nomenclatur
committe
via
ipdimgthla
databas
name
assign
offici
name
b
consid
sequencebas
type
direct
good
method
rapid
new
allel
definit
highresolut
hla
match
reduc
graftversushost
diseas
improv
overal
patient
surviv
hematopoiet
stem
cell
transplant
sanger
sequenc
gold
standard
highresolut
hla
type
sinc
nextgener
sequenc
develop
laboratori
use
luminex
methodolog
hla
type
patient
donor
sequenc
studi
requir
sampl
sent
laboratori
abroad
therefor
implement
next
gener
sequenc
hla
type
urgent
need
countri
aim
implement
clinic
hlang
type
valid
protocol
clinic
use
lab
perform
hlang
type
sampl
librari
prepar
illumina
trusight
hla
sequenc
panel
sequenc
miseq
system
result
analyz
assign
softwar
first
ran
four
batch
six
sampl
three
sampl
ucla
exchang
remain
one
patient
previous
type
luminex
lab
valid
procedur
test
panel
intern
hla
immunogenet
workshop
identifi
two
new
allel
two
sampl
patient
silent
substitut
exon
two
b
locu
ii
nonsynonym
substitut
exon
two
locu
five
sampl
allel
observ
consist
intermedi
resolut
type
among
less
expect
one
accord
frequenc
distribut
allel
caucasian
databas
ambigu
result
common
locu
accord
limit
methodolog
studi
confirm
ng
highli
accur
fast
method
perform
highresolut
hla
type
sinc
low
ambigu
level
found
signific
decreas
turnaround
time
could
achiev
pricai
first
lab
argentina
introduc
method
confirm
match
bone
marrow
transplant
patient
work
done
soon
establish
local
hla
frequenc
allel
level
report
year
old
male
patient
sickl
diseas
frequent
pain
attack
multipl
hospit
admiss
histori
stroke
priapism
acut
chest
syndrom
patient
receiv
multipl
transfus
hemoglobin
baselin
gdl
low
mcv
fl
high
rdw
blood
film
show
microcyt
hypochrom
pictur
notabl
presenc
sickl
cell
hemoglobin
electrophoresi
show
low
fhb
shb
patient
offer
relat
allogen
bmt
possibl
treatment
patient
hla
type
class
ii
perform
use
one
lambda
sequenc
specif
oligonucleotid
probe
sequenc
specif
primer
ssorssp
six
famili
member
hla
type
class
ii
perform
includ
parent
possibl
donor
parent
cousin
result
base
haplotyp
illustr
follow
patient
b
c
father
b
c
mother
b
c
brother
b
c
b
c
b
c
b
c
test
confirm
repeat
test
new
sampl
possibl
sampl
error
exclud
investig
famili
studi
analysi
show
cross
region
patern
locu
patient
show
instead
expect
possibl
rare
cross
must
consid
interpret
unexpect
hla
result
famili
work
bmt
illustr
hla
haplotyp
signific
similar
hla
type
class
ii
parent
explain
presenc
singl
mismatch
class
patient
hematopoiet
stem
cell
transplant
hsct
best
therapi
hematolog
malign
acut
leukemia
although
graft
versusleukemia
gvl
import
approach
prevent
relaps
could
associ
sever
graft
versu
host
diseas
gvhd
similar
cell
nk
cell
may
facilit
engraft
combat
infect
control
malign
cell
caus
gvhd
kir
famili
inhibitoryactiv
receptor
express
mainli
nk
cell
bind
hla
ligand
high
variabl
kir
care
select
donor
base
hla
kir
essenti
optim
hsct
outcom
sinc
donor
kir
potenti
encount
nonselfrecipi
hla
class
epitop
studi
design
find
impact
kirhla
combin
outcom
hsct
patient
acut
leukemia
march
march
total
patient
acut
leukemia
receiv
hsc
follow
one
year
chimer
analysi
day
hsct
period
patient
exclud
analysi
due
death
gvhd
gvl
kir
genotyp
donor
correspond
ligand
recipi
also
investig
aliv
patient
receiv
hlaa
b
hsc
sibl
three
patient
receiv
hsc
opposit
sex
four
patient
aboincompat
one
patient
rhincompat
donor
chimer
observ
none
recipi
studi
time
point
hsct
patient
aliv
least
first
year
posthsct
donor
kirb
haplotyp
five
carri
seven
patient
three
patient
four
patient
result
show
hsct
donor
kirb
haplotyp
bear
recipi
associ
better
outcom
first
year
transplant
obscur
point
clear
analysi
chimer
kirhla
combin
sampl
expir
patient
aplast
anemia
aa
autoimmun
bone
marrow
failur
syndrom
close
link
clonal
hematopoiesi
mechan
allow
hematopoiet
stem
cell
escap
recognit
cytotox
lymphocyt
give
advantag
diseas
progress
identif
specif
clonal
chang
loss
human
leukocyt
antigen
allel
help
diagnosi
bone
marrow
failur
sometim
predict
respons
immunosuppress
therapi
old
male
previous
diagnos
aa
refer
clinic
relaps
two
previou
cours
atgam
unrel
donor
search
initi
howev
third
block
immunosuppress
therapi
achiev
remiss
hsct
postpon
cytogenet
analysi
normal
hlatyp
sbt
indic
patient
homozyg
hla
class
allel
hlaa
b
cw
second
retyp
ng
hla
loci
trusight
hla
sequenc
panel
illumina
reveal
match
allel
hlaa
hlab
heterozyg
result
hlac
second
rare
allel
detail
review
data
show
presenc
secondari
hla
allel
hlaa
b
c
depth
coverag
case
show
loss
heterozygos
lead
incorrect
type
result
homozyg
result
patient
aa
confirm
type
buccal
swab
famili
member
use
type
method
possibl
olga
shragina
viktoria
zakharova
elena
raykina
michael
maschan
alexei
maschan
dmitri
rogachev
nation
research
center
pediatr
hematolog
oncolog
immunolog
moscow
russian
feder
correspond
olgashragina
mailru
correct
hlatyp
result
patient
donor
first
necessari
step
way
success
hematopoiet
stem
cell
transplant
even
differ
one
nucleotid
caus
locu
mismatch
donorpati
pair
induc
wors
outcom
overal
surviv
treatmentrel
mortal
acut
gvhd
huge
allel
multipl
character
gene
hla
complex
pose
seriou
problem
routin
genotyp
loci
recent
genotyp
hla
carri
use
variou
method
base
pcr
ssp
sequencespecif
primer
ssop
sequencespecif
oligonucleotid
probe
sbt
sanger
sequencebas
type
method
allow
determin
chromosomalphas
assess
sequenc
featur
result
consider
ambigu
regard
hla
genotyp
hla
type
method
base
next
gener
sequenc
ng
allow
amplif
full
gene
includ
exon
intron
minim
number
ambigu
result
increas
amount
sequenc
read
per
sampl
locu
allow
studi
larg
number
sampl
simultan
significantli
reduc
per
sampl
cost
type
sinc
implement
hlatyp
ng
hlaa
b
c
test
perform
patient
potenti
relat
donor
miseq
illumina
platform
ngsgo
gendx
ngsengin
gendx
softwar
even
small
number
sampl
novel
allel
c
c
c
detect
novel
allel
detect
addit
studi
requir
sequenc
nucleotid
easili
unload
analysi
program
rapid
progress
ng
technolog
result
signific
chang
medic
genom
method
enabl
us
acceler
polymorph
discoveri
expand
number
known
allel
improv
understand
allel
divers
human
leukocyt
antigen
hla
play
import
role
immun
respons
determin
outcom
transplant
allelelevel
hla
match
donor
recipi
reduc
likelihood
reject
graftversushost
diseas
hla
gene
character
diversifi
polymorph
affect
specif
antigen
present
histocompat
transplant
recent
year
nextgener
sequenc
ng
technolog
allow
us
provid
highest
possibl
resolut
ng
method
base
tradit
pcr
target
region
follow
massiv
parallel
sequenc
amplicon
howev
ampliconbas
method
labori
requir
extens
optim
step
aim
studi
determin
hla
loci
hlaa
b
c
use
alltyp
ng
amplif
kit
one
lambda
dna
sampl
isol
peripher
blood
obtain
bone
morrow
donor
use
chemag
prepito
instrument
type
hla
loci
perform
accord
hla
assay
manual
use
miseq
illumina
platform
raw
sequenc
data
assembl
analyz
typestream
visual
ng
analysi
softwar
studi
new
assay
allow
singl
tube
amplif
hla
loci
complet
remov
need
amplicon
pool
besid
sampl
transfer
directli
librari
prepar
made
readi
sequenc
singl
workday
addit
also
confirm
advantag
ng
use
new
alltyp
kit
possibl
obtain
unambigu
highresolut
genotyp
result
within
two
day
antihla
immun
correl
risk
graft
failur
allohsct
strongli
recommend
screen
recipi
antidsa
especi
hla
mismatch
haploident
famili
donor
object
analyz
incid
antihla
ab
dsa
sera
recipi
candid
allohsct
hospit
donostia
transplant
unit
allohsct
perform
hla
ident
donor
match
unrel
donor
ud
hsct
ud
haplo
hsct
carri
hlaa
b
c
type
screen
hla
specif
ab
luminex
platform
cdc
cytometri
crossmatch
perform
posit
case
result
studi
ud
mismatch
hsct
patient
present
posit
antihla
ab
antib
respect
mfi
none
dsa
haploident
hcst
recipi
posit
result
hla
ab
one
patient
dsa
neg
four
posit
dsa
haploident
donor
candid
hlac
allel
mfi
crossmatch
could
perform
two
dsa
posit
case
one
cytometri
crossmatch
posit
lymphocyt
b
accord
anticlass
ii
dsa
found
accord
recommend
allohsct
haplohsct
protocol
donor
hla
specif
target
posit
dsa
mfi
recipi
exclud
case
altern
donor
found
although
posit
dsa
case
found
incid
antihla
dsa
found
similar
report
studi
patient
screen
antihla
ab
enter
hsct
program
order
inform
sensit
statu
recipi
sever
donor
option
propos
sequenc
base
type
sbt
consid
gold
standard
high
resolut
hla
genotyp
howev
like
hla
type
technolog
certain
limit
next
gener
sequenc
ng
new
method
clinic
research
laboratori
implement
routin
practic
worldwid
introduct
ng
gendx
omixon
laboratori
led
detect
novel
polymorph
hlac
locu
patient
indic
stem
cell
transplant
straight
begin
test
method
valid
select
sampl
includ
rare
allel
one
hlac
combin
c
origin
type
perform
sbt
pcrssp
use
ng
due
separ
allel
sequenc
discov
correct
type
c
novel
allel
c
whole
hlac
gene
sequenc
reveal
mismatch
exon
exon
compar
c
patient
hlamatch
sibl
fulli
match
unrel
donor
found
registri
worldwid
therefor
two
unrel
donor
c
one
mismatch
locu
chosen
confirmatori
type
transplant
donor
mm
success
besid
slight
complic
one
month
hsct
ng
techniqu
place
hla
laboratori
number
differ
hla
allel
continu
increas
demand
nonambigu
type
distinguish
exist
novel
allel
challeng
ng
deliv
way
unambigu
type
whole
hla
gene
allel
separ
high
accuraci
improv
proper
hsct
donor
select
maria
paola
albergoni
daniela
bovo
aurora
strano
roberta
favero
genni
franceschetto
giustina
de
silvestro
roberta
destro
uoc
immunotrasfusional
dimt
padova
azienda
ospedaliera
di
padova
padova
itali
oncoematologia
pediatrica
padova
cord
blood
bank
azienda
ospedaliera
di
padova
padova
itali
correspond
danielabovo
aopdvenetoit
stem
cell
transplant
unrel
cord
blood
cb
unit
treatment
patient
suffer
hematolog
diseas
develop
consider
decad
recent
prefer
choic
haploident
transplant
determin
consist
decreas
cb
use
world
rate
cb
unit
ship
transplant
italian
cord
blood
network
decreas
dramat
nevertheless
mani
transplant
center
tc
still
use
cb
prefer
sourc
stem
cell
hematopoiet
stem
cell
transplant
particular
patient
lack
match
sibl
unrel
donor
andor
requir
urgent
hpc
transplant
fact
one
advantag
use
cb
rapid
procur
padova
cord
blood
bank
pdcbb
forward
differ
tc
cb
unit
report
averag
less
one
day
transplant
center
request
case
hla
laboratori
provid
high
resolut
hr
hla
type
result
one
loci
averag
day
select
procur
issu
accord
tc
shipment
time
requir
minimum
time
three
day
tc
request
hla
confirm
type
took
averag
time
day
rang
data
show
urgent
procur
shipment
less
day
tc
request
increas
issu
cb
unit
type
hla
hr
level
time
first
report
request
support
choic
perform
hr
hla
type
hlaa
b
c
dr
cb
unit
sinc
yet
mandatori
cord
blood
bank
italian
cord
blood
network
addit
bank
cb
higher
tnc
result
cbb
alway
rank
first
posit
cb
releas
rate
releas
unitsbank
unit
prompt
repli
tc
avail
quick
hla
type
result
crucial
element
cb
bank
hla
laboratori
need
activ
involv
strategi
polici
cbb
activ
pdcbb
hla
laboratori
plan
perform
hr
hla
type
remain
cb
unit
higher
tnc
bank
time
need
identifi
unrel
donor
critic
treatment
patient
malign
diseas
hematopoiet
stem
cell
transplant
hsct
aim
studi
compar
time
requir
turkish
patient
receiv
transplant
unrel
donor
turkish
versu
intern
registri
end
retrospect
analyz
data
patient
receiv
unrel
donor
hsct
istanbul
medic
faculti
bone
marrow
bank
tri
delay
defer
transplant
due
bureaucrat
procedur
worsen
clinic
condit
patient
start
donor
search
exclud
analysi
remain
transplant
donor
intern
registri
nation
stem
cell
coordin
center
turkey
turkok
mean
time
donor
search
start
transplant
day
day
intern
donor
day
day
intern
turkish
donor
respect
least
part
due
shorter
time
confirmatori
type
mean
day
day
intern
donor
day
turkish
donor
turkok
establish
year
ago
data
show
work
effici
reduc
donor
search
time
turkish
patient
chimer
key
analysi
monitor
post
hematopoiet
stem
cell
transplant
hsct
chimer
perform
sort
cell
efi
standard
recommend
document
puriti
sort
cell
popul
current
refer
method
analyz
puriti
sort
flow
cytometri
fcm
method
rel
expens
requir
special
laboratori
context
new
nont
genom
kit
accumol
calgari
ab
canada
base
quantif
realtim
pcr
genom
rearrang
tcr
gene
undergon
cell
differenti
seem
interest
nont
genom
kit
method
assess
via
rang
sampl
initi
purifi
easysep
human
whole
blood
posit
select
kit
stemcel
technolog
comparison
fcm
assay
use
cytostat
tetrachrom
kit
beckman
coulter
puriti
cell
sort
estim
calcul
ratio
height
two
peak
nont
peak
ultraconserv
sequenc
peak
obtain
dissoci
curv
amplif
contamin
rate
determin
recipi
lymphopenia
lymphocytosi
detect
nont
cell
contamin
nont
genom
qpcr
kit
correl
fcm
equat
r
method
repeat
reproduc
cv
less
entir
rang
cell
contamin
except
purifi
sampl
detect
limit
dissoci
curv
capabl
accur
detect
nont
cell
contamin
patient
sampl
seri
show
purif
reliabl
cell
total
lymphocyt
ratio
hand
qpcr
nont
genom
kit
effici
tool
allow
accur
assess
contamin
level
sort
cell
sampl
routin
use
help
meet
efi
requir
improv
followup
hsct
recipi
cost
equival
fcm
salli
elfishawi
raafat
abdel
fattah
nation
cancer
institut
cairo
univers
cairo
egypt
correspond
sallyelfishawi
ncicuedueg
hlag
molecul
immunosuppress
function
hlag
inhibit
lysi
nk
cell
alloprolifer
cell
antigenpresent
dendrit
cell
aid
product
regulatori
cell
apoptosi
cell
importantli
bp
delin
polymorph
untransl
region
hlag
control
mrna
stabil
thu
hlag
express
express
human
leukocyt
antigen
g
hlag
associ
graft
versu
host
diseas
stem
cell
transplant
relat
morbid
mortal
order
investig
effect
hlag
bp
delet
transplant
outcom
perform
hlag
genotyp
bp
del
cohort
patientdonor
pair
transplant
match
sibl
donor
bmt
lab
unit
nation
cancer
institut
patient
donor
show
ident
hlag
bp
delet
statu
seventeen
patientdonor
homozyg
bp
delet
show
trend
toward
higher
risk
develop
acut
graftversushost
diseas
agvhd
compar
patient
heterozyg
homozyg
absenc
delet
bp
insert
associ
found
hlag
relaps
patient
therefor
bp
polymorph
could
import
predict
factor
agvhd
follow
bone
marrow
transplant
given
endless
expans
ipdimgthla
databas
essenti
properli
document
entri
order
establish
allel
consid
routin
hla
genotyp
allel
ignor
document
evalu
allel
frequenc
main
world
popul
linkag
disequilibrium
good
rule
thumb
consid
common
allel
gene
frequenc
g
allel
count
n
well
studi
major
popul
mean
well
studi
popul
requir
sampl
least
subject
haplotyp
evalu
allel
realli
common
popul
well
document
rare
allel
consid
inclus
hla
allel
catalogu
use
routin
genotyp
well
document
mean
identif
given
allel
least
time
independ
sampl
differ
lab
consist
geograph
origin
consist
linkag
disequilibrium
studi
evalu
number
rare
allel
regard
consist
geograph
origin
consist
linkag
disequilibrium
major
improv
result
allogen
hsct
driven
deeper
insight
immunolog
stem
cell
transplant
sophist
donor
select
still
failur
rate
allogen
hsct
rel
high
due
relaps
nonrelaps
mortal
addit
immunogenet
donor
select
criteria
would
increas
success
rate
desper
need
current
match
hlaa
b
c
allel
level
still
consid
gold
standard
immunogenet
donor
selectionth
applic
next
gener
sequenc
ng
consider
decreas
cost
highthroughput
genotyp
addit
open
complet
new
opportun
mainli
contrast
sanger
addit
genet
loci
increas
total
cost
minim
hand
retyp
larg
number
sampl
later
time
point
would
requir
signific
invest
propos
appli
forwardlook
profil
genotyp
potenti
stem
cell
donor
profil
includ
sever
factor
report
improv
donor
select
current
consid
clinic
practic
particular
besid
six
hla
gene
hlaa
b
c
complet
kir
gene
famili
allel
level
resolut
blood
group
abo
rh
micab
hlae
anticip
next
year
independ
studi
confirm
least
candid
gene
relev
paramet
donor
select
incorpor
factor
genotyp
profil
sever
million
donor
avail
year
facilit
quick
implement
addit
criteria
therebi
improv
outcom
patient
match
unrel
donor
hsct
hematopoiet
stem
cell
transplant
hsct
hla
mismatch
haploident
donor
mani
patient
cur
option
preexist
donor
specif
antihla
antibodi
dsa
report
implic
graft
failur
frequenc
clinic
impact
remain
unclear
aim
studi
evalu
need
protocol
manag
hematolog
patient
undergo
mismatch
haploident
hsct
prevent
neg
outcom
presenc
hlaimmun
evalu
presenc
dsa
use
luminex
technolog
labscreen
mix
singl
antigen
class
ii
one
lambda
adult
patient
undergo
unrel
mismatch
hsct
usct
haploident
sct
haplosct
hpa
antibodi
detect
use
elisa
kit
immucor
gtipak
auto
patient
unrel
mismatch
donor
time
assay
day
transplant
haploident
sct
time
confirmatori
test
dsa
detect
three
patient
two
patient
underw
haplosct
usct
without
receiv
desensit
treatment
transplant
fail
obtain
allogen
engraft
one
patient
dsa
mfi
second
patient
dsa
mfi
also
antibodi
associ
platelet
transfus
refractori
third
patient
dsa
mfi
antibodi
studi
dsa
patient
associ
graft
failur
despit
mfi
valu
platelet
transfus
refractori
repres
hallmark
dsa
posit
hlaimmun
remain
problem
manag
hematolog
patient
undergo
mismatch
transplant
despit
use
leucodeplet
unit
laboratori
protocol
necessari
monitor
outcom
transplant
aim
current
studi
analyz
characterist
mud
search
procedur
perform
hospit
last
five
year
compar
previou
find
earlier
year
tissu
type
laboratori
rabin
medic
center
facilit
mud
search
procedur
result
allogen
transplant
mud
unrel
cb
haploident
patient
found
allel
mud
mud
found
ldr
median
two
donor
request
high
resolut
hr
type
perform
throughout
search
procedur
likelihood
find
donor
ldr
higher
jewish
nonjewish
patient
versu
p
allel
mud
found
jewish
nonjewish
arab
minor
patient
respect
p
likelihood
find
fulli
match
donor
higher
adult
pediatr
patient
versu
current
studi
larger
portion
patient
transplant
allel
match
donor
comparison
previou
studi
versu
respect
p
elev
possibl
due
overal
growth
ldr
correspond
year
current
donor
search
requir
significantli
lower
number
hr
type
request
carri
registri
comparison
previou
studi
could
relat
higher
resolut
hla
data
provid
registri
recent
year
former
studi
show
signific
gap
likelihood
adult
pediatr
patient
find
fulli
match
donor
intergener
gap
still
current
evid
lower
extent
past
find
may
attribut
effort
ldr
recruit
younger
donor
divers
ethnic
background
find
show
donor
search
procedur
characterist
isra
patient
dynam
influenc
long
term
transform
donor
search
environ
katarina
stingl
jankov
marija
maskalan
zorana
grubic
marija
burek
kamenar
renata
zunec
univers
hospit
centr
zagreb
zagreb
croatia
correspond
kstingl
kbczagrebhr
chimer
analysi
routin
test
perform
order
monitor
engraft
relaps
hsct
goldstandard
method
test
str
analysi
howev
emerg
sensit
qpcrbase
method
made
prefer
method
chimer
analysi
aim
studi
evalu
applic
qpcr
base
chimer
monitor
method
purpos
recipi
donor
pair
test
use
kmrtype
core
kit
gendx
utrecht
netherland
qpcr
carri
use
appli
biosystem
realtim
pcr
system
analysi
perform
use
kmrengin
chimer
analysi
softwar
among
test
subject
patient
transplant
relat
donor
patient
unrel
donor
median
number
inform
marker
calcul
patient
donor
group
follow
patient
relat
donor
rang
relat
donor
rang
patient
unrel
donor
rang
unrel
donor
rang
analysi
inform
individu
marker
reveal
test
marker
eight
marker
inform
case
either
patient
donor
howev
three
marker
place
among
eight
patient
donor
convers
sever
marker
show
low
level
inform
well
high
percentag
atyp
result
conclus
qpcr
method
shown
adequ
major
patient
addit
test
need
four
patient
relat
donor
singl
inform
marker
identifi
first
analysi
improv
qpcr
method
applic
comparison
initi
qpcrbase
method
encourag
although
level
pcrstr
method
applic
still
reach
result
studi
justifi
implement
qpcr
routin
chimer
monitor
procedur
aim
investig
distribut
hla
antibodi
patient
multipl
platelet
transfus
relationship
outcom
platelet
transfus
hla
antibodi
structur
epitop
eplet
patient
serum
group
children
adult
patient
hematolog
diseas
longterm
platelet
transfus
analyz
suggest
platelet
refractori
hlaa
b
type
patient
donor
singl
antigen
bead
use
identifi
specif
hla
antibodi
patient
serum
patientdonor
pair
eplet
base
match
done
hlamatchmak
total
platelet
transfus
children
platelet
transfus
adult
refractori
result
hla
antibodi
specif
show
patient
serum
antibodi
posit
children
patient
serum
antibodi
posit
adult
patient
serum
antibodi
posit
allel
level
antibodi
specif
includ
hlaa
specif
hlab
specif
hlac
specif
detect
posit
children
patient
serum
antibodi
specif
includ
hlaa
specif
hlab
specif
hlac
specif
detect
posit
adult
patient
serum
specif
hla
antibodi
serum
patient
longterm
platelet
transfus
exhibit
certain
characterist
frequent
specif
hlaa
andb
b
respect
frequent
eplet
analysi
antibodi
specif
patient
serum
compat
patient
donor
eplet
level
illustr
might
clinic
import
result
may
need
confirm
larger
set
sampl
recent
killer
immunoglobulin
like
receptor
kir
present
natur
killer
cell
nk
implic
affect
transplant
outcom
total
patient
donor
pair
undergo
tcell
replet
hla
haplomatch
transplant
tata
memori
centr
mumbai
includ
studi
hla
type
kir
genotyp
carri
use
pcrssp
median
overal
surviv
os
month
median
relaps
free
surviv
rf
month
patient
receiv
transplant
male
donor
result
better
outcom
os
p
rf
p
effect
kir
ligand
patient
donor
pair
suggest
mismatch
ligand
result
significantli
better
os
howev
impact
hla
b
ligand
transplant
outcom
suggest
patient
carri
ligand
favor
os
mean
month
rf
mean
month
compar
patient
carri
ligand
os
mean
month
rf
mean
month
although
data
signific
patient
carri
ligand
hla
c
epitop
significantli
better
os
rf
assess
impact
mismatch
donor
kir
receptor
cognat
hla
ligand
patient
transplant
outcom
observ
mismatch
graft
versu
host
direct
led
better
os
also
observ
donor
inhibitori
kir
receptor
mismatch
patient
hla
ligand
led
higher
incid
acut
graft
versu
host
diseas
patient
ligand
receptor
present
donor
result
better
os
rf
conclud
although
hla
match
primari
import
know
patient
kir
ligand
donor
kir
genotyp
could
help
select
best
donor
minim
transplant
relat
complic
transplant
hematopoiet
cell
hsct
unrel
donor
patient
suffer
hematolog
diseas
becom
wellestablish
treatment
modal
howev
transplant
patient
still
face
signific
complic
includ
graftversushostdiseas
gvhd
understand
better
vari
outcom
patient
receiv
transplant
match
allel
hlaa
b
c
loci
role
come
increasingli
focu
due
recombin
hot
spot
hladp
loci
rest
hla
class
ii
region
otherwis
hla
match
donor
mismatch
hladp
express
level
associ
snp
locat
region
utr
gene
predict
outcom
type
hlaa
b
c
match
patientsdonor
pair
addit
hladp
allel
patient
diagnos
acut
myeloid
leukemia
assess
mismatch
optim
perform
full
length
next
gener
sequenc
ng
type
addit
evalu
snp
analyz
sequenc
analysi
ng
data
reveal
high
associ
snp
allel
clinic
outcom
patient
group
indic
possibl
associ
snp
mismatch
patient
donor
small
patient
cohort
found
signific
effect
transplant
relat
mortal
patient
occurr
chronic
graft
versu
host
diseas
donor
appli
univari
analys
although
data
accord
publish
result
larger
number
transplant
requir
definit
proof
method
full
length
ng
type
allow
one
singl
test
allel
resolut
hla
allel
addit
assign
function
snp
therefor
type
strategi
provid
comprehens
risk
assess
hsct
simultan
presenc
hostand
donorderiv
cell
term
mix
chimer
mc
observ
larg
proport
betathalassemia
thal
patient
pt
hematopoiet
stem
cell
transplant
hsct
mc
detect
earli
transplant
often
evolv
toward
complet
chimer
cc
proport
donor
cell
low
mc
lead
graft
reject
persist
mc
pmc
pt
pmc
requir
red
blood
cell
support
cure
diseas
regulatori
type
cell
character
coexpress
abil
secret
associ
pmc
investig
mc
betath
pt
earli
stage
day
allohsct
monitor
amount
residu
host
cell
rhc
bm
pb
cell
observ
pt
show
cc
mc
among
mc
pt
present
mc
level
rhc
mc
level
rhc
mc
level
rhc
interestingli
transplant
pt
show
mc
level
shortli
allohsct
reject
graft
wherea
around
transplant
pt
display
mc
level
progress
cc
interestingli
pt
mc
level
pt
cc
day
posthsct
develop
pmc
one
year
allohsct
pt
reject
graft
develop
cc
develop
pmc
cure
diseas
tcell
clone
cell
peripher
blood
pb
two
pmc
pt
confirm
high
frequenc
cell
clone
present
pb
betath
patient
pmc
moreov
use
show
frequenc
cell
correl
mainten
mc
betath
pt
underw
haploident
hsct
base
data
conclud
cell
easili
detect
pb
reproduc
observ
pb
betath
pt
pmc
sustain
hypothesi
cell
role
promot
longterm
mc
toler
betath
pt
allohsct
silico
predict
highrisk
nonpermiss
donorrecipi
hla
mismatch
unrel
donor
ud
hematopoiet
cell
transplant
hct
attract
yet
elus
object
nonpermiss
tcell
epitop
tce
group
mismatch
defin
alloreact
tcell
crossreact
pattern
allel
identifi
date
tcex
includ
allel
report
common
well
document
cwd
efi
ashi
catalogu
numer
function
distanc
fd
score
system
silico
predict
tce
group
base
median
impact
key
amino
acid
polymorph
exon
develop
allel
tcefd
includ
cwd
allel
assign
tcex
compar
clinic
outcom
associ
nonpermiss
mismatch
defin
tcex
tcefd
patient
receiv
hlamatch
udhct
aml
md
cml
concord
two
model
differ
aris
differ
assign
tcex
tcefd
cwd
allel
assign
tcex
found
cohort
occur
pair
tcex
tcefd
nonpermiss
mismatch
associ
reduc
overal
surviv
hr
p
hr
p
increas
transplantrel
mortal
hr
p
hr
p
well
acut
hr
p
hr
p
chronic
graftversushost
diseas
hr
p
hr
p
find
silico
predict
nonpermiss
mismatch
base
experimentallyelabor
fd
score
feasibl
allel
known
exon
sequenc
improv
predict
major
transplant
outcom
includ
acut
chronic
graftversushost
diseas
import
implic
ud
search
tcefd
like
becom
increasingli
use
new
allel
detect
refin
tissu
type
techniqu
extens
unrel
hct
new
ethnic
group
proofofprincipl
observ
open
new
potenti
avenu
develop
risk
predict
model
across
hla
system
match
hlaa
b
c
allel
epitop
unrel
donor
ud
recipi
significantli
improv
outcom
hematopoiet
stem
cell
transplant
hsct
case
epitop
match
perform
donorrecipi
pair
mismatch
due
weak
linkag
disequilibrium
hla
loci
select
algorithm
base
cell
epitop
group
identifi
mismatch
might
toler
would
increas
risk
gvhd
hsct
aim
phase
one
studi
regard
valid
defin
often
practic
possibl
improv
donor
select
includ
epitop
match
implement
new
search
algorithm
routin
analyz
impact
match
phase
two
b
studi
includ
b
patient
search
ud
initi
b
patient
respect
ud
type
allel
allel
mismatch
donor
recipi
pair
cell
epitop
match
perform
dpb
tce
tool
ipdimgthla
retrospect
first
prospect
second
phase
among
patient
analyz
match
ud
one
ud
phase
one
donorrecipi
pair
allel
match
epitop
match
allel
mismatch
donorrecipi
pair
reveal
predict
permiss
immunogen
donor
gvhd
risk
epitop
match
could
improv
choos
anoth
donor
permiss
mismatch
result
phase
one
suggest
match
hsc
recipi
gvhd
risk
could
decreas
improv
search
algorithm
extend
cell
epitop
match
find
confirm
second
phase
epitop
match
implement
predict
valid
algorithm
abl
find
permiss
donor
patient
hla
phase
haplotyp
switzerland
predict
valu
match
unrel
donor
search
clinic
outcom
hsct
buhler
helen
baldomero
sylvi
ferrarilacraz
nune
alicia
sanchezmaza
stravoula
massouridilevrat
dominik
heim
joerg
halter
gayathri
nair
yve
chalandon
ur
schanz
tayfun
guengoer
grazia
nicoloso
jeanmari
tierci
jakob
passweg
jean
villard
crucial
criterion
success
allogen
hematopoiet
stem
cell
transplant
hla
match
recipi
donor
practic
hla
match
perform
phenotyp
level
recent
studi
propos
match
haplotyp
level
could
benefici
eg
reduc
graft
versu
host
diseas
aim
studi
twofold
first
use
high
resolut
type
patient
live
switzerland
potenti
candid
unrel
donor
search
determin
hla
haplotyp
descent
use
famili
member
sum
rank
two
haplotyp
patient
compar
frequenc
estim
volunt
donor
swiss
registri
use
surrog
predictor
success
search
ie
find
mud
bmdw
databas
second
put
impact
phase
hla
haplotyp
ie
consid
frequent
rare
indirect
paramet
haplotyp
match
clinic
outcom
hsct
analyz
cohort
patient
transplant
mud
patient
mainli
affect
malign
diseas
larg
major
repres
acut
leukemia
myelodysplast
myeloprolif
syndrom
logist
regress
analysi
show
highli
signific
effect
haplotyp
rank
outcom
search
howev
could
find
signific
effect
overal
surviv
acut
chronic
graft
versu
host
diseas
relaps
follow
hsct
despit
consid
differ
frequenc
cutoff
genotyp
subgroup
categor
hla
haplotyp
studi
provid
use
data
optim
unrel
bone
marrow
donor
search
switzerland
beyond
could
confirm
previou
find
match
haplotyp
level
clinic
impact
follow
hsct
due
extrem
polymorph
hla
gene
studi
warrant
better
comprehend
mani
factor
play
alexandr
walencik
estel
geffard
sophi
limou
ann
cesbron
nicola
vinc
pierreantoin
gourraud
ef
centrepay
de
la
loir
nant
franc
inserm
de
nant
nant
franc
inserm
ecol
central
de
nant
nant
franc
correspond
alexandrewalencik
efssantefr
easymatchr
compon
easyhla
web
applic
suit
calcul
probabl
find
hla
match
hsct
donor
recommend
parsimoni
hla
type
strategi
requir
request
blood
sampl
major
challeng
clinic
laboratori
trust
integr
statist
decis
support
program
present
compar
analysi
search
strategi
perform
consecut
patient
cohort
hsct
indic
first
compar
number
expect
donor
obtain
easymatchr
number
obtain
bmdw
book
interrog
found
good
correl
easymatchr
bmdw
book
p
search
weaker
correl
search
less
expect
donor
p
categor
bmdw
book
result
five
categori
favor
favor
unlik
exist
potenti
donor
low
resolut
type
unfavor
potenti
donor
found
correl
number
expect
donor
respect
median
also
retrospect
compar
impact
algorithm
recommend
number
addit
type
request
lab
time
donor
search
recommend
addit
type
depend
threshold
fix
user
easymatchr
recommend
differ
type
threshold
threshold
level
risk
consid
input
compar
standard
strategi
confirmatori
type
request
demonstr
easymatchr
costeffect
consid
threshold
easymatchr
facilit
search
donor
provid
statist
quantifi
argument
support
earli
adopt
altern
option
bmdw
book
favor
improv
effect
diminish
cost
relat
addit
hla
type
pretranspl
donor
specif
antibodi
dsa
associ
poor
outcom
haploident
hematopoiet
stem
cell
transplant
sct
report
case
appear
specif
ab
recipi
rsa
sct
year
old
woman
diagnos
aml
two
induct
cours
failur
receiv
signific
improv
requir
extens
tranfusion
support
match
sibl
suitabl
ud
receiv
peripher
blood
stem
cell
pbsc
haploident
son
sequenti
condit
regimen
highdos
postsct
cyclophosphamid
allel
mismatch
recipientdonor
b
c
donorrecipi
b
c
screen
hla
ab
sab
sct
reveal
presenc
ab
non
dsa
ab
epitop
sever
complic
cholecyst
pulmonari
aspergillosi
occur
aplasia
neutrophil
recoveri
sustain
remain
thrombopen
requir
transfus
pbsc
boost
briefli
effect
gvhd
observ
immunosuppress
promptli
taper
stop
relaps
occur
result
death
one
month
later
five
month
graft
boost
profil
ab
chang
apparit
specif
antihla
epitop
rsa
high
mfi
valu
retrospect
assess
tempor
profil
could
assum
rsa
appear
stop
observ
clinic
eg
form
gvhd
biolog
signific
chang
eg
blood
count
chimer
relaps
highlight
rsa
retrospect
analyz
haploident
sct
perform
center
find
hlaab
post
sct
period
illustr
need
cautiou
prospect
follow
hlaab
particular
rsa
recipi
post
haploident
sct
therefor
clinicalbiolog
signific
appar
rare
occurr
may
unmask
potenti
lead
medic
intervent
previous
describ
pre
sct
alloimmun
involv
dsa
bambino
children
hospit
rome
itali
correspond
paolagiustiniani
opbgnet
pediatr
patient
candid
hematopoiet
stem
cell
transplant
hsct
may
present
circul
antibodi
direct
hla
molecul
due
previou
immun
eg
blood
transfus
sever
studi
show
haploident
hsct
presenc
antihla
antibodi
antigen
encod
nonshar
donor
haplotyp
associ
higher
percentag
reject
recipi
observ
suggest
perform
routin
test
reject
failur
incid
may
relat
median
fluoresc
intens
mfi
antibodi
pattern
type
studi
carri
may
decemb
igg
antihla
antibodi
identif
perform
paediatr
patient
candid
hsct
femal
male
median
age
nine
year
old
first
determin
within
pretranspl
screen
studi
includ
patient
affect
hematolog
malign
acut
lymphoblast
leukemia
acut
myeloid
leukemia
fanconi
anemia
hemophagocyt
lymphohistiocytosi
patient
affect
nonmalign
hematolog
diseas
thalassemia
aplast
anemia
immun
defici
chronic
granulomat
diseas
blackfan
diamond
anemia
antihla
antibodi
identif
perform
luminex
singl
antigen
techniqu
hla
class
ii
igg
antibodi
consid
mfi
cut
valu
patient
affect
nonmalign
hematolog
diseas
found
increas
incid
antihla
igg
antibodi
especi
patient
thalassemia
compar
patient
hematolog
malign
studi
confirm
import
routin
antihla
antibodi
identif
particularli
patient
candid
haploident
hsct
order
start
desensit
procedur
time
gabriela
berardi
cintia
llull
nicola
fernandez
escobar
gregorio
jaimovich
maria
beatriz
rodriguez
pablo
morikon
karin
padro
ulis
toscanini
pricai
bueno
air
argentina
ceht
bueno
air
argentina
correspond
utoscanini
pricaicomar
engraft
monitor
bone
marrow
transplant
usual
perform
genotyp
polymorph
marker
dna
extract
obtain
whole
white
cell
popul
posttranspl
sampl
howev
specif
circumst
analysi
differ
cell
subset
may
approach
detect
chimer
set
method
manual
separ
three
white
cell
subset
subsequ
str
analys
cell
popul
briefli
densiti
gradient
separ
ficollhypaqu
perform
start
acd
anticoagul
whole
blood
subset
sequenti
select
mononuclear
layer
harvest
ficollhypaqu
cell
addit
select
granulocyt
layer
ficollhypaqu
clonal
select
perform
use
monoclon
antibodi
conjug
magnet
bead
easyseptm
hla
chimer
select
kit
separ
puriti
prepar
determin
flow
cytometri
follow
dna
extract
subset
panel
genotyp
dna
extract
analys
first
carri
mixtur
blood
two
healthi
volunt
posttranspl
sampl
patient
sever
clinic
condit
studi
everi
case
statu
whole
white
cell
popul
also
determin
order
compar
subset
result
averag
puriti
subpopul
assess
flow
cytometri
str
analys
cell
subset
show
differ
correl
result
whole
leukocyt
analys
patient
sampl
indic
str
analys
cell
separ
posttranspl
blood
sampl
method
describ
provid
addit
inform
analys
whole
leukocyt
popul
specif
case
aim
prospect
studi
assess
influenc
donor
kir
gene
genotyp
outcom
aml
patient
treat
allohsct
hlaident
sibl
first
complet
remiss
aml
patient
includ
studi
patient
receiv
tcell
replet
bone
marrow
graft
hlaident
sibl
kir
genotyp
perform
pcrssp
kit
olerup
sweden
overal
surviv
os
eventfre
surviv
ef
calcul
kaplanmei
method
compar
logrank
test
os
defin
surviv
allohsct
without
death
caus
ef
defin
surviv
allohsct
complet
remiss
without
death
caus
median
followup
month
rang
estim
os
allohsct
ef
ef
patient
kir
bx
donor
significantli
higher
patient
kir
aa
donor
vs
p
centromer
telomer
kir
b
motif
improv
surviv
surviv
also
higher
recipi
allograft
data
suggest
kir
gene
content
influenc
outcom
allohsct
hlaident
relat
donor
kir
b
haplotyp
express
activ
kir
associ
higher
surviv
probabl
due
graftversusleukemia
effect
allogen
hematopoiet
stem
cell
transplant
allohsct
one
cur
approach
hematolog
malign
best
donor
allohsct
human
leukocyt
antigen
hla
match
sibl
donor
situat
donor
found
altern
hlahaploident
donor
share
least
one
hla
haplotyp
recipi
biolog
parent
children
potenti
haploident
donor
first
success
haploident
allohsct
haplo
allohsct
provid
institut
hematolog
blood
transfus
number
realiz
haplo
allohsct
increas
everi
year
day
haplo
allohsct
perform
total
mostli
patient
suffer
acut
myeloid
leukemia
aml
diagnosi
type
allohsct
nonhaploident
differ
condit
haplo
allohsct
patient
undergo
often
nonmyeloabl
allohsct
patient
undergo
myeloabl
condit
haplo
allohsct
second
transplant
patient
chimer
statu
import
factor
surviv
patient
haplo
allohsct
patient
complet
chimer
surviv
case
hand
patient
mix
chimer
surviv
case
result
differ
nonhaploident
relat
unrel
allohsct
relaps
occur
patient
haplo
allohsct
aml
diagnosi
patient
die
due
relaps
median
complet
chimer
achiev
day
haplo
allohsct
patient
never
achiev
complet
chimer
die
mix
chimer
thu
highrisk
factor
posttransplant
cours
techniqu
use
haploident
transplant
use
cyclophosphamid
posit
impact
sever
outcom
measur
name
overal
surviv
diseasefre
progress
surviv
free
acut
chronic
graft
versu
host
diseas
main
object
prospect
studi
evalu
clinic
signific
antihla
antibodi
earli
complic
outcom
unrel
donor
hematopoiet
stem
cell
transplant
hsct
june
septemb
adult
patient
reach
followup
first
unrel
donor
hsct
die
within
period
recruit
prospect
studi
donorpati
pair
match
hlaa
b
c
loci
addit
loci
type
patient
sera
sampl
collect
schedul
start
condit
treatment
month
hsct
antihla
antibodi
screen
specif
identifi
solidphas
immunoassay
immucor
luminex
platform
hlamatchmak
program
use
perform
structur
hla
class
class
ii
match
eplet
level
patient
median
age
year
rang
patient
men
seventyfour
donorpati
pair
match
patient
achiev
neutrophil
engraft
hsct
patient
secondari
graft
failur
overal
preval
preform
antihla
antibodi
donorspecif
antibodi
found
patient
retain
antihla
antibodi
hsct
presenc
preform
antihla
antibodi
found
associ
develop
earli
grade
iii
iv
acut
graftversushost
diseas
agvhd
posttranspl
complic
p
higher
transplantrel
mortal
p
shorter
overal
surviv
p
preform
antihla
antibodi
affect
engraft
incid
relaps
graft
failur
event
free
surviv
develop
nonagvhd
antihla
antibodi
detect
hsct
impact
develop
earli
complic
outcom
hsct
nine
patient
develop
de
novo
antihla
antibodi
hsct
case
donorspecif
direct
mismatch
preform
antihla
antibodi
impact
develop
sever
agvhd
higher
transplant
relat
mortal
reduc
overal
surviv
unrel
donor
hsct
therefor
routin
test
antihla
antibodi
may
consid
pretranspl
workup
recipi
one
mani
factor
influenc
hematopoiet
stem
cell
transplant
hsct
presenc
donorderiv
alloreact
nk
cell
form
mainli
result
kirhla
ligand
mismatch
three
model
predict
alloreact
nk
cell
format
exist
ligandligand
model
kir
receptorligand
model
kir
haplotyp
model
purpos
studi
analyz
associ
patient
donor
kir
ligand
kir
gene
genotyp
hsct
outcom
see
three
model
best
algorithm
predict
hsct
outcom
investig
group
consist
patientdonor
pair
undergon
unrel
hsct
univers
hospit
centr
zagreb
analysi
accord
ligandligand
model
studi
group
result
four
mismatch
oppos
kirligand
model
patientdonor
pair
kirligand
mismatch
lead
conclus
determin
kir
ligand
mismatch
follow
patientdonor
hla
type
without
kir
genotyp
donor
good
prognost
algorithm
inhibitori
kirhla
ligand
matchesmismatch
determin
kirligand
model
show
benefici
effect
kir
ligand
mismatch
investig
hsct
endpoint
assign
aa
bx
kir
genotyp
patient
donor
patientdonor
combin
aaaa
aabx
bxaa
bxbx
enabl
analysi
accord
third
model
although
statist
signific
differ
found
trend
toward
better
surviv
observ
aa
patient
receiv
bx
graft
conclus
exist
model
predict
alloreact
nk
cell
format
effect
hsct
outcom
ca
nt
give
answer
alon
clarifi
kir
influenc
hsct
outcom
differ
approach
analys
encompass
properti
kir
genesreceptor
kirligand
nk
cell
togeth
need
taken
consider
tsvetelin
lukanov
lyudmila
quin
antoaneta
nedyalkova
bushra
al
hadra
milena
ivanova
elissaveta
naumova
univers
hospit
alexandrovska
sofia
bulgaria
medic
univers
sofia
univers
hospit
alexandrovska
sofia
bulgaria
correspond
tslukanov
yahoocom
bulgarian
bone
marrow
donor
registri
bbmdr
member
wmda
sinc
differ
hla
type
techniqu
use
throughout
year
cdc
ssp
ssop
sbt
hla
profil
donor
diversifi
current
polici
hla
type
donor
state
young
men
women
type
hlaa
b
c
loci
high
resolut
donor
type
hlaa
b
loci
low
resolut
recent
nextgener
sequenc
ng
genotyp
young
donor
implement
one
third
donor
type
high
resolut
almost
half
type
allel
level
within
past
year
sinc
introduct
ng
hla
type
nextgener
sequenc
gener
phaseresolv
unambigu
result
oppos
classic
sanger
sequenc
help
us
precis
obtain
allel
frequenc
bbmdr
donor
ng
technolog
allow
us
shorten
period
hla
type
young
volunt
donor
significantli
increas
throughput
capabl
sever
rare
allel
well
three
new
allel
alreadi
found
due
better
coverag
gene
moreov
ng
kit
includ
lowexpress
loci
addit
increas
qualiti
hla
data
includ
bmdw
may
use
addit
select
criteria
allow
clarif
relev
loci
hsct
conclus
ng
technolog
allow
highqual
hla
data
increas
throughput
registri
reduc
cost
per
sampl
compar
sanger
sequenc
high
resolut
data
shorten
donor
search
procedur
provid
accur
match
improv
patient
surviv
substanti
reduc
problem
donor
nonidentif
addit
better
character
hla
genet
divers
within
patient
popul
help
predict
probabl
find
match
unrel
donor
time
chang
hsct
strategi
cmv
match
achiev
transplant
undertaken
use
blood
group
match
compat
donor
look
time
taken
identifi
final
donor
transplant
ie
time
initi
search
receipt
verif
type
sampl
donor
select
transplant
time
taken
median
day
rang
day
figur
improv
day
rang
day
last
year
audit
period
final
two
year
audit
search
process
involv
identifi
altern
donor
transplant
case
due
final
donor
select
transplant
subsequ
avail
donat
occur
due
varieti
reason
includ
donor
withdraw
fail
medic
deferr
due
medic
reason
audit
data
reflect
strategi
util
uk
donor
possibl
improv
hla
data
uk
registri
loss
heterozygos
hla
region
may
provid
tumor
cell
mechan
escap
immun
surveil
partial
complet
delet
hla
locu
chromosom
shown
solid
tumor
hematolog
malign
includ
leukemia
phenomenon
pose
challeng
histocompat
test
sinc
stem
cell
transplant
hla
homozyg
donor
mistyp
patient
may
lead
fatal
graft
versu
host
diseas
moreov
patient
often
drawn
transplant
workup
time
diagnosi
may
signific
number
malign
cell
circul
case
year
old
femal
aml
patient
present
refer
bone
marrow
transplant
hla
type
peripher
blood
use
high
resolut
sso
method
show
homozyg
type
loci
except
c
locu
next
gener
sequenc
ng
type
howev
reveal
presenc
previous
undetect
hla
b
allel
present
allel
imbal
investig
sensit
hla
type
method
detect
underrepres
haplotyp
homozyg
sampl
mix
ratio
sampl
test
ng
use
holotyp
kit
omixon
high
resolut
sso
method
use
labtyp
xr
one
lambda
notabl
ng
method
abl
detect
quantifi
presenc
underrepres
hla
allel
level
low
show
higher
sensit
sso
method
studi
highlight
import
confirmatori
type
patient
hematolog
malign
fals
homozygos
hla
may
increas
risk
gvhd
homozyg
hla
result
confirm
second
hla
type
remiss
sampl
buccal
sampl
hla
type
ng
sensit
techniqu
identif
hla
allel
underrepres
due
malign
induc
loss
heterozygos
affect
region
relaps
malign
diseas
remain
one
import
complic
allogen
stem
cell
transplant
allohsct
poorli
control
current
use
method
substanti
contribut
posttranspl
mortal
success
transplant
depend
develop
graft
versu
leukemia
gvl
reaction
case
hlamatch
transplant
depend
respons
mismatch
minor
histocompat
antigen
miha
prevent
relaps
facilit
gvl
allohsct
could
supplement
adopt
transfer
donorderiv
cell
modifi
miha
specif
cell
receptor
tcr
clinic
relev
miha
present
frequent
hla
allel
optim
allel
frequenc
express
ideal
limit
hematopoiet
tissu
present
frequent
hlaa
allel
optim
allel
distribut
around
european
popul
immunogen
allel
therefor
immunogen
mismatch
occur
hlaa
match
transplant
case
also
antigen
deriv
gene
specif
express
hematopoiet
tissu
overexpress
mani
leukemia
project
aim
develop
method
adopt
cell
therapi
target
hlaa
donor
obtain
naiv
cell
perform
antigenspecif
expans
use
peptideload
dendrit
cell
isol
specif
cell
tetram
cytotox
confirm
specif
lysi
hlaa
lcl
cell
puls
exogen
peptid
expans
obtain
set
specif
tcr
sequenc
alpha
beta
chain
clone
one
tcr
lentivir
vector
harvest
lentivir
supernat
perform
lentivir
transduct
cell
next
plan
confirm
cytotox
activ
transduc
cultur
hlaa
lcl
cell
present
either
endogen
exogen
peptid
assess
clinic
implic
cytotox
activ
confirm
patientderiv
leukemia
sampl
method
immunotherapi
earli
stage
develop
research
regard
effect
need
blood
transfus
current
therapeut
support
use
mani
patholog
hemorrhag
context
andcanc
etc
combin
effect
popul
growth
age
well
advanc
medicin
need
red
blood
cell
increas
year
advent
gener
red
blood
cell
vitro
stem
cell
could
long
run
supplement
suppli
need
even
replac
erythroid
cultur
access
use
cocktail
sever
cytokin
must
optim
mani
factor
interven
process
prolifer
differenti
recent
demonstr
human
leukocyt
antigen
g
molecul
hlag
may
impact
prolif
mechan
express
molecul
prolifer
differenti
erythroid
progenitor
within
cultur
media
could
therefor
potenti
increas
erythropoiesi
product
yield
three
human
cultur
cord
blood
pool
induc
erythroid
differenti
vitro
addit
erythropoietin
day
phenotyp
express
hlag
determin
flow
cytometri
confoc
microscopi
western
blot
transcript
express
analyz
revers
transcriptionquantit
polymeras
chain
reaction
rtqpcr
cell
express
erythroid
marker
matur
erythroblast
express
hlag
demonstr
nondefin
cell
confoc
microscopi
express
confirm
techniqu
includ
rtqpcr
data
suggest
hlag
molecul
express
either
immatur
matur
erythroid
cell
cultur
model
molecul
interest
prolif
differenti
phenomena
certain
cell
type
express
impact
must
objectifi
erythroid
line
use
sensit
techniqu
effici
red
cell
cultur
model
around
adult
suffer
chronic
kidney
diseas
ckd
chronic
respiratori
diseas
crd
respect
among
patient
advanc
ill
evolv
endstag
diseas
becom
candid
kidney
lung
transplant
develop
precis
medicin
applic
kidney
lung
transplant
patient
order
monitor
individu
trajectori
posttranspl
outcom
use
data
divat
donne
informatise
et
valide
en
transplant
colt
cohort
lung
transplant
studi
togeth
inform
patient
renal
lung
transplant
includ
clinic
immunolog
item
collect
sinc
present
two
person
contextu
algorithm
popul
contextu
compar
data
trajectori
given
patient
subpopul
similar
characterist
select
filter
nearest
neighbor
approach
referenti
contextu
compar
data
trajectori
given
patient
extrem
group
defin
clinician
acut
graft
reject
humor
reject
cellular
reject
toler
compar
properti
algorithm
individu
determin
refer
group
level
exampl
normal
assess
neighbor
given
kidney
transplant
patient
moll
creatinin
level
posttransplant
find
percentil
respect
precis
medicin
applic
therefor
facilit
access
larg
amount
data
allow
visual
comparison
order
optim
medic
care
guid
clinic
decis
final
aim
extend
algorithm
variou
chronic
medic
condit
set
improv
patient
care
applic
easyhla
solid
organ
transplant
donorrecipi
pair
cohort
statist
upgrad
hla
type
research
use
estel
geffard
alexandr
walencik
sophi
limou
paulin
scherdel
adrien
tissot
divat
investig
colt
investig
gill
blancho
magali
giral
antoin
magnan
ann
cesbron
nicola
vinc
pierreantoin
gourraud
inserm
de
nant
nant
franc
ef
centr
pay
de
la
loir
nant
franc
correspond
nicolasvinc
univnantesfr
hla
polymorph
central
role
clinic
research
howev
larg
size
dataset
usual
difficult
analyz
hla
type
wide
array
techniqu
partial
overlap
loci
differ
resolut
easyhla
softwar
suit
deliv
statist
updat
hla
inform
hla
type
resolut
easyhla
userfriendli
web
applic
avail
http
hlaunivnantesfr
present
use
publish
haplotyp
frequenc
solv
type
ambigu
predict
hlatyp
loci
hlaupgrad
well
haplotyp
pair
appli
hlaupgrad
two
solid
organ
transplant
cohort
includ
serolog
genotyp
donorrecipi
pair
kidney
transplant
divat
cohort
lung
transplant
colt
cohort
colt
hlaupgrad
resolv
genotyp
highresolut
subject
confid
predict
untyp
hlac
locu
subject
confid
use
high
resolut
type
imput
haplotyp
pair
high
confid
averag
valu
predict
probabl
rang
easyhla
tool
facilit
analysi
immunogenet
paramet
graft
surviv
kidney
lung
transplant
patient
addit
provid
new
function
immunogenom
paramet
analyz
hlaexpr
imput
hlac
express
hlaaa
provid
amino
acid
equival
hla
allel
hlakirlig
give
kir
ligand
classif
hla
allel
easyhla
facilit
largescal
analysi
promot
multifacet
hla
expertis
beyond
allel
associ
hla
region
arguabl
import
part
human
genom
due
peculiar
complex
research
hesit
work
region
recent
develop
genom
biolog
equal
appli
hla
region
tool
may
look
daunt
nonspecialist
facilit
research
genom
biolog
especi
hla
scientist
develop
simpl
onlin
tool
first
tool
snpsop
facilit
examin
function
snp
genom
user
simpli
enter
snp
id
search
box
select
number
tool
list
provid
inform
function
includ
eqtl
statu
public
cite
snp
app
open
web
tool
separ
tab
browser
display
inform
specif
snp
queri
new
tool
ad
search
menu
relev
one
publish
second
tool
hlasnp
onlin
sql
databas
also
avail
lightweight
microsoft
access
databas
offlin
use
allow
user
queri
snp
within
extend
hla
region
obtain
detail
inform
integr
databas
bring
togeth
inform
either
extract
relev
genomewid
databas
includ
genom
locat
eqtlmeqtl
statu
function
score
locat
within
cpg
islandstranscript
factor
microrna
bind
site
chromatin
featur
chromatin
interact
gwasphewa
diseas
associ
literatur
proxi
statu
hla
allel
immunochip
data
ihwg
cell
line
proxi
statu
hla
supertyp
ancestr
lineag
genotyp
examin
cell
line
manual
curat
databas
also
constantli
updat
inform
current
literatur
relat
genom
featur
hla
region
diseas
associ
tool
trial
final
verif
phase
develop
fulli
function
onlin
may
hope
tool
introduc
life
scientist
interest
hla
region
research
latest
advanc
genom
biolog
widespread
use
next
gener
sequenc
hla
genotyp
led
rapid
increas
discoveri
novel
allel
unfortun
mani
allel
sequenc
submit
ipdimgthla
ipdkir
databas
compris
code
sequenc
hla
exon
encod
antigen
recognit
domain
imped
establish
longreadbas
genotyp
technolog
desir
novel
allel
character
submit
fulllength
known
allel
extend
cover
complet
gene
sequenc
manual
annot
submiss
fulllength
sequenc
ipdimgt
hla
ena
databas
timeconsum
errorpron
task
develop
publish
typeload
tool
take
fulllength
sequenc
novel
hla
allel
fasta
format
input
automat
annot
creat
file
necessari
submiss
reduc
manual
effort
submiss
implement
web
applic
run
linux
server
use
dkm
life
scienc
lab
success
submit
novel
hla
allel
enabl
widespread
use
tool
lab
adapt
typeload
make
avail
window
standalon
applic
easili
use
standard
pc
without
depend
softwar
typeload
automat
detect
null
allel
gener
prematur
stop
codon
frameshift
mutat
featur
enhanc
integr
ena
autom
submiss
api
typeload
also
implement
experiment
support
annot
submiss
kir
allel
hope
increas
conveni
scope
typeload
foster
submiss
fulllength
sequenc
ipdimgthla
ipdkir
databas
ultim
promot
widespread
use
fulllength
sequenc
genotyp
hla
kir
hla
imput
snp
power
statist
altern
expens
ng
hla
type
extens
studi
use
snp
genotyp
grew
extrem
fast
much
work
still
need
increas
capac
studi
hla
allel
associ
differ
diseas
fill
gap
genom
data
avail
hla
allel
studi
propos
facilit
hla
imput
snp
studi
develop
snphla
refer
consortium
snphla
refer
consortium
main
object
bring
togeth
immunogeneticist
scientist
order
build
sever
larg
refer
panel
hla
imput
snp
genotyp
share
refer
panel
within
publicli
avail
databas
inde
imput
accuraci
depend
refer
panel
qualiti
well
match
queri
data
eg
ancestri
background
genom
array
coverag
alreadi
access
larg
cohort
ethnic
divers
individu
hla
type
snp
genotyp
offer
provid
consortium
refer
panel
logist
includ
access
highcomput
infrastructur
necessari
refer
panel
build
exampl
hlaa
took
cpuhr
individu
allel
snp
build
refer
panel
use
hibag
refer
panel
bag
hibag
r
packag
use
bootstrap
sampl
dataset
anonym
therefor
releas
public
databas
develop
ambiti
tool
encourag
will
particip
larg
hla
type
snp
data
join
project
contribut
develop
consortium
empow
immunogenet
commun
shift
immunogenom
associ
era
recent
sequenc
exon
encod
antigen
recognit
site
ar
rule
common
well
defin
cwd
null
allel
consid
gold
standard
high
resolut
type
hla
gene
mainli
due
limit
older
gener
sequenc
technolog
well
known
variat
site
gene
could
modul
knock
express
hla
protein
advanc
gener
sequenc
technolog
pacbio
smrt
sequenc
made
possibl
perform
high
volum
high
throughput
hla
class
whole
gene
type
laboratori
perform
whole
gene
sequenc
class
gene
one
routin
type
method
sinc
juli
type
sampl
use
whole
gene
class
sequenc
pacbio
smrt
platform
pcr
amplicon
span
region
utr
sampl
novel
variat
ar
exon
sampl
novel
variat
nonar
region
sampl
novel
intron
sequenc
found
sampl
variat
nonar
exon
could
result
prematur
stop
codon
nonsens
protein
three
sampl
variat
intron
boundari
nonar
exon
predict
prematur
stop
codon
sampl
variat
spliceosom
site
intron
could
chang
length
translat
protein
caus
prematur
stop
codon
nonsens
protein
whole
gene
sequenc
also
enabl
us
identifi
known
new
marker
haplotyp
popul
specif
variat
code
noncod
sequenc
marker
could
import
predictor
level
histocompat
patient
donor
cell
result
indic
enough
convinc
data
chang
definit
gold
standard
hla
class
type
whole
gene
sequenc
includ
exon
intron
convent
high
resolut
hla
type
technolog
produc
ambigu
result
often
necessari
perform
addit
test
resolv
ambigu
next
gener
sequenc
ng
promis
technolog
overcom
problem
determin
hla
compat
donor
recipi
phaseresolv
hla
type
result
report
preliminari
experi
introduc
ng
technolog
use
alltyp
kit
ng
ion
chef
platform
follow
typestream
softwar
analysi
thermo
fisher
one
lambda
canoga
park
ca
usa
hlaa
b
c
loci
loci
amplifi
singl
pcr
reaction
avoid
need
amplicon
pool
fiftythre
sampl
total
allel
includ
studi
previous
type
highresolut
use
combin
sanger
sequenc
sequencespecif
primer
ssp
sequencespecif
oligonucleotid
probe
ssop
technolog
record
twofield
level
mean
read
length
bp
averag
read
depth
key
exon
maximum
minimum
overal
concord
refer
type
obtain
one
hlac
allel
assign
softwar
allel
type
minimum
level
two
field
threefield
level
reach
class
allel
respect
final
allel
resolut
achiev
hlaa
c
hlab
allel
conclus
ngsbase
hla
type
much
potenti
replac
routin
clinic
sbt
type
power
provid
allel
level
type
clinic
relev
hla
loci
within
work
day
excel
sequenc
coverag
streamlin
workflow
overal
low
cost
typestream
analysi
softwar
correctli
assign
allel
high
percent
concord
among
mani
factor
influenc
clinic
success
hsct
polymorph
classic
hla
gene
repres
one
major
barrier
nextgener
sequenc
ng
recent
becom
use
techniqu
high
resolut
hr
hla
type
present
studi
describ
valid
ng
technolog
introduct
routin
activ
laboratori
allel
resolut
ar
hla
type
analyz
dna
sampl
use
nxtype
ng
alltyp
kit
ng
first
ion
torrent
pgm
subsequ
platform
follow
typestream
softwar
analysi
thermo
fisher
one
lambda
canoga
park
ca
usa
loci
hlaa
b
c
total
allel
obtain
reproduc
method
repeat
hla
type
dna
sampl
time
total
test
subsequ
compar
result
previous
obtain
allel
studi
concord
result
analyz
dna
sampl
previous
type
hr
level
observ
two
differ
previou
sbt
analysi
solv
two
cistran
ambigu
c
vs
c
hla
allel
observ
specif
haplotyp
due
linkag
disequilibrium
ld
certain
allel
recent
improv
nextgener
sequenc
ng
technolog
enabl
us
handl
peculiar
mhc
notabl
tight
ld
gene
well
high
degre
polymorph
order
assign
hla
haplotyp
allel
level
greek
popul
context
ihw
famili
includ
parent
sibl
subject
greek
origin
type
loci
hlaa
b
c
ng
technolog
instrument
chemistri
illumina
miseq
chemistri
cycl
standard
flow
cell
size
illumina
trusight
hla
omixon
holotyp
hla
kit
use
hla
haplotyp
count
frequenc
estim
accord
number
parent
haplotyp
identifi
whole
cohort
addit
haplotyp
count
famili
subject
calcul
one
haplotyp
observ
haplotyp
frequenc
hlaa
haplotyp
found
three
subject
member
two
famili
haplotyp
frequenc
confirm
hlaa
haplotyp
defin
lowresolut
molecular
techniqu
common
greek
caucasian
result
use
refer
data
control
diseas
associ
studi
well
popul
genet
alic
p
pedersen
menaka
andersen
tore
jensen
mart
k
viken
depart
immunolog
oslo
norway
correspond
mavik
oushfno
well
known
certain
hla
allel
associ
diseas
test
hlab
use
support
diagnos
ankylos
spondyl
hlab
associ
diseas
laboratori
number
sampl
test
hlab
per
week
around
method
like
real
time
pcr
quick
test
multipl
sampl
simultan
previou
hlab
real
time
pcr
type
base
primer
exon
util
sybr
green
melt
curv
detect
hlab
posit
sampl
howev
primer
use
fail
detect
sever
hlab
allel
could
lead
fals
neg
result
aim
make
triplex
realtim
assay
fewer
fals
neg
result
chang
sybr
green
taqman
probe
detect
first
design
probe
hlab
exon
assay
secondli
perform
literatur
search
identifi
pcrbase
hlab
assay
select
primer
probe
exon
assay
new
method
triplex
pcr
combin
assay
exon
exon
commerci
rnasep
assay
instrument
use
laboratori
quantstudio
flex
life
technolog
use
pipet
robot
plate
flexibl
run
sampl
per
run
triplex
pcr
optim
regard
amount
assay
dna
input
reaction
annealingelong
temperatur
valid
method
run
sampl
type
previou
hlab
assay
panel
sampl
select
hlab
especi
set
sampl
variou
hlab
allel
cover
common
allel
consid
variou
diseas
associ
found
differ
hlab
allel
report
result
hlab
posit
neg
result
manual
score
regist
cycl
threshold
therebi
assign
result
either
posit
neg
presenc
hlab
allel
valid
gave
concord
earlier
result
confirm
previou
method
probabl
led
fals
neg
fals
posit
result
combin
hlab
assay
exon
reduc
possibl
fals
neg
posit
result
exclud
complet
method
robust
hand
give
us
flexibl
cost
effect
method
hlab
type
marin
cargou
charlen
bouthemi
mami
ralazamahaleo
gwendalin
guidicelli
jonathan
visentin
centr
hospitali
universitair
de
bordeaux
bordeaux
franc
correspond
jonathanvisentin
chubordeauxfr
human
leukocyt
antigen
hla
genotyp
next
gener
sequenc
ng
widespread
aim
evalu
perform
nxtype
kit
one
lambda
perform
thermo
fischer
scientif
reagent
ion
ext
kit
chef
ion
chip
platform
first
run
carri
laboratori
allow
dna
patient
extern
profici
test
ept
control
dna
includ
run
type
hlaa
b
c
loci
median
sampl
load
per
chip
observ
two
dropout
among
allel
type
anoth
method
among
new
allel
detect
softwar
typestream
ipdimgthla
databas
releas
two
confirm
sanger
sbt
mismatch
locat
key
exon
consid
probabl
new
unconfirm
mismatch
nonkey
exon
intron
other
reject
homopolym
nucleotid
doublet
repeat
low
read
depth
read
high
background
addit
allel
see
comparison
like
allel
obtain
ssoxr
patient
evidenc
concord
hlaa
b
loci
second
field
resolut
hlac
loci
result
respect
consist
common
linkag
disequilibrium
inde
observ
addit
allel
fals
detect
softwar
ept
sampl
obtain
consensu
result
allel
first
second
field
third
field
fourth
field
resolut
conclus
nxtype
kit
display
satisfactori
perform
experienc
user
easili
manag
fals
new
allel
caus
homopolym
frequent
propos
assign
improv
order
elimin
supernumerari
allel
nevertheless
easili
detect
studi
linkag
disequilibrium
gendx
ngsgo
workflow
hla
type
use
nextgener
sequenc
ng
consist
four
practic
step
amplif
librari
prepar
sequenc
data
analysi
four
step
librari
prepar
labor
intens
interspers
incub
decreas
handson
time
reduc
risk
human
error
ngsgo
librari
prepar
autom
start
finish
use
liquid
handler
workstat
describ
result
autom
ngsgo
librari
prepar
illumina
beckman
coulter
biomek
workstat
workflow
fulli
autom
amplicon
pool
final
librari
make
complet
handsoff
accommod
overnight
run
allow
oper
step
away
machin
biomek
setup
includ
thermal
cycler
plate
magnet
two
peltier
devic
cool
plate
tube
gripper
tool
reagent
reservoir
liquid
wast
dispos
pipet
perform
two
pipet
tool
setup
allow
flexibl
process
four
sampl
per
run
number
loci
per
run
three
box
pipet
tip
use
sampl
panel
variabl
number
sampl
process
biomek
subsequ
pool
librari
sequenc
miseq
system
result
data
analyz
ngsengin
softwar
gendx
read
depth
mappabl
nois
level
sequenc
data
review
show
autom
workflow
result
high
qualiti
read
accur
type
conclud
autom
ngsgo
librari
prepar
biomek
yield
good
consist
librari
signific
reduct
handson
time
luyanda
laura
kwofi
pieter
w
meyer
univers
pretoria
pretoria
south
africa
correspond
luyandakwofi
gmailcom
countri
transplant
guidelin
advoc
screen
kidney
transplant
patient
serum
donorspecif
antihla
antibodi
antibodi
play
crucial
role
graft
reject
eventu
graft
loss
therefor
detect
cytotox
antibodi
one
import
investig
undertaken
potenti
organ
transplant
workup
three
procedur
compar
detect
cytotox
antibodi
identifi
best
suit
optim
pretranspl
donorrecipi
match
serum
sampl
renal
transplant
recipi
await
transplant
test
presenc
hla
antibodi
cdc
fcxm
immucor
luminex
base
dsa
crossmatch
method
use
donor
lymphocyt
two
patient
posit
hla
class
crossmatch
method
test
two
patient
cdcfcxm
patient
dsa
identifi
one
patient
cdcfcxm
posit
neg
cdcfcxm
cdc
show
high
percentag
posit
hla
class
ii
dsa
identifi
two
patient
fcxm
one
four
noncongru
cdc
hla
class
iiposit
sampl
analyz
lymphocyt
singl
antigen
lsa
assay
none
hla
class
ii
antibodi
present
thu
indic
four
sampl
identifi
cdc
falseposit
result
suggest
cdc
hla
class
ii
method
diagnost
applic
high
falseposit
rate
cdc
hla
class
test
limit
applic
cadav
donor
transplant
may
benefici
live
relat
donor
transplant
use
conjunct
anoth
sensit
crossmatch
method
dsa
fcxm
method
show
equival
perform
howev
one
patient
posit
fcxm
reaction
neg
dsa
identifi
establish
patient
presensit
hla
class
ii
antibodi
per
lsa
specif
antibodi
donor
hla
class
ii
allel
therefor
conclud
dsa
could
possibl
add
valu
presensit
kidney
transplant
patient
screen
identifi
presensit
patient
may
reject
donor
graft
due
absenc
donorspecif
antibodi
hla
type
alway
necessari
execut
hematopoiet
stem
cell
transplant
scientif
societi
recommend
extend
highresolut
type
hla
allel
transplant
unrel
haploident
identicalrel
donor
laboratori
perform
highresolut
type
dna
sequenc
sanger
method
use
onecapillari
instrument
abi
prism
reason
possibl
run
mani
sequenc
short
time
strategi
execut
pcrsbt
exon
hla
class
loci
without
use
gssp
primer
addit
exon
led
result
mani
ambigu
due
heterozyg
posit
nonsequenc
exon
therefor
necessari
repeat
test
use
pcrssp
method
also
perform
highresolut
class
ii
type
use
pcrssp
method
strategi
demand
lot
work
part
oper
long
time
obtain
final
result
sinc
use
sequenc
dx
capillari
life
technolog
allow
us
abl
run
mani
sequenc
short
time
thu
also
abl
extend
dna
sequenc
hlaclass
ii
loci
sbtexceller
kit
gendx
also
use
gssp
primer
addit
exon
solv
ambigu
new
strategi
allow
us
obtain
high
resolut
result
ambigu
without
resort
use
pcrssp
therefor
save
lot
time
effort
part
oper
opinion
pcrsbt
sanger
method
use
sequenc
excel
strategi
achiev
unequivoc
highresolut
result
futur
would
like
improv
strategi
introduc
ng
ideal
obtain
result
allel
resolut
test
larg
number
sampl
reinhard
kelsch
hann
graw
bram
luiken
daniel
mathow
sake
van
wageningen
malt
heyer
benjamin
vogel
rafael
alvarez
sirak
kifl
institut
transfus
medicin
transplant
immunolog
germani
gendx
utrecht
netherland
tecan
switzerland
correspond
rkelsch
unimuensterd
hlatyp
nextgener
sequenc
ng
yield
higher
resolut
hlatyp
approach
amongst
differ
supplier
ng
platform
predominantli
illumina
ion
torrent
system
current
use
ngsbase
hla
type
gendx
ngsgo
workflow
despit
advantag
term
hlatyp
resolut
ng
sampl
process
compar
labori
issu
circumv
use
robot
show
result
ngsgo
workflow
illumina
sequenc
autom
freedom
evo
ng
workstat
dna
librari
prepar
consist
dna
fragment
adapt
ligat
index
cleanup
pool
step
complet
workflow
freedom
evo
ng
workstat
set
perform
librari
prepar
four
sampl
pcr
index
step
perform
offlin
thermocycl
allow
workflow
optim
dual
indic
well
format
appli
facilit
autom
index
test
reliabl
autom
workflow
run
dna
sampl
eight
consecut
posit
one
plate
result
differ
index
librari
librari
pool
sequenc
illumina
miseq
system
cycl
number
read
per
librari
rang
time
averag
read
read
mappabl
rang
locu
mappabl
case
valid
perform
run
independ
sampl
panel
conclud
freedom
evo
ng
workstat
use
success
execut
ngsgo
workflow
hla
type
ng
autom
workflow
fast
effici
solut
accur
hla
type
gdna
sampl
applic
ng
technolog
provid
rapid
allel
hla
type
enabl
better
match
improv
clinic
outcom
patient
ng
primer
fullgen
hla
class
type
establish
current
commerci
ng
primer
class
ii
type
amplifi
whole
gene
result
type
ambigu
studi
fullgen
amplif
ng
type
develop
use
previous
report
primer
librari
prepar
carri
use
illumina
trusight
hla
librari
kit
sequenc
miseq
gendx
ngsengin
analysi
ng
type
valid
intern
histocompat
immunogenet
workshop
profici
test
sampl
stem
cell
donor
sampl
previous
type
pcrssop
concord
achiev
two
method
show
field
discrep
fortyeight
sampl
also
amplifi
librari
prepar
use
one
lambda
librari
kit
ion
chef
sequenc
ion
analysi
hla
type
use
typestream
show
concord
histor
pcrssop
type
phase
ambigu
observ
system
due
long
intron
gene
limit
technolog
addit
singl
pcr
amplif
multiplex
primer
previous
report
fullgen
primer
develop
ng
type
preliminari
result
type
sampl
miseq
eight
sampl
ion
show
concord
previou
ng
type
furthermor
ambigu
previous
observ
primer
exclud
exon
resolv
ng
type
fullgen
develop
valid
primer
also
multiplex
produc
singl
amplif
fullgen
sequenc
loci
ng
type
work
reduc
amplif
requir
hla
class
ii
ng
type
help
streamlin
workflow
reduc
cost
improv
test
turnaround
time
next
gener
sequenc
increasingli
consid
gold
standard
method
hla
type
context
french
organ
blood
transfus
etabliss
du
sang
ef
develop
nation
research
develop
r
program
provid
complet
rang
reagent
instrument
lead
fast
simpl
robust
ng
strategi
develop
tool
cover
phase
ng
process
apart
sequenc
reaction
speciallydesign
ngmix
amplifi
classic
nonclass
class
class
ii
gene
hlaa
b
c
e
f
g
amplicon
fragment
achiev
ngfrag
novel
instrument
recent
develop
ef
less
one
minut
allow
ultrasonicationbas
fragment
sampl
uniqu
singl
step
highli
standard
sonic
step
gener
fragment
uniform
rang
optim
size
averag
bp
elimin
requir
perform
timeconsum
fragment
size
select
purif
step
librari
subsequ
gener
less
one
hour
use
nglib
specif
reagent
produc
normal
librari
without
need
perform
extra
pcr
reaction
tag
librari
molar
consist
reliabl
quantifi
use
ngquant
qpcr
method
use
specif
probe
sequenc
reaction
perform
miseq
system
illumina
analysi
ngview
data
compil
interpret
softwar
design
ef
method
use
gener
result
homozyg
refer
cell
line
random
bmvd
sampl
previous
genotyp
anoth
ng
commerci
product
omixon
result
present
along
import
aspect
technic
advantag
ef
ng
approach
step
process
descript
allel
system
observ
linkag
disequilibrium
classic
nonclass
hla
gene
descript
new
allel
time
prepar
abstract
allel
discov
method
alreadi
list
ipdimgthla
databas
sandra
g
guerra
siobhan
hamiltonjon
colin
j
brown
cristina
v
navarret
winni
chong
nh
blood
transplant
london
unit
kingdom
great
britain
correspond
sandraguerra
nhsbtnhsuk
high
resolut
hla
type
ng
reduc
need
extend
type
registri
donor
result
faster
identif
match
unrel
stem
cell
donor
nh
cord
blood
bank
nhscbb
donat
ng
type
sinc
divers
cohort
donor
london
selfreport
ethnic
lead
inaccuraci
ethnic
data
studi
dna
sampl
nhscbb
donor
compris
european
caucasoid
mix
ancestri
south
asian
african
caribbean
asian
central
east
south
east
asia
middl
eastern
south
american
jewish
ng
type
hlaa
b
c
use
one
lambda
nxtype
sampl
alltyp
sampl
kit
ion
ion
chef
system
analyz
use
typestream
visual
pypop
softwar
analysi
reveal
distinct
allel
k
hlaa
k
b
c
nxtype
alltyp
kit
show
resolut
noncommon
allel
includ
b
c
expect
overal
haplotyp
analysi
show
frequent
probabl
haplotyp
latter
frequent
probabl
haplotyp
european
caucasoid
furthermor
addit
type
reveal
increas
level
divers
within
overal
cohort
applic
hla
loci
resolut
ng
reveal
increas
level
divers
nhscbb
incorpor
data
coupl
ethnic
data
could
lead
improv
donor
select
human
killercel
immunoglobulinlik
receptor
kir
report
effect
hlamatch
hematopoiet
stem
cell
transplant
outcom
facilit
select
potenti
stem
cell
donor
base
kir
genotyp
establish
exonbas
ng
workflow
kir
type
use
workflow
million
donor
type
thousand
novel
kir
allel
sequenc
discov
present
new
longrang
amplif
approach
develop
fulllength
character
submiss
novel
kir
allel
base
data
haplotyp
kir
sequenc
project
design
comprehens
longrang
pcrapproach
specif
amplif
kir
gene
amplifi
distinct
kir
gene
includ
utr
set
forward
revers
primer
use
variou
combin
result
amplicon
kb
length
evalu
specif
approach
gener
long
sequenc
read
use
pacif
bioscienc
sequel
smrt
technolog
primer
combin
averag
least
read
map
target
kir
gene
assay
success
adapt
differ
sampl
type
includ
dna
extract
buccal
swab
known
challeng
target
longrang
pcr
gener
refer
qualiti
sequenc
novel
kir
allel
appli
dualsequenc
approach
combin
data
longand
shortread
technolog
success
employ
method
amplifi
sequenc
novel
kir
allel
sampl
submit
sequenc
ipdkir
databas
contribut
consider
knowledg
kir
divers
histogenet
ossin
ny
unit
state
america
correspond
nezih
histogeneticscom
dna
sequenc
exon
encod
antigen
recognit
site
ar
consid
gold
standard
high
resolut
type
hla
class
ii
well
known
variat
site
whole
gene
could
modul
knock
express
hla
protein
laboratori
perform
inphas
long
rang
sequenc
class
ii
gene
one
routin
type
method
sinc
juli
type
sampl
use
approach
pacbio
smrt
sequenc
platform
pcr
amplicon
span
intron
intron
intron
gene
sampl
novel
variat
class
ii
ar
exon
sampl
novel
variat
nonar
region
close
sampl
novel
intron
sequencesw
found
sampl
variat
nonar
exon
could
result
prematur
stop
codon
nonsens
protein
sampl
variat
intron
spliceosom
site
could
chang
length
translat
protein
caus
prematur
stop
codon
nonsens
protein
howev
sequenc
long
intron
region
class
ii
gene
still
challeng
certain
region
long
homopolym
short
tandem
repeat
region
could
pcr
well
sequenc
artifact
better
method
develop
current
mask
region
analysi
inphas
long
rang
sequenc
class
ii
gene
import
step
forward
rais
bar
high
resolut
gold
standard
hla
type
improv
dna
sampl
collect
yield
longer
amplicon
size
facilit
achiev
whole
gene
class
ii
sequenc
accomplish
today
smrt
technolog
sequenc
amplicon
recent
studi
indic
hsct
mismatch
donor
recipi
major
histocompat
complex
mhc
class
chainrel
molecul
mica
may
implic
sever
mismatch
classic
hla
gene
consequ
ad
marker
donor
recruit
genotyp
profil
adapt
ng
algorithm
nextyp
obtain
genotyp
result
mica
far
nextyp
support
gene
hlaa
b
c
e
abo
rhd
kir
highthroughput
genotyp
given
indic
micb
match
might
also
relev
donor
select
decid
genotyp
loci
multiplex
setup
setup
compris
primer
individu
amplicon
exon
singl
amplicon
span
exon
therebi
abl
uniqu
determin
known
mica
micb
allel
particular
sequenc
polymorph
resolv
unambigu
sequenc
employ
wellestablish
concept
involv
illumina
miseq
hiseq
instrument
cope
lack
locu
specif
primer
design
took
advantag
quantit
algorithm
develop
kir
genotyp
valid
workflow
carri
use
sampl
known
genotyp
mica
micb
respect
mica
micb
genotyp
full
concord
pretyp
result
remain
three
mica
one
micb
sampl
result
obtain
due
pcr
failur
sinc
start
routin
type
potenti
donor
newli
ad
loci
type
result
identifi
posit
unambigu
regard
first
field
resolut
mica
micb
type
result
unambigu
observ
potenti
new
allel
result
thu
mica
micb
type
result
valuabl
contribut
standard
type
profil
potenti
stem
cell
donor
welsh
transplant
immunogenet
laboratori
pontyclun
unit
kingdom
great
britain
correspond
walesnhsuk
uk
neqa
h
scheme
assess
particip
abil
correctli
hla
type
sampl
field
resolut
howev
introduct
next
gener
sequenc
technolog
enabl
laboratori
routin
hla
type
sampl
higher
resolut
extern
qualiti
assess
eqa
scheme
exist
introduc
pilot
eqa
scheme
monitor
field
hla
type
result
particip
invit
hla
type
scheme
blood
sampl
field
resolut
particip
could
report
combin
field
result
combin
hla
loci
result
assess
lab
test
sampl
result
allel
report
field
resolut
highest
number
field
result
report
hlab
c
allel
report
unambigu
field
result
eg
b
report
unambigu
field
result
eg
b
contain
report
multipl
allel
ambigu
field
eg
b
highest
proport
unambigu
field
result
report
hlaa
result
least
dpba
highest
proport
field
ambigu
report
result
none
report
six
allel
result
particip
agreement
exampl
hlac
allel
report
c
c
c
c
new
discrep
allel
involv
c
find
discrep
field
hla
type
show
eqa
scheme
requir
uk
neqa
h
formal
assess
result
report
field
scheme
killercel
immunoglobulinlik
receptor
kir
encod
gene
leukocyt
receptor
complex
lrc
gene
highli
polymorph
level
structur
variant
copynumb
variat
furthermor
kir
gene
show
high
degre
sequenc
homolog
characterist
make
challeng
design
specif
amplif
perform
reliabl
analysi
result
accur
identif
kir
allel
present
sampl
enabl
highresolut
kir
genotyp
develop
ngsbase
strategi
involv
whole
gene
amplif
kir
gene
use
kirspecif
primer
amplifi
one
kir
gene
amplicon
process
librari
prepar
ngsgo
gendx
sequenc
illumina
miseq
platform
bp
result
sequenc
genotyp
ngsengin
softwar
gendx
use
kir
databas
ipdkir
multipl
ihwg
sampl
known
unknown
kir
genotyp
analyz
use
new
strategi
proofofconcept
studi
kir
framework
gene
demonstr
amplif
sequenc
subsequ
type
success
major
sampl
mani
sampl
could
type
unambigu
despit
fact
phase
fulli
accomplish
due
length
gene
kb
kir
gene
locusspecif
amplif
subsequ
analysi
prove
challeng
larg
due
high
degre
homolog
sequenc
gene
present
result
proof
concept
show
feasibl
perform
kir
genotyp
framework
gene
high
resolut
possibl
allel
level
use
short
read
sequenc
technolog
illumina
new
type
strategi
may
attract
altern
exist
kir
genotyp
assay
determin
kir
gene
content
limit
resolut
complex
sequenc
method
aim
sequenc
entir
lrc
simplic
assay
would
allow
integr
assay
alreadi
exist
ngsgo
workflow
hla
gendx
benefit
combin
kir
hla
type
highresolut
level
mhc
class
cattl
highli
divers
includ
larg
copi
number
variat
polymorph
mhc
class
gene
knowledg
divers
mostli
limit
allel
divers
haplotyp
structur
three
full
haplotyp
character
haplotyp
contain
least
one
four
classic
class
gene
gene
classic
gene
belong
one
six
differ
allel
group
date
cattl
class
allel
deposit
ipdmhc
databas
deriv
holstein
breed
high
structur
divers
made
difficult
assembl
fulli
character
region
short
sequenc
read
produc
second
gener
sequenc
target
genom
enrich
roch
nimblegen
seqcapez
probe
subsequ
longread
singlemolecul
realtim
smrt
sequenc
abl
de
novo
assembl
five
holstein
mhc
haplotyp
use
individu
mhc
homozyg
herd
approxim
base
map
cattl
chromosom
locat
within
target
region
includ
class
ii
region
produc
averag
coverag
allel
content
correct
assembl
first
time
confirm
locat
classic
gene
haplotyp
gener
full
gene
sequenc
current
adapt
analysi
pipelin
heterozyg
anim
identifi
new
mhc
haplotyp
allel
confid
develop
understand
cattl
mhc
evolut
vicki
van
sandt
aleksandar
senev
johan
kerkhof
ming
li
tommi
liu
heylen
christin
mariepaul
emond
belgian
red
crossfland
mechelen
belgium
immucor
mountain
view
ca
unit
state
america
immucor
transplant
diagnost
nijlen
belgium
correspond
vickyvansandt
rodekruisb
next
gener
sequenc
separ
allel
make
test
sensit
also
prone
cross
contamin
next
ng
increas
hla
genotyp
resolut
allel
resolut
howev
clear
cut
especi
allel
differ
number
short
tandem
repeat
str
map
power
versu
pitfal
ng
workflow
evalu
mia
fora
test
sensit
impact
cross
contamin
assess
valu
allel
resolut
look
qualiti
str
call
compar
result
third
gener
smrt
sequenc
tg
pacbio
sanger
data
mia
fora
ng
test
sensit
high
result
minimum
coverag
concord
refer
genotyp
allel
re
ngl
hlaa
ngl
ngl
hlab
c
dq
dp
evalu
impact
cross
contamin
spike
homozyg
sampl
ngl
dna
refer
sampl
ngl
class
data
show
impact
cross
contamin
class
ii
data
second
allel
ad
homozyg
result
start
spike
concentr
ngl
impact
cross
contamin
seen
even
data
reflect
power
limit
ng
interpret
algorithm
allel
imbal
toler
class
ii
allel
especi
dq
mia
fora
allel
resolut
reproduc
one
fourth
field
discord
allel
call
demonstr
robust
workflow
softwar
analysi
homopolym
region
mia
fora
ng
data
show
confid
call
limit
background
read
indel
pacbio
cc
circular
consensu
correct
read
data
sampl
show
significantli
higher
background
homopolym
region
str
one
nucleotid
show
divers
distribut
number
repeat
ng
data
render
allel
resolut
case
question
analysi
tg
data
sampl
still
go
sue
davey
dimitra
niokou
zareen
deplano
monica
kyriac
trevor
green
vasnti
jesanihethcoat
thusa
sathananthan
colin
brown
nh
blood
transplant
london
unit
kingdom
great
britain
correspond
suerdavey
aolcom
use
next
gener
sequenc
ng
hla
type
increas
throughout
europ
although
ng
advantag
hla
allel
level
definit
complex
laboratori
protocol
present
practic
challeng
compar
previou
hla
type
technolog
nhsbt
colindal
develop
inhous
protocol
consist
dna
purif
dna
quantif
normal
whole
gene
pcr
amplif
hlaa
b
c
amplicon
quantif
pool
librari
prepar
use
trusighthla
illumina
follow
sequenc
miseq
singl
sampl
requir
sampl
transfer
step
addit
pipet
event
increas
pipet
step
includ
sampl
transfer
process
batch
sampl
well
physic
demand
present
manual
pipet
associ
risk
repetit
strain
transfer
step
potenti
sampl
mix
contamin
minim
risk
implement
autom
step
ng
protocol
use
biomek
liquid
handl
robot
program
beadbas
purif
dna
librari
prepar
made
avail
beckman
coulter
remain
autom
process
develop
inhous
facilit
sampl
track
applic
nhsbt
colindal
first
uk
laboratori
implement
whole
gene
ng
stem
cell
registri
hla
type
use
inhous
protocol
autom
ng
pipelin
reduc
handson
time
compar
manual
protocol
manual
pipet
limit
prepar
bulk
reagent
sampl
transfer
use
liquid
handl
robot
associ
sampl
track
softwar
decreas
risk
human
error
provid
assur
sampl
integr
also
less
oper
depend
enabl
high
throughput
hla
type
donor
per
year
hla
type
stem
cell
transplant
diagnost
requir
highresolut
type
combin
class
class
ii
hla
gene
donor
recipi
evid
genotyp
nonclass
hlae
gene
may
also
clinic
signific
may
impact
transplant
outcom
enabl
hlae
genotyp
high
allel
level
resolut
develop
ngsbase
strategi
involv
pcr
amplif
hlae
gene
librari
prepar
ngsgo
gendx
sequenc
illumina
miseq
platform
genotyp
ngsengin
softwar
gendx
type
base
whole
hlae
gene
includ
exon
intron
type
multipl
ihwg
ucla
gdna
sampl
n
valid
perform
assay
hlae
amplif
highli
robust
give
type
result
concord
expect
pretyp
present
result
show
sampl
unambigu
hlae
genotyp
field
level
obtain
allel
identifi
belong
hlae
hlae
group
howev
allel
sequenc
variat
intron
exon
also
identifi
albeit
much
lower
frequenc
also
includ
new
allel
submit
ipdimgthla
databas
expand
list
known
hlae
allel
new
strategi
allow
extend
alreadi
exist
ngsgo
workflow
class
class
ii
hlae
ultim
hla
type
base
full
spectrum
clinic
relev
hla
loci
one
singl
assay
amalia
dinou
maria
spyropoulouvlach
vasiliki
vrani
efstathio
michalopoulo
catherin
stavropoulosgioka
hellen
cord
blood
bankbiomed
research
foundat
academi
athen
athen
greec
alexandra
gener
hospit
athen
athen
greec
gener
hospit
athen
ggennimata
athen
greec
correspond
adin
bioacademygr
hla
type
requir
unrel
donor
cord
blood
unit
chang
year
reflect
chang
methodolog
use
wherea
first
registri
establish
donor
list
hlaa
b
serolog
type
today
donor
cbu
dna
type
hlaa
b
c
mostli
sbt
type
list
registri
avail
year
repeat
unless
request
discrep
reveal
alway
due
sampl
mixup
cleric
error
accuraci
method
use
hellen
cord
blood
bank
hcbb
cbu
type
perform
pcrsso
hlaa
b
c
sinc
hlaa
b
c
loci
ng
correspond
mother
also
type
nimamatch
purpos
also
help
resolv
ambigu
spot
sampl
mixup
recent
cb
unit
initi
type
pcrsso
lifecod
immucor
labtyp
onelambda
nation
tissu
type
center
retyp
ng
holotyp
omixon
hcbb
hla
type
lab
use
dna
sampl
obtain
result
concord
first
field
except
one
sampl
b
locu
cbu
type
file
hlab
ng
type
reveal
hlab
mother
type
hlab
hlab
respect
loci
consist
initi
type
sampl
sampl
mixup
could
dismiss
initi
type
report
request
one
cbu
found
propos
assign
b
b
consist
unphas
polymorph
quick
search
show
ca
nt
differenti
pcrssp
unfortun
databas
contain
matern
type
corrupt
initi
type
could
reexamin
twin
softwar
b
pair
best
match
present
nonexon
mismatch
obtain
phase
sequenc
appear
b
pair
assign
use
mother
type
refer
exampl
illustr
power
ng
methodolog
resolv
phase
ambigu
especi
class
gene
univers
complutens
madrid
region
blood
center
centro
de
transfus
madrid
spain
immunogenet
universidad
del
nort
barranquilla
colombia
correspond
arnaizvil
hotmailcom
america
first
inhabit
popul
amerindian
na
dene
eskimo
underw
drastic
popul
reduct
gene
exchang
european
african
arriv
ad
barranquilla
popul
may
good
model
studi
present
day
popul
admixtur
south
america
hlaa
b
dna
type
perform
unrel
individu
origin
area
speak
spanish
show
appar
european
african
mix
characterist
hla
genet
european
african
featur
found
show
amerindian
characterist
contrast
neighbor
cuban
popul
amerindian
charact
appear
popul
ossetian
vladikavkaz
russia
uniqu
among
ethnic
group
caucasu
region
wherea
geograph
neighbor
speak
caucasian
languag
ossetian
speak
iranian
languag
belong
indoeuropean
languag
famili
could
possibl
descend
scythiansarmatian
tribe
alan
therefor
assess
ossetian
immunogenet
profil
particular
interest
one
hundr
twentyseven
healthi
potenti
bone
marrow
donor
registri
nation
research
center
hematolog
moscow
type
hlaa
b
c
luminex
immucor
usa
donor
vladikavkaz
ossetian
nation
frequent
allel
hlaa
locu
frequenc
three
common
allel
hlab
locu
b
b
b
hlac
locu
c
frequenc
c
c
among
allel
hla
class
ii
gene
preval
one
hundr
thirtyeight
fivelocu
haplotyp
variant
identifi
among
ossetian
arlequin
frequent
haplotyp
frequenc
r
haplotyp
found
case
thu
popul
ossetian
vladikavkaz
combin
featur
european
asian
popul
indic
high
frequenc
allel
variant
b
b
b
distinct
featur
ossetian
high
frequenc
hlab
allel
dr
haplotyp
compar
russian
world
popul
popul
ossetian
uniqu
materi
inclus
registri
potenti
bone
marrow
donor
sinc
presenc
repres
uniqu
genotyp
regist
increas
chanc
find
unrel
donor
patient
rare
hla
genotyp
determin
incid
hla
haplotyp
associ
cd
group
pediatr
patient
slovak
popul
cd
evalu
risk
antigen
develop
cd
import
examin
clinic
practic
assess
whether
doubl
dose
associ
gene
affect
predisposit
cd
group
patient
includ
patient
cd
women
men
age
year
histolog
confirm
diagnosi
cd
hla
alleleshaplotyp
determin
pcrssp
commerci
kit
bag
health
care
gmbh
germani
statist
analysi
use
chtest
pcorr
odd
ratio
valid
test
hla
haplotyp
associ
cd
group
cd
patient
follow
frequenc
haplotyp
allel
haplotyp
allel
haplotyp
allel
patient
genotyp
one
associ
hla
haplotyp
patient
haplotyp
predisposit
cd
immunogenet
analysi
base
molecular
genet
confirm
associ
antigen
allel
cd
slovak
popul
frequenc
patient
group
control
popul
antigen
associ
cd
neg
patient
repres
addit
genet
risk
combin
genet
risk
antigen
cd
character
slovak
popul
follow
valu
frequenc
cd
patient
frequenc
popul
specif
predict
valu
posit
find
patient
doubl
dose
associ
allel
compos
homozyg
show
significantli
higher
risk
develop
cd
comparison
patient
one
dose
allel
turkan
patiroglu
murat
cansev
aykut
poyraz
erciy
univers
kayseri
turkey
correspond
turkanp
erciyesedutr
combin
immunodefici
cid
primari
immunodefici
diseas
sever
loss
b
lymphocyt
function
lymphopenia
import
find
diagnosi
cid
therefor
plan
screen
lymphopenia
cord
blood
sampl
labor
complet
blood
count
cbc
measur
cord
blood
sampl
everi
babi
born
hospit
januari
decemb
lymphocyt
count
classifi
neonat
lymphopenia
immunolog
investig
includ
serum
immunoglobulin
level
lymphocyt
subgroup
chest
radiographi
thymu
shadow
evalu
newborn
lymphopenia
studi
cbc
measur
cord
blood
sampl
labor
lymphopenia
found
mean
lymphocyt
count
calcul
two
newborn
lymphopenia
cid
accord
immunolog
investig
one
patient
cid
rag
defici
lymphopenia
occur
may
includ
infecti
genet
system
iatrogen
caus
earli
diagnosi
cid
lifesav
neonat
screen
lymphopenia
import
earli
diagnosi
cid
samara
region
locat
southeastern
part
european
territori
russia
middl
volga
region
chelyabinsk
region
situat
km
east
samara
region
slope
south
ural
transur
major
popul
two
region
ethnic
russian
accord
last
popul
censu
samara
region
chelyabinsk
region
habit
russian
present
studi
initi
investig
hla
allel
haplotyp
divers
two
russian
popul
hla
type
perform
use
sso
ssp
techniqu
low
resolut
hlaa
b
analyz
hla
data
cord
blood
unit
samara
region
cord
blood
bank
bone
marrow
donor
chelyabinsk
region
blood
transfus
station
donor
cbu
parent
survey
accord
genealog
recommend
live
full
time
samara
chelyabinsk
region
despit
fact
frequent
allel
popul
found
signific
differ
presenc
samara
popul
vs
chelyabinsk
popul
vs
vs
b
vs
b
vs
b
vs
allel
frequenc
locu
found
signific
differ
although
saw
differ
allel
frequenc
frequent
haplotyp
popul
found
russian
differ
popul
samara
chelyabinsk
region
small
differ
hla
allel
frequenc
side
top
frequent
haplotyp
data
hla
allel
haplotyp
frequenc
primarili
intend
popul
genet
purpos
diseas
associ
studi
sever
acut
respiratori
syndrom
sar
known
first
major
epidem
begin
centuri
caus
thousand
infect
worldwid
china
place
epidem
origin
sever
affect
popul
around
world
highli
infecti
diseas
caus
novel
coronaviru
sarscov
immun
reaction
still
remain
unclear
human
leukocyt
antigen
hla
variat
report
associ
wide
rang
infect
due
essenti
role
immun
respons
aim
describ
genet
pattern
hlaa
b
c
loci
recov
sar
patient
beij
examin
associ
hla
gene
suscept
resist
sar
use
data
north
chines
bone
marrow
donor
control
total
recov
chines
han
sar
patient
recruit
donat
convalesc
plasma
particip
unrel
diagnos
accord
world
health
organ
case
definit
sar
hla
highresolut
type
carri
use
sbt
report
novel
allel
offici
assign
world
health
organ
nomenclatur
committe
april
identifi
volunt
chines
cord
blood
donor
donor
dna
amplifi
sequenc
alleleseqr
sequenc
kit
sequenc
reaction
product
process
abi
dna
analyz
analyz
assign
softwar
nucleotid
sequenc
hlaa
hlab
hlac
exon
exon
exon
analyz
dna
sequenc
result
locu
sampl
match
known
allel
combin
low
resolut
type
perform
use
gt
hla
ssp
type
kit
locu
type
character
novel
allel
sampl
exon
sequenc
allel
amplifi
separ
use
tbg
groupspecif
sequenc
kit
present
studi
abl
describ
coverag
fulllength
hla
sequenc
phase
genotyp
singular
divers
associ
hla
allel
haplotyp
evid
result
obtain
convent
hla
type
method
therefor
level
resolut
obtain
ng
allow
studi
detail
hla
divers
code
noncod
sequenc
level
hla
type
data
spanish
cohort
also
collect
part
intern
histocompat
immunogenet
workshop
ihiw
studi
unrel
subject
ng
hla
result
may
contribut
use
refer
sourc
futur
popul
studi
diseas
associ
studi
healthi
control
group
futur
plan
unrel
bone
marrow
donor
registri
hlaa
frequent
hla
haplotyp
detect
common
hla
haplotyp
studi
group
initi
data
regard
haplotyp
show
similar
frequenc
haplotyp
observ
previou
studi
center
hlaa
b
c
haplotyp
allel
frequenc
well
preliminari
haplotyp
frequenc
correspond
frequenc
respect
hla
allel
haplotyp
greek
european
popul
result
use
popul
diseas
associ
studi
genet
distanc
studi
balkan
mediterranean
area
patern
case
well
hsct
sot
take
account
hladp
implement
donor
specif
antibodi
monitor
maria
anagnostouli
serafeim
katsavo
artemio
artemiadi
medic
school
athen
nation
kapodistrian
univers
aeginit
hospit
athen
greec
correspond
managnost
meduoagr
multipl
sclerosi
ms
studi
demyelin
diseas
central
nervou
system
affect
mainli
young
adult
earlyonsetm
eom
pediatricadolesc
rare
ms
manifest
repres
case
role
allel
well
establish
adultonsetm
aom
confirm
mani
caucasian
popul
hellen
includ
allel
frequenc
eom
found
differ
variou
ethnic
group
preponder
hellen
eom
patient
recent
carriag
allel
identifi
anoth
genet
predispos
factor
develop
aom
hellen
caucasian
popul
total
absenc
studi
regard
allel
frequenc
eom
though
prompt
team
examin
characterist
group
hellen
ms
patient
recruit
eom
aom
patient
genotyp
polymorph
allel
obtain
formal
consent
hlagenotyp
perform
sequenc
specif
oligonucleotid
sso
techniqu
compar
allel
frequenc
eom
aom
subgroup
well
sampl
hellen
healthi
control
genotyp
previou
studi
allel
aom
patient
significantli
lower
vs
higher
vs
vs
vs
allel
frequenc
healthi
control
patient
age
ms
onset
aao
younger
year
significantli
lower
frequenc
vs
also
found
eom
patient
significantli
higher
frequenc
aom
patient
vs
previous
confirm
distinct
profil
eom
aom
along
discov
differ
allel
frequenc
studi
highlight
possibl
fundament
role
genom
determin
aao
ms
result
need
replic
larger
ms
cohort
differ
ethnic
group
aim
individu
therapeut
decisionmak
futur
antonio
arnaizvillena
jose
palaciogrub
ester
cristina
campo
javier
alonsorubio
ignacio
juarez
jorg
nieto
shadallah
fareq
salih
manuel
rawand
alqadi
univers
complutens
madrid
region
blood
center
centro
de
transfus
madrid
spain
dohuk
special
laboratori
center
dohuk
iraq
correspond
arnaizvil
hotmailcom
kurd
iraq
dohuk
erbil
area
north
iraq
analyz
hla
gene
hla
genet
profil
compar
kurdish
group
iran
tbilisi
georgia
caucasu
also
worldwid
popul
total
hla
chromosom
use
genet
distanc
neighbor
join
dendrogram
correspond
analys
carri
haplotyp
hlab
present
three
analyz
kurdish
popul
hlaa
present
iraqi
georgian
kurd
haplotyp
common
iranian
iraqi
kurd
hla
hla
other
lower
frequenc
hla
studi
conclus
kurd
probabl
belong
ancient
mediterranean
middl
east
caucasian
genet
substratum
present
result
previous
obtain
us
kurd
may
use
medicin
futur
kurd
transplant
program
hla
epidemiolog
hla
link
diseas
pharmacogenom
hlaassoci
drug
side
effect
also
anthropolog
discuss
one
ancient
kurd
ancestor
group
hurrian
year
bc
genet
distanc
neighbor
join
correspond
analys
also
show
azeri
close
kurd
shown
closer
mediterraneancaucasu
hla
profil
gorgan
turkmen
shown
closer
central
asia
profil
expect
shown
three
differ
iranian
popul
accord
languag
histori
geographi
gorgan
kurd
azeri
genet
close
fact
old
azeri
languag
adari
iranian
languag
turkic
one
nowaday
speak
also
present
studi
support
aryan
invas
east
accord
mani
previou
studi
final
result
use
establish
prevent
medicin
program
transplant
hla
pharmacogenomicsdiseas
linkag
univers
complutens
madrid
region
blood
center
centro
de
transfus
madrid
spain
dohuk
special
laboratori
center
dohuk
iraq
correspond
arnaizvil
hotmailcom
hlag
hlaa
frequenc
analyz
amerindian
ecuador
hlag
allel
frequenc
found
closer
amerindian
maya
guatemala
uro
peru
closer
european
one
far
east
asian
group
particularli
regard
hlag
allel
hlaga
haplotyp
calcul
first
time
amerindian
remark
hlag
allel
found
low
frequenc
like
amerindian
maya
uro
also
found
haplotyp
belong
group
allel
hlaa
previous
postul
hlag
appear
hlaa
haplotyp
middl
eastern
mediterranean
may
hypothes
evolut
hlag
exist
primarili
one
hla
extant
extinct
haplotyp
whether
haplotyp
place
middl
east
world
area
includ
america
howev
highest
present
day
hlag
frequenc
found
middl
eastern
mediterranean
cinzia
vecchiato
evi
lochmann
ivo
gentilini
ospedal
di
bolzano
bolzano
itali
correspond
cinziavecchiato
sabesit
ibmdr
donor
centr
south
tyrol
start
activ
donor
subscrib
donat
sbt
type
systemat
use
registri
donor
subscript
new
donor
sampl
type
high
resolut
hlaa
b
c
accord
polici
ambigu
accept
null
allel
involv
moreov
decid
solv
ambigu
hla
class
type
data
enter
registri
present
less
ambigu
ongo
studi
hla
allel
frequenc
popul
observ
thank
introduct
sbt
twelv
allel
consid
rare
detect
sampl
detect
null
allel
b
c
six
allel
meet
definit
well
defin
accord
mack
sj
et
al
tissu
antigen
previous
report
caucasian
popul
nine
new
allel
identifi
describ
four
new
allel
locat
locu
b
two
new
allel
locu
c
one
locu
six
differ
alreadi
known
allel
encompass
exon
result
differ
protein
antigen
bind
site
sinc
rare
allel
could
dismiss
report
consid
like
found
retrospect
studi
demonstr
even
caucasian
popul
repres
bone
marrow
registri
rare
infrequ
describ
allel
imposs
detect
data
confirm
relev
highresolut
type
subscript
bone
marrow
donor
order
select
suitabl
donor
patient
wait
bone
marrow
transplant
accept
time
also
put
attent
import
share
type
data
better
knowledg
popul
genet
dissemin
confirm
rare
allel
hla
paramount
import
improv
field
immunogenet
well
daili
work
histocompat
laboratori
hlac
allel
yet
confirm
found
spanish
patient
diagnos
psoriasi
complet
hla
class
type
sampl
follow
b
c
dnabas
hla
class
type
perform
pcrssop
luminex
method
use
lifecod
hla
type
kit
genprob
accord
manufactur
instruct
howev
studi
low
resolut
pcrssp
use
fluogen
technolog
plausibl
type
option
given
softwar
c
sampl
also
studi
sequenc
type
obtain
found
luminex
confirm
result
c
import
note
lowresolut
kit
allow
detect
rare
allel
also
case
may
lead
incorrect
lowresolut
type
luminex
technolog
improv
resolut
thu
detect
possibl
allel
variant
summari
found
rare
hlac
allel
spanish
patient
complet
studi
gene
sequenc
allel
confirm
hla
loci
among
polymorph
gene
human
genom
mechan
gener
polymorph
within
mhc
includ
point
mutat
gene
convers
recombin
event
provid
mean
gener
novel
haplotyp
routin
hla
type
identifi
suspect
unequ
cross
short
arm
chromosom
year
old
patient
bengali
origin
affect
adrenoleukodystrophi
ald
demyelin
diseas
inherit
sexlink
recess
trait
allogen
bone
marrow
transplant
treatment
stop
worsen
effect
ald
peripher
blood
sampl
collect
patient
well
parent
one
brother
hlaa
b
c
allel
type
pcrsso
one
lambda
inc
pcrssp
olerup
ssp
locu
investig
sbt
analysi
trough
sequenc
exon
forward
revers
direct
one
lambda
inc
provid
result
without
ambigu
basi
famili
type
haplotyp
assign
follow
father
haplotyp
b
b
mother
haplotyp
c
c
patient
inherit
haplotyp
ad
brother
bc
haplotyp
patient
appear
homozyg
thu
appar
specif
deriv
mother
str
analysi
perform
powerplex
hs
promega
coamplifi
singl
pcr
loci
fga
tpox
vwa
amelogenin
penta
e
penta
confirm
sibl
relationship
among
individu
gener
hla
haplotyp
lack
specif
like
due
unequ
crossov
occur
meiosi
previou
gener
ie
recombin
event
happen
break
occur
precis
homolog
point
two
chromatid
strand
henc
result
local
duplic
genet
materi
one
chromatid
complementari
delet
result
gener
new
haplotyp
carlo
h
parga
lozano
franklin
torr
arac
garcia
universidad
del
barranquilla
colombia
universidad
libr
barranquilla
colombia
correspond
pargacarlo
yahoocom
barranquilla
citi
northern
colombia
citi
high
rate
immigr
last
year
mainli
central
asia
africa
europ
caus
signific
miscegen
popul
along
nativ
amerindian
region
individu
barranquilla
type
detect
allel
hla
allel
frequenc
chromosom
analyz
compar
colombian
amerindian
popul
use
genet
distanc
neighbor
join
dendrogram
nj
correspond
analysi
frequent
allel
sever
new
haplotyp
obtain
frequent
accord
nj
result
correspond
analysi
popul
relat
amerindian
due
presenc
group
nj
phylogenet
tree
base
analys
found
close
relationship
indigen
peopl
colombia
mainli
indigen
sierra
nevada
de
santa
marta
sever
haplotyp
report
previous
popul
barranquilla
relat
amerindian
directli
suggest
miscegen
therefor
futur
studi
includ
mestizo
caucasian
asian
black
popul
obtain
better
phylogenet
relationship
hla
type
patient
multipl
myeloma
brother
sister
found
new
allel
three
five
sibl
onelambda
rsso
type
luminex
togeth
analysi
softwar
fusion
gave
type
result
first
allel
famili
part
haplotyp
similar
normal
part
haplotyp
sure
right
result
reason
type
next
gener
sequenc
ng
develop
workflow
base
long
rang
pcr
lrpcr
ng
therefor
design
differ
hla
locu
andor
allel
specif
lrpcr
sequenc
gener
amplicon
miseq
platform
illumina
subsequ
ng
data
evalu
perform
two
differ
hla
softwar
tool
omixon
twin
omixon
ngsengin
gendx
phase
sequenc
align
accord
individu
singl
nucleotid
variant
snv
pattern
present
end
allelespecif
contig
final
align
contig
done
aliview
muscl
bioedit
clustalw
softwar
along
publish
ipdimgthla
databas
sequenc
fulllength
sequenc
analysi
describ
allel
unravel
quit
high
similar
allel
new
allel
found
point
mutat
c
cgc
tgc
result
arginin
r
cystein
c
exon
supplementari
cystein
seem
caus
question
q
express
three
allel
lrpcr
ng
includ
phase
sequenc
analysi
reveal
unambigu
fulllength
sequenc
new
allel
result
protein
addit
amino
acid
hla
c
delet
one
nucleotid
penultim
exon
caus
frameshift
elong
addit
amino
acid
cytoplasm
tail
far
unknown
mechan
elong
switch
c
c
allel
therefor
expect
novel
hlab
variant
could
null
allel
well
answer
question
perform
serolog
type
hlaa
b
cw
help
cdc
type
tray
onelambda
verifi
mutat
exon
b
new
found
ng
use
sanger
sequenc
analysi
specif
amplif
sequenc
primer
serolog
type
reveal
follow
antigen
pattern
sanger
sequenc
analysi
confirm
minor
sequenc
differ
b
b
posit
recognit
b
new
cdc
type
show
allel
express
cell
surfac
protein
fold
correctli
function
respect
signal
transduct
need
elucid
state
point
mutat
outsid
exon
allel
part
b
group
approach
appli
lrpcr
ng
includ
phase
sequenc
analysi
abl
determin
complet
gene
sequenc
hlab
patient
includ
individu
age
rang
year
old
diagnos
hbc
infect
control
group
consist
healthi
peopl
age
rang
year
old
gene
polymorph
gt
determin
polymeras
chain
reaction
restrict
fragment
length
polymorph
among
particip
hb
agposit
compar
hb
agneg
tt
gt
genotyp
frequent
hbc
patient
compar
control
group
statist
signific
associ
frequenc
allel
patient
normal
popul
studi
show
genotyp
tt
marri
group
higher
singl
group
signific
differ
allel
frequenc
patient
group
studi
indic
tt
gt
genotyp
may
influenc
increas
suscept
hbc
infect
nextgener
sequenc
increasingli
use
transplant
set
also
method
choic
indepth
analysi
populationspecif
hla
genet
architectur
linkag
variou
diseas
respect
ethnic
admixtur
characterist
east
croatian
popul
aim
investig
frequenc
linkag
seven
hla
loci
healthi
unrel
blood
donor
volunt
year
median
age
origin
four
eastern
croatia
counti
genom
dna
extract
hla
genotyp
determin
use
highresolut
omixon
holotyp
hla
kit
illumina
miseq
sequenc
platform
hlaa
b
c
loci
sequenc
entir
length
intron
intron
intron
collect
read
analyz
use
omixon
twin
softwar
ipdimgt
hla
databas
releas
allel
frequenc
linkag
disequilibrium
statist
obtain
direct
count
pypop
softwar
arlequin
use
haplotyp
frequenc
mlem
algorithm
hardyweinberg
departur
guothompson
test
total
allel
determin
thirdfourth
field
resolut
identifi
genet
marker
allopurinolinduc
scar
carri
casecontrol
associ
studi
hla
class
b
type
perform
complement
depend
cytotox
cdc
patient
allopurinolinduc
scar
control
individu
group
allopurinoltoler
subject
group
healthi
subject
gener
popul
describ
first
time
posit
associ
antigen
allopurinolinduc
scar
tunisian
popul
comparison
frequenc
antigen
patient
control
group
signific
vs
p
vs
p
respect
antigen
frequenc
tunisian
popul
found
significantli
associ
allopurinolinduc
scar
detect
case
control
group
control
group
unlik
find
associ
studi
describ
first
time
antigen
associ
allopurinol
induc
scar
south
tunisian
popul
blood
donor
join
bbmr
hlaa
b
c
type
use
whole
gene
ng
methodolog
whole
gene
type
system
use
publish
primer
implement
analysi
first
donor
reveal
high
level
divers
allel
unambigu
identifi
north
european
africanafricancaribbean
chines
donor
review
compar
eleven
allel
identifi
three
group
northern
european
donor
compris
largest
group
n
highest
divers
allel
twentyf
allel
identifi
group
whilst
identifi
one
individu
four
allel
present
panel
phenotyp
frequenc
donor
african
ancestri
differ
allel
identifi
group
ten
occur
northern
european
chines
cohort
six
occur
one
individu
four
allel
present
peopl
phenotyp
frequenc
twenti
differ
allel
identifi
group
chines
donor
five
allel
identifi
north
european
african
group
two
found
six
eight
chines
donor
phenotyp
frequenc
assign
allel
without
use
g
group
nomenclatur
problemat
ng
type
system
howev
type
unambigu
defin
data
show
similar
hla
loci
allel
characterist
particular
ethnic
group
match
wide
consid
select
unrel
stem
cell
donor
knowledg
rel
frequenc
occurr
allel
differ
ethnic
group
contribut
estim
likelihood
identifi
match
donor
complet
genom
sequenc
clarifi
degre
recombin
within
allel
develop
workflow
base
long
rang
pcr
lrpcr
next
gener
sequenc
ng
therefor
design
differ
hla
locu
andor
allel
specif
lrpcr
sequenc
gener
amplicon
miseq
platform
illumina
subsequ
ng
data
evalu
perform
two
differ
hla
softwar
tool
omixon
twin
omixon
ngsengin
gendx
phase
sequenc
align
accord
individu
singl
nucleotid
variant
snv
pattern
present
end
allelespecif
contig
final
align
contig
done
aliview
muscl
bioedit
clustalw
softwar
along
publish
ipdimgthla
databas
sequenc
fulllength
sequenc
analysi
show
insert
part
donor
acceptor
restrict
exon
lrpcr
ng
includ
phase
sequenc
analysi
reveal
unambigu
fulllength
sequenc
allel
extend
upfront
genotyp
profil
registri
sampl
includ
mica
micb
gene
gene
show
high
degre
sequenc
homolog
establish
multiplex
pcr
amplifi
exon
exon
amplicon
span
exon
use
ng
base
workflow
genotyp
registri
donor
report
observ
allel
frequenc
predominantli
european
cohort
unpreced
depth
studi
allow
us
observ
describ
mica
allel
distinguish
protein
code
level
thirteen
abund
allel
account
cumul
allel
frequenc
least
frequent
allel
account
less
newli
develop
ngsbase
genotyp
approach
offer
opportun
analyz
genet
divers
mica
micb
larg
cohort
highresolut
function
aim
ihiw
compon
immunogenet
age
identifi
new
biomark
success
age
focus
immun
respons
gene
collabor
studi
show
kir
functionallyrelev
haplotyp
import
factor
control
cmv
infect
elderli
cytokin
genotyp
relat
increas
antiinflammatori
profil
posit
associ
longev
longev
popul
studi
associ
posit
select
haplotyp
shown
protect
diseas
therefor
within
ihiw
appli
ng
approach
order
precis
identifi
immunogenet
determin
success
age
statist
signific
associ
longev
observ
hla
allel
haplotyp
among
allel
c
shown
part
ancestr
haplotyp
relat
one
hallmark
age
shift
immun
respons
although
associ
autoimmun
confer
better
immun
respons
viral
infect
data
confirm
clarifi
posit
associ
age
haplotyp
addit
b
haplotyp
shown
protect
hematolog
malign
significantli
increas
elderli
result
allow
elucid
hla
associ
longev
suggest
hla
allel
haplotyp
could
inform
immunogenet
marker
success
age
discoveri
potenti
new
marker
influenc
longev
suscept
age
relat
diseas
contribut
develop
strategi
rejuven
immun
system
prevent
replic
senesc
june
high
resolut
hlatyp
set
unrel
hematopoiet
stem
cell
transplant
hsct
donor
search
carri
laboratori
year
old
acut
myeloid
leukemia
patient
initi
blood
sampl
hlatyp
sequencebas
type
use
gener
well
antigenspecif
primer
due
unexpect
result
sampl
retest
use
next
gener
sequenc
ng
longrang
pcr
methodolog
initi
type
reveal
normal
hlab
allel
well
chimer
b
new
hlab
variant
point
mutat
consist
c
base
chang
posit
exon
result
amino
acid
chang
serin
phenylalanin
posit
identif
dual
hlab
allel
made
possibl
hlab
specif
sequenc
primer
allow
sequenc
phase
ng
test
show
preval
allel
variant
carri
point
mutat
repres
patient
overal
hlab
locu
content
order
exclud
possibl
point
mutat
leukemiaassoci
addit
mouth
swab
specimen
request
result
sampl
confirm
initi
type
subsequ
highresolut
type
patient
two
son
b
b
respect
disclos
mutationfre
b
variant
pass
patient
descend
consid
similar
result
blood
saliva
sampl
conjunct
high
preval
rate
new
allel
variant
plausibl
presum
latter
must
arisen
earli
phase
patient
embryogenesi
henc
like
express
nonblood
cell
well
patient
final
transplant
unavoid
ballel
mismatch
peripher
blood
stem
cell
pbsc
graft
patient
case
perfect
exampl
modern
hlatyp
techniqu
unravel
rare
genet
alter
potenti
signific
patient
treatment
prognosi
could
go
unnot
still
use
albeit
outdat
methodolog
extens
linkag
disequilibrium
ld
extend
hla
xhla
region
wellknown
also
data
suggest
differ
rest
genom
haplotypespecif
ld
current
algorithm
consid
ld
beyond
kb
given
xhla
cover
mb
use
haploview
analyz
immunochip
data
hlatyp
ihwg
refer
cell
line
cover
whole
xhla
genom
project
data
replic
pair
snp
map
extrem
end
xhla
show
longrang
ld
r
strongest
longrang
ld
r
observ
common
snp
hla
specif
longestrang
absolut
ld
r
note
exclus
hlaa
exclus
second
longestrang
ld
r
exclus
ancestr
haplotyp
ah
hlaa
fact
hundr
addit
snp
pair
strong
ld
r
within
genom
rang
uniqu
snp
pair
specif
show
strong
ld
project
data
popul
level
ethnic
effort
confirm
longrang
ld
exist
xhla
uniqu
one
ancestr
haplotyp
result
suggest
gwa
associ
snp
particularli
difficult
interpret
strong
ld
among
may
extend
beyond
mb
sinc
although
antigenrel
fluctuat
hlac
c
surfac
express
report
african
american
app
et
al
scienc
coher
data
exist
european
caucasian
furthermor
still
unclear
extent
two
known
crelat
polymorph
predict
c
express
level
aim
studi
shed
light
question
quantifi
c
surfac
express
healthi
german
blood
donor
also
genotyp
rs
ct
rs
in
del
c
express
buffycoat
deriv
lymphocyt
caucasian
individu
determin
flow
cytometri
previous
describ
app
et
al
scienc
subject
also
genotyp
rs
ct
rs
insdel
ng
median
intens
fluoresc
coeffici
calcul
c
allotyp
implement
linear
regress
model
accordingli
rs
genotyp
c
antigen
imput
flow
cytometri
measur
reveal
highli
signific
overlap
result
app
et
al
african
american
c
allotyp
divid
highand
lowexpress
one
discrep
observ
concern
c
impact
two
polymorph
c
surfac
express
data
confirm
associ
in
genotyp
lower
express
level
howev
regard
rs
insdel
appear
result
strong
linkag
disequilibrium
ld
genotyp
p
common
low
express
c
c
allotyp
sinc
high
express
yet
less
common
c
c
also
found
strong
ld
p
in
allel
rs
ct
hand
appear
better
predict
c
express
level
result
c
express
level
european
caucasian
highli
match
african
american
previous
report
app
et
al
addit
data
impli
ct
probabl
reliabl
c
express
surrog
marker
insdel
undeni
definit
conclus
drawn
research
requir
addit
caucasian
ethnic
oliv
baboon
often
serv
model
speci
immun
responserel
studi
renal
xenotransplant
research
therefor
knowledg
mhckir
interact
need
speci
human
mutual
exclus
epitop
map
alpha
domain
class
molecul
posit
may
act
substrat
antibodi
divers
kir
allotyp
epitop
also
document
macaqu
specif
molecul
shown
recogn
broad
rang
mhc
class
molecul
also
motif
therefor
search
presenceabs
motif
mhc
class
molecul
oliv
baboon
record
macaqu
ident
motif
nlrialr
locat
paana
b
molecul
conserv
slrnlrg
motif
howev
present
two
paana
two
paanb
allotyp
well
paanb
lineag
member
addit
canon
motif
nlrnlrg
present
respons
bind
also
present
sever
paana
allotyp
includ
paana
lineag
nucleotid
sequenc
form
separ
branch
phylogenet
tree
cluster
allel
encod
canon
motif
may
indic
special
function
molecul
nowaday
one
import
issu
success
human
tissu
transplant
find
compat
donor
multipl
hla
loci
besid
avail
hla
genotyp
data
million
stem
cell
donor
throughout
world
deep
knowledg
occurr
hla
haplotyp
differ
popul
also
great
potenti
context
haplotyp
compat
may
decreas
risk
graft
versu
host
diseas
among
put
undesir
consequ
transplant
addit
haplotyp
frequenc
linkag
disequilibrium
inform
popul
genet
analyz
effect
demographi
andor
natur
select
hla
molecular
evolut
public
first
efi
catalogu
common
welldocu
cwd
hla
allel
object
efi
popul
genet
work
group
creat
record
common
hla
haplotyp
current
haplotyp
estim
genotyp
use
appropri
expectationmaxim
algorithm
often
welldetermin
linkag
disequilibrium
signific
test
addit
famili
segreg
analys
essenti
confirm
presenc
haplotyp
differ
popul
thu
start
analyz
larg
databas
multilocu
genotyp
avail
famili
data
aim
constitut
repositori
confirm
welldetermin
cwd
hla
haplotyp
europ
pilot
studi
propos
specif
criteria
defin
cwd
haplotyp
present
preliminari
map
multilocu
haplotyp
across
contin
also
show
implement
new
haplotyp
viewer
hlaneteu
gene
rate
tool
use
transplant
popul
genet
studi
human
leukocyt
antigen
hla
loci
highli
polymorph
serv
key
role
immun
respons
histocompat
howev
allel
phase
inform
vital
detail
analysi
therefor
construct
highresolut
haplotyp
databas
provid
power
tool
downstream
analys
greatli
support
studi
popul
genet
diseas
associ
signific
work
done
haplotyp
frequenc
often
restrict
resolut
field
tradit
method
addit
previou
work
usual
reli
imput
make
use
exclus
homozyg
cell
line
lastli
knowledg
major
hla
loci
yet
haplotyp
togeth
prompt
need
overcom
aspect
one
analysi
demonstr
method
build
high
resolut
hla
haplotyp
major
hla
loci
without
reli
imput
approxim
famili
trio
sequenc
use
ng
technolog
individu
sampl
genotyp
high
resolut
hla
loci
use
ng
analysi
softwar
manual
review
confirm
four
haplotyp
famili
trio
gener
phase
analysi
mendelian
constraint
ambigu
result
member
share
heterozyg
genotyp
resolv
use
coalescencebas
imput
result
resolut
show
possibl
haplotyp
result
famili
trio
success
resolv
complet
haplotyp
increas
ambigu
resolv
linkag
disequilibrium
measur
gene
phase
expectationmaxim
algorithm
implement
comparison
pedigre
analysi
imput
result
show
larg
highresolut
hla
haplotyp
databas
success
construct
famili
trio
serv
valuabl
resourc
downstream
analysi
popul
diseas
associ
studi
thoma
goeuri
jose
nune
alicia
sanchezmaza
univers
geneva
geneva
switzerland
correspond
thomasgoeuri
unigech
due
complex
fluctuat
select
pressur
act
hla
gene
unravel
molecular
evolutionari
histori
region
remain
tough
task
present
origin
approach
question
use
identif
pattern
similar
sequenc
base
transit
probabl
purpos
comput
markov
chain
known
dna
sequenc
taken
ipdimgthla
databas
differ
gene
region
intron
exon
utr
hla
loci
transit
probabl
sequenc
extens
analyz
identifi
emerg
pattern
includ
tdistribut
stochast
neighbor
embed
tsne
princip
compon
analysi
pca
result
plot
class
sequenc
reveal
greater
similar
within
gene
region
among
mean
gene
region
includ
intron
similar
equival
gene
region
gene
region
gene
suggest
fullgen
duplic
event
three
hlaa
b
c
loci
common
origin
consist
current
hypothes
hla
class
evolut
plot
obtain
class
ii
gene
display
distinct
pattern
exon
sequenc
code
beta
chain
hla
molecul
form
outlier
group
compar
sequenc
result
select
pressur
act
peptidebind
region
hla
molecul
anoth
unexpect
find
great
similar
differ
intron
well
differ
exon
within
among
hladr
dp
lesser
extent
dq
gene
wherea
intron
exon
dissimilar
suggest
distinct
origin
class
ii
intron
one
side
class
ii
exon
side
final
exon
sequenc
also
display
two
differenti
cluster
correspond
two
nonoverlap
allel
group
suggest
peculiar
evolutionari
histori
locu
determin
peripher
blood
cord
blood
hlac
antigen
express
level
mrna
transcript
level
chines
popul
highresolut
hlac
sequenc
type
perform
use
pcrsbt
peripher
blood
total
hlac
mrna
transcript
level
analyz
qpcr
use
locusspecif
primer
peripher
blood
analyz
qpcr
hlac
c
c
c
mrna
transcript
level
use
allelespecif
primer
hlac
antigen
express
level
analyz
flow
cytometri
genotyp
determin
sequenc
among
healthi
volunt
seventeen
hlac
allel
detect
mean
level
hlac
antigen
express
level
peripher
blood
mfi
signific
differ
hlac
antigen
express
level
hlac
antigen
express
level
higher
c
lower
c
mean
level
hlac
mrna
transcript
peripher
blood
hlac
show
higher
mrna
transcript
level
statist
signific
p
among
cord
blood
sampl
eighteen
hlac
allel
detect
mean
level
hlac
mrna
transcript
level
signific
differ
hlac
mrna
transcript
level
cord
blood
hlac
antigen
express
level
highest
genotyp
lowest
genotyp
moder
genotyp
chines
han
popul
complet
linkag
disequilibrium
hlac
complet
linkag
disequilibrium
hlac
peripher
blood
hlac
antigen
express
level
mrna
transcript
level
associ
hlac
allotyp
chines
han
popul
hlac
allel
complet
linkag
disequilibrium
genotyp
divid
higher
express
level
lower
express
level
group
hla
system
show
combin
extens
polymorph
conserv
haplotyp
allel
haplotyp
frequenc
hla
gene
vari
greatli
across
human
popul
mani
allel
haplotyp
regionspecif
popul
latin
america
complex
histori
migrat
result
broad
varieti
admixtur
proport
involv
mainli
european
african
nativ
american
compon
hypothes
admixtur
proport
latin
american
popul
approxim
base
put
continent
origin
extend
hla
haplotyp
determin
highresolut
hlaa
b
c
allel
sampl
healthi
subject
mestizo
popul
costa
rican
central
valley
provinc
guanacast
mexican
mexico
citi
nicaraguan
plu
costa
rican
afrocaribbean
descent
amerindian
costa
rica
estim
extend
haplotyp
form
diplotyp
subject
assign
put
continent
origin
base
allel
linkag
present
haplotyp
result
show
great
degre
allel
haplotyp
divers
within
across
popul
extend
haplotyp
privat
mestizo
popul
show
haplotyp
three
ancestr
continent
region
albeit
significantli
differ
proport
p
larg
european
compon
costa
rican
mestizo
central
valley
haplotyp
strong
african
compon
costa
rican
mestizo
guanacast
haplotyp
larger
nativ
american
compon
among
nicaraguan
haplotyp
mexican
haplotyp
mestizo
amerindian
afrodescend
costa
rica
show
high
proport
nativ
american
african
haplotyp
respect
albeit
evid
gene
flow
continent
group
multidimension
scale
analys
compar
hla
profil
popul
larg
set
indigen
popul
iberia
subsaharan
africa
america
reflect
differenti
admixtur
process
overal
novel
approach
reaffirm
complex
latin
american
popul
genet
confirm
use
detail
analysi
hla
allel
haplotyp
understand
process
cigdem
kekik
sonay
temurhan
sebahat
u
akgul
yasar
k
caliskan
yasemin
ozluk
serra
ertan
erol
demir
figen
abatay
halil
yazici
aydin
turkmen
kilicarslan
isik
mehmet
sever
fatma
oguz
savran
istanbul
faculti
medicin
istanbul
turkey
correspond
citcim
gmailcom
iga
nephropathi
igan
frequent
primari
glomerular
diseas
import
caus
endstag
renal
diseas
esrd
studi
aim
investig
whether
snp
cfh
gene
gene
gene
defa
gene
hla
risk
factor
esrd
igan
patient
patient
control
dna
sampl
isol
peripher
blood
edta
hla
type
perform
luminex
onelambda
hla
type
kit
snp
detect
perform
sequenc
base
type
sbt
one
hundr
eighteen
patient
mf
mean
age
clinic
followup
data
control
mf
mean
age
includ
studi
twenti
eight
patient
reach
esrd
mf
mean
age
follow
period
found
allel
significantli
higher
igan
control
compar
igan
patient
allel
significantli
higher
esrd
patient
present
studi
result
indic
snp
hla
allel
associ
suscept
predict
paramet
igan
reach
esrd
igan
detect
relationship
presenc
allel
igan
suscept
may
shed
light
etiolog
diseas
show
allel
allel
may
predispos
esrd
turkish
nephropathi
patient
although
genet
factor
thought
play
role
pathogenesi
diseas
etiolog
igan
unclear
genu
cardu
fringillida
famili
includ
goldfinch
siskin
redpol
greenfinch
crossbil
mani
speci
classifi
within
genu
relat
genera
group
use
molecular
systemat
mitochondri
cytochrom
b
mt
cyt
b
gene
accord
eurasian
siskin
c
spinu
extant
direct
ancestor
sever
north
american
finch
north
americansouth
american
radiat
may
origin
eurasian
siskin
extinct
rel
present
work
aim
perform
studi
transspeci
transcontinent
analys
mhc
major
histocompat
complex
class
allel
sever
genu
carduelisspinu
speci
order
draw
evolutionari
conclus
sever
wild
bird
speci
belong
genera
cardu
spinu
found
two
match
mhci
dna
allel
differ
south
american
siskin
dna
level
also
observ
eurasian
siskin
share
protein
pine
siskin
anoth
three
south
american
siskin
eight
south
american
siskin
speci
also
share
mhc
protein
addit
studi
songbird
mhc
class
intron
longer
gallu
gallu
drawn
follow
conclus
present
first
direct
evid
minim
essenti
mhc
exist
bird
one
main
definit
charact
ie
small
intron
size
hold
songbird
also
report
mhc
gene
transspeci
evolut
exist
bird
show
also
first
time
worldwid
bird
speci
keep
mhc
protein
dna
allel
new
evid
mhc
allel
conserv
eurasian
cardu
spinu
ancient
south
american
siskin
recent
million
year
support
eurasian
siskin
parent
speci
american
genu
cardu
spinu
speci
uncertain
whether
eurasian
siskin
extant
rel
initi
holoart
distribut
includ
america
antonio
arnaizvillena
ana
carballo
ignacio
juarez
ester
cristina
campo
rawand
alqadi
jorg
nieto
manuel
jose
palaciogrub
univers
complutens
madrid
region
blood
center
centro
de
transfus
madrid
spain
dohuk
special
laboratori
center
dohuk
iraq
correspond
arnaizvil
hotmailcom
atlant
europ
popul
analyz
hla
gene
order
establish
relationship
among
popul
standard
genet
statist
softwar
analys
use
celtic
popul
british
isl
french
breton
genet
found
close
togeth
irish
welsh
orkney
island
scottish
french
breton
galician
spanish
basqu
portugues
cluster
togeth
da
genet
distanc
correspond
analysi
neighbor
join
dendrogram
genet
shown
suffic
determin
popul
migrationrelated
aristotl
herodotu
place
celt
iberia
chromosom
marker
high
iberia
celtic
european
popul
mention
probabl
stem
iberian
ice
refuge
last
glaciat
ancient
celt
languag
gaelic
translat
iberiantartesian
languag
suggest
celt
iberian
name
classic
author
constitut
popul
hand
gene
analysi
canari
island
ancient
inhabit
guanch
b
abund
iberian
script
also
found
canari
island
c
establish
north
africaiberia
ancient
gene
flow
evid
demic
diffus
eastern
western
mediterranean
accord
human
ancient
skeleton
studi
notic
mesolithicneolith
transit
fact
suggest
ancient
canari
island
may
includ
within
iberiancelt
popul
conclus
celt
concentr
atlant
europ
iberian
celt
mention
classic
author
probabl
refer
popul
live
iberian
peninsula
spainportug
addit
north
african
berber
ancient
canari
island
also
belong
group
postul
farmer
demic
diffus
east
west
mediterranean
direct
never
occur
mari
fechtenbaum
judith
desoutt
vincent
goeb
nicola
guillaum
amien
univers
medic
center
amien
franc
correspond
guillaumenicola
chuamiensfr
spondyloarthr
inflammatori
chronic
diseas
hlab
allel
explain
part
genet
howev
gene
could
particip
physiopatholog
group
diseas
major
histocompat
complex
class
polypeptiderel
sequenc
mica
encod
glycoprotein
mediat
activ
receptor
express
nk
tcell
methionin
vs
valin
posit
exon
result
strong
met
weak
val
bind
receptor
mica
allel
caus
prematur
stop
codon
lead
truncat
protein
synthesi
polymorph
result
allel
associ
low
cc
cc
high
gg
tt
cytotox
activ
primari
object
studi
determin
whether
polymorph
mica
loci
associ
spondyloarthr
ankylos
spondyloarthr
psoriat
arthriti
one
hundr
sixtytwo
patient
spondyloarthr
includ
frequenc
metval
mica
mutat
ct
cg
polymorph
compar
healthi
control
polymorph
report
cohort
adjust
hlab
statu
methionin
metmet
metval
significantli
associ
spondyloarthr
compar
control
ci
wherea
valval
mica
cc
protect
ci
ci
ci
adjust
hlab
cc
remain
protect
spondyloarthr
ci
hand
studi
cohort
homozygos
mica
protect
ankylos
spondyloarthr
cc
valval
protect
psoriat
arthriti
conclus
mica
polymorph
relat
low
cytotox
activ
nkcell
protect
arthriti
diseas
deep
sequenc
tail
overlap
read
provid
phase
inform
thu
hla
allel
sequenc
automat
data
analysi
also
provid
allel
level
genotyp
heterogen
combin
gene
present
mexican
depend
region
oaxaca
citi
found
aztec
warrior
popul
result
admixtur
spaniard
nativ
local
group
mainli
mixteco
zapoteco
african
gene
pool
prevail
select
bm
donor
oaxaca
citi
dna
sampl
hla
type
amplif
long
rang
pcr
full
gene
coverag
class
class
ii
includ
exon
amplicon
sampl
pool
tag
sampl
time
sequenc
miseq
instrument
analys
sequenc
done
mia
fora
softwar
genotyp
assign
unambigu
allel
frequenc
calabria
southernmost
region
italian
peninsula
surround
tyrrhenian
sea
west
ionian
sea
east
separ
sicili
strait
messina
south
calabria
suffer
mani
invas
centuri
around
greek
occupi
territori
becam
magna
grecia
bruzi
indoeuropean
popul
found
cosenza
iv
bc
rome
conquer
calabria
iiibc
byzantin
domin
region
first
saracen
attack
occur
arab
presenc
end
norman
constitut
duchi
calabria
angevin
aragones
last
invad
correspond
analysi
first
axi
second
axi
compar
frequenc
hlaa
b
c
allel
reggio
calabria
cosenza
catanzaro
vibo
valentia
provinc
popul
repres
modern
descend
invad
greec
turkey
albania
tunisia
napl
sicili
franc
catalan
basqu
south
spain
sweden
jordan
outlin
hla
data
avail
allelefrequ
net
calabrian
adult
stem
cell
donor
observ
tight
cluster
compos
calabrian
greek
sicili
napl
albania
tunisia
also
observ
two
small
cluster
first
compos
franc
sweden
second
compos
catalan
basqu
spain
franc
turkey
turkey
calabria
spain
calabrian
show
immunogenet
fingerprint
deriv
colon
greek
magna
grecia
sicili
byzantin
albania
angevin
napl
arabian
tunisia
unexpectedli
calabrian
nearer
tunisian
turkish
influenc
byzantin
mark
proxim
albanian
turkish
saracen
made
incurs
without
settl
calabria
inbreed
local
popul
convers
greek
found
coloni
magna
graecia
tunisia
mayb
calabrian
close
tunisian
human
leukocyt
antigen
hla
consid
import
genet
risk
factor
rheumatoid
arthriti
ra
chronic
system
inflammatori
autoimmun
diseas
unknown
etiolog
allel
encod
share
epitop
five
amino
acid
sequenc
motif
residu
chain
known
associ
onset
sever
diseas
frequenc
genotyp
associ
ra
vari
within
differ
geograph
area
aim
studi
evalu
distribut
allel
patient
ra
sinj
region
sr
rest
splitdalmatia
counti
sdc
well
determin
associ
allel
sever
progress
ra
patient
analyz
patient
healthi
subject
sr
well
patient
ra
healthi
subject
rest
sdc
lowresolut
genotyp
perform
use
pcrsso
luminex
platform
highresolut
type
allel
perform
use
pcrssp
patient
ra
sr
frequenc
allel
significantli
higher
patient
rest
sdc
vs
allel
frequenc
significantli
lower
vs
differ
frequenc
allel
patient
respect
frequenc
acut
phase
reactant
rheumatoid
factor
higher
share
epitop
posit
patient
sr
compar
share
epitop
posit
patient
rest
sdc
respect
share
epitop
posit
patient
sr
also
show
higher
diseas
activ
sever
degre
function
disabl
p
sever
radiolog
damag
compar
seposit
patient
rest
sdc
find
indic
higher
incid
sever
form
ra
sinj
region
could
explain
higher
frequenc
certain
share
epitop
allel
patient
sr
compar
patient
rest
sdc
durat
success
rate
unrel
donor
search
hematopoiet
stem
cell
transplant
greatli
depend
patient
hla
type
studi
hla
haplotyp
frequenc
croatian
bone
marrow
registri
reveal
frequent
haplotyp
rest
defin
less
frequent
rare
includ
least
one
hla
allel
observ
three
time
maximum
popul
aim
studi
analyz
patient
transplant
unrel
donor
uhc
zagreb
patient
famili
deriv
haplotyp
investig
distribut
hla
haplotyp
order
evalu
probabl
find
donor
nation
intern
registri
group
patient
receiv
transplant
nation
donor
group
differ
haplotyp
found
group
patient
found
intern
donor
group
divers
haplotyp
much
higher
differ
haplotyp
hlaa
haplotyp
show
highest
frequenc
group
howev
presenc
significantli
higher
group
respect
p
hla
genotyp
consist
two
frequent
haplotyp
well
genotyp
consist
one
frequent
one
less
frequent
haplotyp
significantli
present
group
group
vs
p
vs
respect
genotyp
less
frequent
haplotyp
significantli
observ
group
vs
p
state
genotyp
consist
one
less
frequent
one
rare
haplotyp
found
six
patient
intern
donor
one
patient
nation
donor
data
suggest
presenc
least
one
frequent
haplotyp
serv
posit
predict
factor
find
donor
registri
patient
bear
less
frequent
rare
haplotyp
mostli
benefit
find
donor
worldwid
identif
hla
allel
frequenc
essenti
element
donorrecipi
match
process
kidney
bone
marrow
transplant
time
analysi
genet
heterogen
within
particular
geograph
area
import
tool
character
popul
group
constitut
basic
element
anthropolog
studi
studi
hla
type
test
perform
peripher
blood
lymphocyt
serolog
method
cdc
complement
depend
cytotox
molecular
biolog
method
ssp
sequenc
specif
primer
sso
sequencespecif
oligonucleotid
sampl
collect
individu
enrol
wait
list
transplant
center
chisinau
iasi
well
volunt
donor
enrol
nation
registri
hematopoiet
stem
cell
voluntari
donor
romania
statist
analysi
data
allow
us
calcul
rel
frequenc
compar
result
data
avail
caucasian
popul
among
popul
republ
moldova
hierarchi
common
allel
follow
hlaa
b
b
b
analysi
iasi
group
led
follow
hierarchi
b
b
b
studi
repres
first
compar
hla
genet
profil
popul
republ
moldova
romanian
region
moldova
present
data
consid
preliminari
requir
signific
extens
subgroup
chisinau
well
inclus
entir
popul
republ
moldova
human
killercel
immunoglobulinlik
receptor
kir
gene
play
import
role
immun
system
report
affect
hematopoiet
stem
cell
transplant
hsct
outcom
kir
specif
affin
influenc
multipl
facet
allel
polymorph
therefor
high
resolut
kir
genotyp
might
contribut
toward
improv
donor
select
success
hsct
previous
report
establish
approach
base
next
gener
sequenc
ng
gener
high
resolut
kir
genotyp
data
success
valid
implement
workflow
octob
sinc
genotyp
one
million
stem
cell
donor
registri
sampl
kir
high
resolut
base
experi
optim
nextyp
analysi
softwar
qualiti
control
monitor
precis
use
set
sampl
howev
unlik
hla
genotyp
extern
profici
test
servic
yet
avail
comprehens
high
resolut
kir
genotyp
therefor
exchang
sampl
previous
analyz
comprehens
kir
base
ng
captur
sequenc
data
ping
pipelin
genotyp
call
individu
kir
gene
level
concord
ping
data
detail
reanalysi
discord
result
identifi
potenti
spuriou
genotyp
result
data
reevalu
ping
data
still
progress
agre
common
comprehens
genotyp
set
given
earli
day
comprehens
high
resolut
kir
genotyp
conjunct
limit
coverag
kir
divers
ipdkir
databas
comparison
result
obtain
use
independ
approach
essenti
spot
systemat
bias
shortcom
studi
demonstr
matur
current
approach
underscor
comprehens
high
resolut
kir
genotyp
possibl
high
throughput
set
interact
hepat
stellat
nk
cell
import
determin
liver
fibrosi
progress
regress
chronic
alcohol
consumpt
produc
alter
innat
immun
system
develop
liver
cirrhosi
biolog
mechan
unknown
nk
cell
express
kirreceptor
interact
hla
class
ligand
regul
activ
associ
would
use
clinic
practic
diagnos
patient
even
adjust
possibl
treatment
aim
studi
determin
role
telomer
inhibitor
kir
gene
alcohol
cirrhosi
genom
dna
extract
peripher
blood
automat
extract
kir
gene
determin
alcohol
cirrhosi
patient
control
use
pcrssp
method
patient
group
accord
whether
viral
infect
data
show
similar
frequenc
group
appear
increas
group
differ
signific
increas
frequenc
nonvir
patient
respect
control
also
observ
vs
decreas
observ
viral
respect
nonvir
patient
telomer
akir
gene
increas
patient
significantli
increas
similar
trend
observ
patient
without
viral
infect
final
influenc
three
centromer
kir
gene
jointli
analyz
increas
observ
patient
alcohol
cirrhosi
without
associ
viral
infect
conclus
gene
appear
repres
popul
patient
alcohol
cirrhosi
abl
particip
biolog
mechan
cirrhot
process
previou
studi
suggest
rat
harbor
repertoir
mhc
class
ibreact
activ
receptor
induc
adaptivelik
allorespons
provid
molecular
function
evid
stimulatori
receptor
inhibitori
counterpart
recogn
two
distinct
mhc
class
ib
molecul
molecul
recogn
pair
receptor
although
ligand
categor
nonclass
share
structur
featur
classic
class
molecul
display
gain
loss
haplotyp
variat
ligandbind
sever
stimulatori
receptor
appear
stronger
inhibitori
counterpart
observ
dramat
expans
express
highli
alloreact
nk
cell
subset
periton
caviti
rat
repeat
mhc
class
ib
alloimmun
demonstr
direct
involv
activ
receptor
induct
potent
nk
cell
allorespons
vivo
kir
hla
genotyp
influenc
clinic
outcom
relaps
patient
treat
lenalidomidebas
regimen
poor
known
impact
highrisk
young
hri
mm
patient
gener
aim
studi
evalu
kir
hla
genotyp
influenc
clinic
outcom
hrymm
patient
kir
gene
hla
ligand
analyz
healthi
subject
control
mm
patient
use
genotyp
ssp
sso
kit
hrymm
patient
median
age
year
male
treat
upfront
novel
agentsbas
induct
treatment
follow
consolid
one
autolog
stem
cell
transplant
randomli
assign
lenalidomid
mainten
progress
evalu
role
kir
express
kir
haplotyp
aabx
progress
free
surviv
first
second
line
treatment
hrymm
patient
predictor
outcom
complet
remiss
achiev
induct
treatment
ldh
consolid
treatment
p
mainten
monoclon
compon
diagnosi
lack
kir
frequent
mm
healthi
subject
vs
p
median
followup
month
hrymmpati
carri
longer
pf
without
versu
month
although
signific
differ
overal
surviv
os
nt
signific
differ
kir
haplotyp
aabx
frequenc
mm
versu
healthi
patient
howev
hrymmpati
bx
haplotyp
associ
longer
pf
versu
month
without
effect
os
multivari
analysi
complet
remiss
achiev
induct
consolid
treatment
predictor
outcom
independ
kir
haplotyp
genet
kir
bx
haplotyp
associ
clinic
outcom
hrymmpati
impli
role
nk
cytotox
mm
residu
cell
data
need
confirm
larger
prospect
seri
psoriasi
multifactori
diseas
strong
genet
suscept
compon
hlac
allel
found
strongli
associ
popul
worldwid
function
data
support
pathogenet
role
allel
psoriasi
still
lack
recent
year
killercel
immunoglobulinlik
receptor
kir
express
cell
surfac
natur
killer
nk
cell
arous
consider
interest
bind
affin
specif
hlac
molecul
present
studi
compar
distribut
hlac
kir
genotyp
sardinian
psoriat
patient
healthi
control
statist
analysi
comparison
perform
two
group
reveal
significantli
higher
frequenc
group
psoriat
patient
vs
also
studi
hlac
higher
frequenc
patient
compar
control
vs
p
prompt
us
appli
genegen
interact
test
result
show
locu
independ
associ
moreov
associ
influenc
clinic
paramet
onset
age
psoriasi
area
psoriasi
sever
index
pasi
famili
histori
psoriasi
result
support
hypothesi
independ
psoriasi
suscept
factor
differ
mechan
action
hlac
relapsingremit
multipl
sclerosi
rrm
chronic
inflammatori
disord
central
nervou
system
sardinia
much
higher
incid
preval
mainland
itali
literatur
diseas
found
associ
allel
code
hla
class
ii
molecul
particular
would
seem
haplotyp
contain
allel
predispos
effect
sardinian
popul
studi
evalu
role
natur
killer
cell
immunoglobulinlik
receptor
kir
hla
class
ligand
suscept
rrm
homogen
group
patient
affect
rrm
compar
group
healthi
control
certain
sardinian
origin
group
evalu
presenceabs
singl
kir
gene
ligand
well
activ
andor
inhibitori
kir
gene
present
respect
genotyp
cohort
rrm
strongli
associ
haplotyp
p
analog
find
fusco
et
al
activ
kir
gene
high
affin
ligand
observ
significantli
higher
frequenc
patient
control
ci
p
studi
show
kir
hla
class
molecul
involv
onset
rrm
howev
mechan
underli
activ
inhibit
natur
killer
cell
remain
clarifi
research
requir
shed
light
precis
role
kir
hla
class
ligand
within
context
kir
modul
inhibitionactiv
nk
cell
interact
hla
ligand
exampl
cytotox
cytokin
product
polymorph
nk
cell
depend
allotyp
andor
target
two
lineag
allotyp
one
evolv
balanc
select
present
popul
mestizo
result
triraci
admixtur
compris
mediterranean
gene
brought
spaniard
african
compon
came
bantu
slave
nativ
gene
differ
ethnic
group
inhabit
mexico
aim
studi
determin
profil
mestizo
type
sbt
segreg
allel
locu
well
hla
class
allel
mexican
mestizo
donor
unrel
mexican
registri
donormo
chosen
year
femal
kir
type
protocol
follow
accord
p
norman
sbt
perform
use
sequenc
hla
type
done
luminex
ssop
method
kir
allel
type
analyz
assign
sbt
softwar
allel
frequenc
af
obtain
direct
count
hla
analysi
done
match
dna
softwar
presenc
shown
subject
eighteen
differ
allel
found
frequent
one
ligand
present
carri
allel
allel
interestingli
new
allel
detect
snp
similar
af
observ
mexican
mestizo
usa
hispan
differ
mexican
show
clear
differ
venezuelan
warao
bari
yucpa
indian
mexican
vari
compar
african
asian
european
middl
eastern
tanzania
zimbabw
group
share
similar
sinc
bantu
differ
reflect
divers
nk
repertoir
natur
select
probabl
due
exposur
distinct
pathogen
particular
environ
popul
immunolog
respons
evolv
infect
ethnic
nk
cell
donor
origin
recogn
kill
residu
leukem
cell
cure
malign
patient
hsc
transplant
set
nk
cell
function
regul
killer
cell
immunoglobulinlik
receptor
kir
recogn
cognat
locusspecif
hla
class
molecul
target
cell
depend
specif
amino
acid
residu
posit
motif
hla
class
molecul
hla
motif
crucial
predict
donor
nk
cell
capac
malign
recipi
due
hla
polymorph
recombin
mutat
event
polymorph
hla
molecular
interfac
encount
kir
molecul
hlab
molecul
express
motif
hlaa
molecul
express
motif
motif
ident
ligand
bind
kir
etc
figur
role
hla
motif
bind
kir
analyz
hla
kir
crystallograph
data
compar
physic
involv
amino
acid
sequenc
common
hla
class
molecul
crystallograph
data
five
short
linear
sequenc
motif
describ
physic
bound
kir
whole
hla
kir
interfac
common
hla
class
molecul
found
motif
combin
includ
combin
molecul
nonkirlig
nol
except
includ
motif
b
match
b
differ
posit
sever
nol
molecul
ident
motif
differ
ident
differ
motif
posit
hlaa
molecul
isoleucin
instead
threonin
posit
substitut
known
increas
affin
etc
regular
except
use
predict
kir
ligat
among
less
frequent
hla
molecul
base
amino
acid
motif
whole
hla
kir
interfac
predict
might
improv
select
optim
hsct
donor
malign
patient
success
cancer
therapi
depend
adequ
clinic
procedur
aim
elimin
tumor
cell
also
function
state
patient
immun
system
nk
cell
cytotox
regul
interact
killer
immunoglobulinlik
receptor
kir
human
leukocyt
antigen
hla
class
ligand
target
cell
differ
bind
affin
receptor
iiia
iggcoat
tumor
cell
thu
conceiv
kir
gene
content
may
contribut
function
nk
cell
modul
immun
respons
breast
cancer
bc
bc
progress
metastas
link
antitumor
immun
respons
inefficaci
therefor
investig
combin
effect
kir
gene
hlac
ligand
togeth
suscept
progress
develop
bc
italian
patient
match
control
ctr
gene
polymorph
investig
pcrssp
method
type
kir
receptor
pcrsbt
hlac
allel
result
type
bc
pt
italian
femal
ctr
show
predispos
effect
aggress
neoplasm
stage
iiiiv
consid
gene
alon
iiiiv
stage
vs
combin
vs
contrari
gene
link
haplotyp
seem
protect
aggress
neoplasm
vs
vs
vs
respect
synerg
absenc
two
kir
gene
increas
occurr
advanc
bc
vs
ctr
regard
atg
gt
gene
polymorph
describ
higher
frequenc
haplotyp
bc
ctr
group
even
though
llff
genotyp
present
mainli
control
vs
find
evid
potenti
role
kirgen
content
togeth
hlac
ligand
bc
tumor
progress
suggest
develop
breast
cancer
result
disord
immun
regul
studi
analyz
kir
haplotyp
carri
allel
origin
unequ
cross
code
surfac
receptor
share
ectodomain
transmembran
cytoplasm
region
aim
use
ssppcr
approach
firstli
determin
kir
repertoir
cohort
individu
investig
presenc
donor
character
cenb
region
lack
andor
ie
gene
locat
well
donor
two
cenb
region
sinc
presenc
true
region
one
haplotyp
might
mask
presenc
contract
cenb
region
one
detect
use
set
primer
specif
amplifi
hybrid
gene
thereaft
sequenc
specif
pcr
product
demonstr
junction
point
ident
donor
identifi
final
major
individu
cohort
parent
children
includ
cohort
perform
kir
haplotyp
evalu
combin
famili
segreg
welldefin
kir
haplotyp
featur
analysi
clearli
indic
present
two
differ
haplotyp
share
centromer
region
differ
telomer
region
particular
found
individu
haplotyp
character
telb
motif
carri
previous
describ
also
donor
haplotyp
character
tela
region
given
crucial
role
kir
variabl
modul
nk
cell
educ
consecut
respons
viral
infect
pregnanc
allogen
transplant
think
detect
improv
accuraci
kir
repertoir
analysi
might
routin
includ
kir
genotyp
studi
compar
mammalian
speci
pig
thought
possess
rel
natur
killer
nk
cell
receptor
gene
includ
minim
set
killer
lectinlik
receptor
klr
singl
killer
immunoglobulin
ig
like
receptor
kir
question
function
three
describ
leukocyt
iglik
receptor
lilr
kir
lilr
encod
leukocyt
receptor
complex
lrc
also
contain
sever
iglik
receptor
mani
involv
innat
immun
character
base
earli
genom
assembl
includ
previou
pig
refer
genom
assembl
use
shortread
sequenc
technolog
well
known
introduc
error
immun
gene
complex
recent
updat
assembl
releas
base
longread
sequenc
technolog
analys
found
lrc
new
assembl
almost
contigu
singl
gap
compar
gap
contain
total
lilr
gene
gene
fragment
new
gene
miss
previou
assembl
elsewher
lrc
identifi
novel
gene
possess
long
intracellular
tail
two
iglik
domain
also
identifi
second
highli
similar
pseudogen
short
intracellular
tail
haplotyp
phylogenet
novel
gene
relat
other
lrc
yet
form
distinct
clade
novel
inhibitori
gene
variabl
number
shorttail
gene
identifi
genom
assembl
divers
rang
speci
includ
pseudogen
human
transcriptom
analysi
reveal
novel
inhibitori
gene
six
function
lilr
gene
highli
express
porcin
peripher
blood
contrast
singl
kir
gene
bare
express
confirm
lack
function
discoveri
sever
new
leukocyt
receptor
pig
help
inform
futur
investig
function
porcin
immun
cell
aim
studi
analyz
influenc
alcohol
cirrhosi
patient
assess
coexist
viral
infect
genom
dna
extract
peripher
blood
automat
extract
kir
gene
determin
alcohol
cirrhosi
patient
control
use
pcrssp
method
patient
group
accord
whether
viral
infect
respect
classifi
accord
zygos
result
show
signific
differ
frequenc
kir
gene
control
patient
except
gene
whose
frequenc
significantli
lower
patient
control
caus
pathogenesi
autoimmun
diseas
influenc
environment
genet
risk
factor
hla
system
shown
play
import
role
suscept
variou
diseas
particularli
immun
autoimmun
base
rheumat
diseas
preval
among
popul
estim
spain
affect
peopl
year
age
particular
psoriasi
hlac
shown
associ
increas
risk
lower
age
onset
diseas
aim
work
evalu
frequenc
hlac
patient
variou
rheumat
diseas
patient
healthi
peopl
type
hlac
dnabas
hlac
type
perform
pcrssop
luminex
method
use
lifecod
hla
type
kit
genprob
accord
manufactur
instruct
use
luminex
compar
group
patient
group
healthi
peopl
signific
valu
p
result
obtain
use
chisquar
test
confid
interv
comparison
healthi
peopl
patient
rheumat
diseas
show
signific
differ
hlac
p
hlac
p
hlac
detect
healthi
peopl
patient
hlac
detect
healthi
peopl
patient
patient
stratifi
epitop
nt
find
associ
summari
studi
suggest
hlac
could
risk
factor
rheumat
diseas
hlac
protect
factor
howev
studi
need
futur
confirm
result
studi
aim
evalu
psoriasi
relat
allel
frequent
calabrian
popul
affect
patient
allel
usual
relat
patholog
addit
purpos
understand
whether
hla
type
help
clinician
order
choos
effect
treatment
studi
still
progress
carri
calabrian
psoriasi
patient
age
year
one
collect
clinic
inform
particularli
focus
clinic
phenotyp
sign
best
treatment
outcom
unrel
calabrian
individu
age
year
enrol
volunt
potenti
bone
marrow
donor
calabrian
registri
ibmdr
italian
bone
marrow
donor
registri
select
estim
hlac
locu
frequenc
popul
reliabl
control
sampl
distribut
allel
variabl
hla
allel
hla
type
c
locu
perform
use
luminex
sso
technolog
lowmedium
definit
pcrssp
method
high
resolut
allel
frequenc
obtain
direct
count
result
show
calabrian
popul
homogen
genet
suscept
c
close
relat
wors
symptom
frequenc
c
frequenc
studi
hla
translat
point
view
could
futur
valid
tool
identifi
patient
psoriasi
high
risk
develop
arthriti
undertak
earliest
effect
individu
therapeut
strategi
reduc
disabl
improv
patient
life
qualiti
tumor
necrosi
factor
tnf
alpha
major
proinflammatori
cytokin
involv
immun
respons
ibd
moreov
use
biolog
agent
particularli
antitnfalpha
revolution
treatment
ibd
includ
cd
aim
studi
investig
influenc
two
singl
nucleotid
polymorph
snp
tnfalpha
gene
promot
risk
phenotyp
crohn
diseas
romanian
popul
genotyp
cd
patient
healthi
control
tnfalpha
use
taqman
allel
discrimin
assay
realtim
pcr
system
appli
biosystem
thermo
fisher
scientif
usa
associ
test
polymorph
perform
softwar
packag
plink
v
control
patient
hardyweinberg
equilibrium
investig
snp
frequenc
minor
allel
significantli
higher
cd
patient
control
carrier
allel
gaaa
genotyp
frequent
among
patient
vs
minor
allel
overrepres
patient
eim
vs
result
show
tnfalpha
gene
polymorph
influenc
risk
phenotyp
crohn
diseas
romanian
popul
psoriasi
chronic
inflammatori
relapsingremit
diseas
multifactori
etiolog
space
genet
predisposit
sever
trigger
environment
factor
class
hla
complex
known
chief
suscept
factor
particular
certain
determin
associ
earli
onset
sever
grade
diseas
moreov
sever
observ
suggest
suscept
psoriasi
could
determin
imbal
signal
activ
inhibitori
kir
receptor
whose
hla
antigen
consid
natur
ligand
investig
associ
hla
class
kir
ligand
predisposit
psoriasi
use
psoriat
patient
genotyp
pcrsso
techniqu
healthi
control
although
hlac
significantli
higher
patient
vs
differ
frequenc
epitop
two
cohort
hla
allel
motif
increas
individu
psoriasi
compar
control
vs
data
reproduc
examin
kir
ligand
albeit
statist
differ
vs
particular
present
patient
respect
control
interestingli
psoriat
patient
show
signific
decreas
hlaa
allel
ligand
inhibitori
vs
inhibitori
bind
motif
molecul
may
better
ligand
consid
may
also
recogn
allotyp
psoriasi
nk
cell
mostli
carri
inhibitori
receptor
low
express
type
evid
diseas
induc
sustain
intrins
inflammatori
state
celiac
diseas
intoler
situat
gluten
genet
suscept
individu
chronic
inflamm
observ
intestin
mucosa
patient
consequ
villou
atrophi
hyperplasia
lymphocyt
infiltr
occur
cours
diseas
celiac
diseas
deriv
variat
number
gene
environment
factor
studi
observ
diseas
associ
especi
allel
studi
aim
compar
allel
turkish
celiac
patient
healthi
individu
addit
relat
allel
celiac
diseas
examin
total
celiac
patient
healthi
individu
includ
type
perform
lowresolut
sequenc
specif
oligonucleotid
probe
ssop
method
result
analyz
pearson
chisquar
statist
packag
social
scienc
window
version
test
allel
significantli
higher
allel
significantli
lower
patient
control
group
p
accord
rel
risk
analysi
individu
allel
high
risk
diseas
develop
allel
significantli
higher
patient
healthi
individu
p
accord
rel
risk
analysi
individu
allel
high
risk
diseas
develop
found
significantli
higher
patient
control
group
p
accord
rel
risk
analysi
individu
allel
high
risk
diseas
develop
respect
conclus
statist
signific
associ
celiac
diseas
allel
data
compat
literatur
tinu
autoimmun
diseas
character
simultan
presenc
tubuleinterstiti
nephriti
uveiti
rare
diseas
may
respons
kidney
failur
affect
young
peopl
age
year
mostli
observ
femal
ratio
compar
male
seem
link
defect
cellmedi
immun
delay
hypersensit
phenomena
appear
tmediat
inflammatori
lymphocyt
state
mechan
would
seem
involv
alter
creactiv
protein
mcrp
autoantigen
common
uvea
renal
tubular
cell
tinu
seem
strongli
associ
hla
subtyp
specif
risk
factor
identifi
addit
interstiti
nephriti
uveiti
patient
tinu
may
also
system
symptom
fever
weight
loss
asthenia
malais
anorexia
abdomin
lumbar
pain
well
skin
rash
report
case
year
old
child
arriv
pediatr
er
fever
uveiti
gener
condit
appear
discret
asthenia
skin
pallor
bodi
temperatur
c
laboratori
test
show
anemia
high
level
ve
pcr
ocular
examin
requir
confirm
uveiti
multistick
urin
test
detect
proteinuria
andglycosuria
requir
urgent
hospit
admiss
gener
condit
stabl
feverish
manifest
laboratori
test
perform
exclud
viral
infect
torch
neg
result
urin
exam
twice
stay
multistick
test
everi
morn
normal
abdomin
echo
observ
pharyng
swab
show
posit
sbega
antibiot
therapi
initi
persist
normoglycem
glycosuria
associ
bilater
uveiti
increas
microalbuminuria
urinari
globulin
led
us
suspect
tinu
type
hla
confirm
suspect
diagnost
behcet
diseas
discov
turkish
dermatolog
professor
hulusi
behcet
diseas
describ
three
symptom
recurr
oral
aphtha
genit
wound
uveiti
later
reveal
show
system
cours
joint
vascular
intestin
pulmonari
neurolog
involv
studi
aim
investig
hlab
suballel
high
resolut
identifi
frequent
observ
allel
patient
evalu
associ
hlab
suballel
diseas
pathogenesi
patient
appli
izmir
tepecik
educ
research
hospit
tissu
type
laboratori
purpos
suballel
type
hlab
posit
patient
perform
sequencespecif
primer
polymeras
chain
reaction
pcrssp
seventythre
healthi
hlab
posit
bone
marrow
donor
use
control
group
data
patient
healthi
individu
compar
result
evalu
pearson
chisquar
analysi
associ
hlab
allel
frequenc
patient
control
group
statist
signific
p
wherea
found
signific
hlab
p
associ
suballel
majorminor
organ
involv
reveal
two
suballel
significantli
differ
organ
involv
aim
studi
analyz
correl
cytogenet
profil
genotyp
caucasoid
patient
mm
northwest
region
russia
genotyp
perform
pcrssp
studi
cytogenet
abnorm
perform
standard
gtgmethod
interphas
fish
analys
lsi
pvalu
less
consid
statist
signific
previou
studi
cytokin
polymorph
allow
us
describ
genotyp
neg
prognost
marker
associ
develop
mm
tt
tt
gg
gg
gr
cc
codon
gg
posit
prognost
marker
gr
patient
presenc
neg
posit
marker
togeth
gr
regist
also
studi
patient
normal
abnorm
cytogenet
profil
observ
frequenc
abnorm
cytogenet
transform
gr
notic
lower
compar
gr
vs
differ
frequenc
patient
posit
prognost
marker
normal
cytogenet
profil
compar
patient
neg
mix
genotyp
normal
cytogenet
profil
regist
p
gr
frequenc
cytogenet
abnorm
remark
higher
compar
patient
normal
profil
vs
patient
gr
frequenc
normal
cytogenet
profil
notic
higher
patient
aberr
vs
result
allow
describ
tt
tt
gg
gg
marker
associ
presenc
cytogenet
abnorm
cc
codon
gg
indic
normal
cytogenet
profil
patient
mm
although
patient
neg
posit
prognost
marker
seem
chanc
find
cytogenet
abnorm
much
higher
compar
patient
posit
prognost
marker
report
associ
genet
variant
receptor
psychiatr
disord
inconsist
populationbas
studi
thu
far
bipolar
disord
bd
genotyp
polymorph
two
independ
sampl
expos
differ
environment
stimuli
french
south
indian
tamil
bd
patient
quantit
circul
plasma
level
latter
subsampl
popul
allel
genotyp
frequenc
differ
significantli
case
control
either
polymorph
upon
stratifi
base
age
onset
found
associ
variant
howev
c
allel
ci
cc
genotyp
ci
associ
earli
onset
diseas
french
sampl
compar
lateonset
bd
similar
trend
observ
indian
popul
also
found
plasma
level
significantli
higher
bd
also
patient
residu
phase
remiss
compar
control
respect
find
favor
possibl
transethn
implic
genet
divers
bd
reinforc
notion
import
marker
oper
inflammatori
process
diseas
link
human
parvoviru
infect
develop
chronic
diseas
includ
inflamm
autoimmun
diseas
cancer
investig
nonstructur
protein
consid
doubleedg
sword
pathogenesi
investig
possibl
role
modul
inflammatori
respons
trigger
develop
cancer
cell
line
use
common
epitheli
cell
biolog
research
plasmid
contain
fulli
sequenc
gene
name
transfect
cell
use
lipofectamin
evalu
transfect
effici
express
green
fluoresc
protein
gfp
evalu
fluoresc
microscopi
hour
posttransfect
mock
transfect
cell
use
control
group
percentag
apoptot
cell
measur
flow
cytometri
furthermor
cellular
supernat
collect
hour
posttransfect
determin
type
quantiti
cytokin
produc
treat
untreat
cell
use
flow
cytometri
commerci
avail
legendplex
human
thelper
cytokin
panel
use
percentag
apoptosi
signific
chang
treat
cell
mock
hour
posttransfect
concentr
releas
cytokin
interleukin
il
ifngamma
tnfalpha
increas
hour
posttransfect
overal
result
suggest
proinflammatori
cytokin
level
increas
follow
express
involv
upregul
inflammatori
reaction
therefor
function
may
play
role
progress
chronic
inflammatori
diseas
well
cancer
schizophrenia
multifactori
chronic
diseas
character
heterogen
psychiatr
manifest
aetiolog
still
clear
although
sever
recent
studi
agre
relat
schizophrenia
lowgrad
chronic
inflammatori
diseas
determin
infect
nonpsychiatr
autoimmun
disord
system
lupu
erythematosu
psoriasi
celiac
diseas
moreov
use
specif
antipsychot
drug
reduc
inflamm
patient
affect
autoimmun
diseas
undergo
biolog
treatment
show
decreas
psychiatr
symptom
sever
gwa
found
genet
variant
nearbi
insid
mhc
region
confirm
pivot
implic
hla
key
regul
immun
respons
hla
allel
associ
better
respons
advers
drug
reaction
gene
like
link
schizophrenia
studi
still
progress
aim
evalu
autoimmun
diseas
andor
adr
relat
hla
allel
schizophren
patient
alleleshaplotyp
particular
frequenc
date
patient
differ
schizophren
profil
type
hlaa
b
c
loci
use
lowmedium
resolut
ssoluminex
technolog
result
obtain
highlight
presenc
least
one
autoimmun
diseas
relat
allel
patient
also
adr
relat
allel
observ
one
autoimmun
haplotyp
found
anoth
allel
frequenc
regist
possibl
obtain
specif
data
eventu
autoimmun
comorbid
extend
research
autoantibodi
specif
diseas
marker
attent
individu
drug
reaction
might
complet
result
despit
low
number
patient
type
data
interest
confirm
larger
individu
sampl
hla
type
schizophren
patient
near
futur
could
becom
valid
clinic
tool
accur
person
therapeut
rout
genet
variabl
gene
may
modul
suscept
rheumatoid
arthriti
respons
treatment
itnf
respons
treatment
itnfalpha
effect
week
compar
week
especi
femal
patient
women
carri
allel
respond
better
treatment
week
observ
compar
cc
genotyp
respons
itnfalpha
effect
patient
low
stage
diseas
rheumatoid
factor
rf
posit
doubl
posit
citrulin
ccp
protein
rf
rfposit
patient
especi
women
character
higher
degre
diseas
compar
rfneg
case
men
higher
activ
diseas
itnfalpha
treatment
therefor
remiss
diseas
common
women
polymorph
import
role
ra
may
potenti
influenc
risk
diseas
itnfalpha
therapi
effect
patient
outcom
francisco
perea
abel
merced
angel
concha
amanda
teresa
cabrera
federico
garrido
francisco
ruizcabello
natalia
aptsiauri
hospit
universitario
virgen
de
la
niev
granada
spain
universidad
de
granada
granada
spain
complejo
hospitalario
universitario
la
spain
de
biosanitaria
alejandro
otero
granada
spain
universidad
de
granada
granada
spain
correspond
naptsiauri
ugr
analyz
sampl
nonsmal
cell
lung
cancer
nsclc
simultan
express
hla
class
hlai
molecul
object
demonstr
impact
two
independ
mechan
cancer
immun
escap
loss
tumor
hlai
upregul
although
direct
associ
tumor
stagegrad
hlai
express
analyz
separ
obtain
statist
signific
result
combin
hlai
express
classifi
tumor
four
group
hlai
express
appear
import
factor
associ
bigger
tumor
size
hlai
neg
tumor
major
tumor
advanc
stage
comparison
thu
tumor
aggress
immun
escap
phenotyp
interestingli
hlai
posit
tumor
lack
express
immun
reject
phenotyp
show
less
advanc
stage
compar
tumor
notabl
also
found
associ
express
hlai
lymphat
spread
n
high
proport
tumor
involv
one
lymph
node
compar
detect
among
hlai
addit
tumor
lowest
grade
infiltr
nonpermiss
structur
tumor
encapsul
stroma
interestingli
patient
tendenc
better
surviv
patient
tumor
posit
marker
conclus
demonstr
lack
hlai
posit
express
repres
aggress
tumor
phenotyp
character
greater
tumor
size
advanc
stage
lymph
node
involv
reduc
tumor
immun
infiltr
nonpermiss
tumor
tissu
organ
mani
studi
show
genet
compon
psoriasi
patient
firstdegre
rel
psoriasi
fivefold
increas
risk
develop
diseas
mani
children
psoriasi
firstdegre
rel
diseas
particular
associ
hlac
basi
studi
conduct
research
aim
identifi
hla
allel
involv
region
purpos
focus
attent
patient
plaqu
psoriasi
studi
conduct
total
number
patient
divid
follow
common
allel
control
patient
c
c
allel
observ
associ
c
allel
psoriasi
patient
f
affect
plaqu
psoriasi
subject
hlac
type
present
c
c
c
allel
type
patient
plaqu
psoriasi
f
present
c
c
peopl
psoriasi
f
type
posit
result
c
c
although
associ
psoriasi
c
allel
wide
report
previou
studi
associ
c
allel
also
appear
import
studi
therefor
seem
appropri
restrict
immunogenet
studi
c
allel
alon
extend
whole
c
locu
analyz
sequenti
nucleotid
hlac
allel
associ
psoriasi
show
c
c
allel
share
nucleotid
sequenc
particular
posit
presenc
alanin
place
threonin
found
alloantigen
hypothes
alanin
may
play
import
role
associ
hla
psoriasi
locat
helix
domain
bind
site
peptid
involv
present
antigen
lymphocyt
order
lymphocyt
activ
product
histolog
cytokin
psoriasi
take
place
promot
must
present
lymphocyt
associ
hla
antigen
could
explain
need
associ
skin
diseas
particular
hla
antigen
bladder
cancer
bca
one
common
cancer
term
incid
bladder
cancer
second
prostat
cancer
among
urinari
tract
cancer
incid
continu
rise
bca
common
men
elderli
age
patient
pathogenesi
bladder
cancer
inflammatori
process
mediat
cytokin
play
import
role
recent
attent
also
drawn
import
subpopul
helper
cell
either
tumor
growth
progress
respons
bcg
therapi
given
crucial
role
impair
cytokin
express
predisposit
bladder
cancer
present
studi
analyz
polymorph
gene
impact
pathogenesi
bladder
cancer
singl
nucleotid
polymorph
snp
g
c
gene
genotyp
patient
malefemal
bladder
carcinoma
bca
healthi
subject
malefemal
genotyp
perform
use
allel
discrimin
method
taqman
snp
genotyp
assay
differ
frequenc
allel
genotyp
individu
without
bca
evalu
polymorph
p
howev
found
trend
lower
frequenc
aa
homozyg
compar
individu
carri
g
allel
ga
gg
genotyp
bladder
cancer
patient
control
ci
moreov
observ
patient
ct
genotyp
less
prone
bladder
cancer
patient
tt
genotyp
differ
genotyp
frequenc
reach
statist
signific
ci
stratifi
gender
note
aa
genotyp
less
frequent
femal
bca
patient
compar
healthi
woman
differ
reach
statist
signific
ci
snp
male
subject
ct
genotyp
often
repres
control
group
comparison
men
bca
ci
result
strictli
confirm
associ
investig
polymorph
suscept
bca
indic
studi
extend
larger
group
patient
worldwid
studi
demonstr
major
genet
suscept
factor
type
diabet
organ
specif
autoimmun
diseas
howev
haplotyp
predispos
equal
hlag
nonclass
class
molecul
involv
induct
mainten
toler
therefor
implic
pathogenesi
autoimmun
diseas
transplant
hlag
bp
insertiondelet
polymorph
associ
mrna
posttranscript
regul
induct
hlag
express
dendrit
cell
diabet
mediat
inhibit
autolog
cell
activ
indic
role
diabet
pathogenesi
condit
analysi
affect
famili
reveal
novel
associ
around
hlag
locu
present
studi
evalu
hlag
bp
indel
polymorph
among
case
north
india
ethnic
match
healthi
control
hc
bp
allel
frequent
cohort
vs
hc
genotyp
analysi
reveal
higher
percentag
case
insin
homozyg
segreg
studi
cohort
basi
presenc
absenc
suscept
allel
reveal
interest
result
among
group
low
shlag
secretari
genotyp
bp
frequent
patient
wherea
high
secretari
genotyp
bp
frequent
hc
among
cohort
low
secretari
genotyp
frequent
case
vs
find
suggest
presenc
high
shlag
secretari
genotyp
probabl
inhibit
autoreact
cell
control
ii
cohort
inhibit
probabl
possibl
due
presenc
low
secretari
bp
genotyp
preliminari
find
suggest
hlag
polymorph
may
influenc
diabet
pathogenesi
present
estim
shlag
level
cohort
correl
find
may
reveal
clinic
relev
inform
proinflammatori
cytokin
belong
cytokin
famili
cytokin
necessari
differenti
lymphocyt
subtyp
lymphocyt
involv
chronic
inflammatori
diseas
one
key
element
inflammatori
process
mediat
thelper
cell
also
play
import
role
pathogenesi
cancer
produc
predominantli
activ
dc
macrophag
believ
sever
singlenucleotid
polymorph
snp
signific
effect
suscept
mani
tumor
sinc
chronic
inflamm
contribut
pathogenesi
bladder
cancer
bca
polymorph
gene
may
associ
suscept
diseas
assess
whether
polymorph
receptor
gene
associ
risk
bladder
cancer
follow
snp
gene
cc
test
allel
discrimin
method
use
genotyp
snp
taqman
assay
bladder
cancer
patient
healthi
subject
geograph
region
poland
found
patient
genotyp
cc
cc
less
suscept
bca
possess
allel
ac
aa
genotyp
ci
p
notic
frequenc
allel
higher
bca
patient
healthi
control
differ
reach
statist
signific
investig
group
bca
patient
control
vs
distribut
allel
genotyp
snp
similar
bca
patient
control
haplotyp
analysi
show
haplotyp
haplotyp
ag
frequent
repres
patient
bca
increas
risk
bca
ci
result
indic
polymorph
gene
may
consid
potenti
lowrisk
factor
bladder
cancer
result
must
confirm
studi
b
lymphocyt
attenu
btla
one
member
immunoglobulin
superfamili
like
neg
regul
immun
respons
high
express
btla
ligand
herp
viru
entri
mediat
hvem
observ
hematolog
cancer
cell
although
btla
play
import
role
maintain
immun
homeostasi
publish
data
relationship
polymorph
gene
encod
btla
suscept
multipl
myeloma
mm
aim
studi
evalu
associ
three
polymorph
btla
gene
select
base
result
previou
work
bcell
chronic
lymphocyt
leukemia
suscept
multipl
myeloma
polish
popul
follow
snp
btla
gene
locat
intron
near
gene
posit
intragen
region
investig
genotyp
done
use
allel
discrimin
method
taqman
snp
genotyp
assay
patient
mm
healthi
control
region
poland
distribut
allel
genotyp
btla
snp
similar
mm
patient
control
howev
note
patient
aa
genotyp
less
prone
mm
patient
carri
c
allel
cacc
genotyp
differ
reach
statist
signific
ci
moreov
haplotyp
estim
analysi
indic
haplotyp
agc
repres
frequent
mm
patient
significantli
increas
risk
mm
ci
result
present
studi
strictli
confirm
associ
investig
btla
gene
polymorph
suscept
multipl
myeloma
indic
haplotyp
agc
might
risk
factor
suscept
mm
main
object
studi
analyz
mechan
respons
loss
hla
class
hlai
express
lung
cancer
extract
dna
rna
genet
analysi
tumor
cell
isol
hlai
neg
tumor
laser
microdissect
found
loss
heterozygos
loh
chromosom
region
major
caus
loss
hlai
haplotyp
signific
number
case
analyz
addit
rtpcr
analysi
reveal
decreas
express
heavi
chain
hc
hla
antigen
process
machineri
apm
gene
studi
conclud
total
loss
hlai
express
lung
cancer
caus
two
mechan
affect
hla
gene
decreas
express
apm
gene
accord
studi
frequenc
loh
high
lung
cancer
may
even
underestim
fact
studi
tumor
classifi
hlai
neg
present
nt
know
frequenc
hlai
posit
tumor
might
also
high
consequ
also
analyz
incid
six
human
lung
cancer
cell
line
appar
normal
cell
surfac
express
hlai
molecul
genom
type
hlai
three
reveal
exist
homohemizygos
compat
loss
hla
haplotyp
anoth
cell
line
also
homozyg
hlab
c
loci
use
gch
array
analysi
cell
line
verifi
result
genom
type
thu
skme
cell
line
show
larg
loss
chromosom
cell
line
present
delet
short
arm
chromosom
affect
b
c
loci
conclus
studi
show
hlai
alter
high
incid
lung
cancer
may
undetect
tradit
method
analysi
use
includ
immunohistochemistri
flow
cytometri
sequenc
detect
larg
genet
delet
implic
complement
pathway
neurodevelopment
innat
immun
process
suggest
involv
neuropsychiatr
disord
increas
schizophrenia
sz
low
system
lupu
erythematosu
sle
notion
recent
demonstr
report
correl
copi
number
variat
cnv
structur
indel
hervk
retroviru
high
express
molecul
risk
sz
data
bipolar
disord
bd
compon
correspond
function
differ
isoform
encod
polymorph
loci
lead
function
import
cnv
structur
size
variat
indel
hervk
thu
analyz
genet
divers
bipolar
disord
bd
sz
sle
case
control
design
bd
sz
sle
healthi
subject
enrol
jipmr
india
includ
studi
qpcr
use
determin
cnv
distribut
compar
chi
squar
test
found
among
test
group
common
cnv
variant
two
copi
allel
ii
frequenc
one
copi
copi
allel
higher
bd
compar
hc
iii
frequenc
copi
copi
allel
higher
sle
compar
hc
respect
iv
frequenc
two
copi
allel
higher
hc
bd
sz
sle
frequenc
one
copi
allel
higher
control
compar
sle
preliminari
data
show
vari
profil
among
studi
group
especi
higher
copi
number
diseas
group
compar
hc
ongo
analysi
includ
divers
circul
level
fine
genet
dissect
cluster
along
descript
clinic
subset
may
provid
insight
biolog
psychiatr
autoimmun
condit
classic
autoimmun
hepat
aih
togeth
primari
biliari
cirrhosi
pbc
primari
scleros
cholang
psc
form
three
main
categori
autoimmun
liver
diseas
preval
aih
estim
rang
inhabit
despit
abund
inform
literatur
immunopathogenet
mechan
aih
report
attempt
unravel
role
hlag
molecul
develop
diseas
well
known
hlag
molecul
involv
modul
immun
respons
capabl
promot
strong
tolerogen
effect
prompt
us
retrospect
analyz
total
sardinian
patient
diagnos
type
aih
metabol
genet
caus
hepatopathi
exclud
patient
patient
control
type
high
resolut
next
gener
sequenc
allel
polymorph
rare
hlag
locu
immunogenet
characterist
aih
patient
compar
healthi
individu
sardinian
voluntari
bone
marrow
donor
registryno
differ
observ
hlag
allel
frequenc
patient
aih
type
healthi
control
instead
frequenc
haplotyp
much
higher
patient
compar
control
vs
ci
higher
frequenc
haplotyp
correspond
increas
express
hlag
molecul
patient
affect
therefor
possibl
hypothes
hlag
molecul
express
patient
well
tolerogen
function
capabl
exert
function
endoplasm
reticulum
aminopeptidas
trim
hla
class
bind
precursor
optim
length
antigen
peptid
load
onto
hla
class
molecul
transport
cell
surfac
present
cell
nk
cell
hlac
molecul
express
placent
trophoblast
may
interact
killer
immunoglobulinlik
receptor
kir
decidu
nk
cell
surfac
therefor
investig
whether
polymorph
kir
hlac
gene
predispos
recurr
spontan
abort
test
women
least
two
miscarriag
fertil
control
women
use
taqman
snp
genotyp
assay
type
hlac
kir
gene
determin
pcrssp
statist
signific
differ
genotyp
allel
frequenc
control
group
patient
estim
use
twosid
fisher
exact
test
chisquar
test
homozyg
women
genotyp
preval
recurr
miscarriag
group
p
patient
carri
posit
hlac
also
patient
carri
kir
bx
higher
frequenc
miscarriag
group
fertil
women
howev
signific
p
p
respect
found
also
associ
genotyp
patient
posit
hlac
group
p
recurr
miscarriag
moreov
observ
higher
frequenc
combin
kir
bx
genotyp
patient
miscarriag
p
kir
bx
genotyp
decreas
patient
group
comparison
fertil
women
p
conclus
snp
context
hlac
kir
bx
genotyp
could
associ
suscept
recurr
miscarriag
iga
defici
common
primari
immunodefici
human
estim
preval
posit
neg
associ
hla
allel
iga
defici
previous
report
suggest
involv
genet
factor
develop
diseas
aim
studi
evalu
hla
allel
distribut
cohort
iga
defici
patient
cantabria
northern
spain
studi
preval
commonli
associ
diseas
hlaa
b
c
allel
studi
patient
male
femal
iga
defici
healthi
control
chi
squar
fisher
exact
test
use
statist
analysi
iga
defici
patient
signific
posit
associ
hlaa
b
b
c
allel
found
contrast
hlaa
b
b
c
c
c
drb
drb
allel
signific
frequent
control
group
among
patient
iga
defici
asymptomat
recurr
infect
celiac
diseas
autoimmun
disord
hypothyroid
rheumatoid
arthriti
vitiligo
scleroderma
crohn
diseas
idiopath
thrombocytopen
purpura
insulindepend
diabet
mellitu
document
case
final
allerg
manifest
includ
rhiniti
asthma
atop
dermat
found
patient
result
regard
iga
deficiencyhla
associ
coincid
previou
studi
perform
spanish
popul
first
time
weak
protect
role
b
c
c
c
allel
found
hand
clinic
profil
iga
defici
popul
differ
previous
report
spanish
popul
coeliac
diseas
specif
hla
haplotyp
abil
effici
present
gliadin
peptid
reactiv
cell
gut
approxim
celiac
patient
express
ci
tran
remaind
patient
carri
studi
femal
male
unrel
celiac
patient
diagnos
singl
center
northern
greec
fulfil
espghan
diagnost
criteria
subject
analysi
order
analyz
hladq
distribut
determin
diseas
risk
confer
differ
hladq
type
control
group
consist
healthi
unrel
individu
diseas
risk
express
n
n
number
subject
among
present
one
patient
consid
diseas
preval
gener
popul
n
calcul
percentag
control
particular
haplotyp
multipli
divid
percentag
patient
hladq
type
ci
tran
andor
detect
patient
control
patient
carri
neither
homozyg
base
hladq
genotyp
obtain
gradient
diseas
risk
rang
highest
risk
subject
carri
follow
tran
presenc
without
led
diseas
likelihood
presenc
beta
chain
usual
present
haplotyp
without
suscept
allel
result
diseas
risk
second
predispos
genotyp
present
effect
also
evid
absenc
occurr
allel
subject
rais
risk
suggest
asymptomat
rel
patient
carri
monitor
often
highest
diseas
risk
haplotyp
earli
diagnosi
behcet
diseas
autoimmun
vascul
disord
character
triad
recurr
oral
ulcer
genit
ulcer
ocular
involv
might
lead
blind
patient
suffer
diseas
preval
behcet
diseas
report
histor
distribut
among
geograph
area
along
ancient
silk
road
long
known
strong
associ
incid
behcet
diseas
class
hlab
allel
mainli
hlab
clarifi
diseas
associ
hla
behcet
diseas
particip
ihiw
hla
ng
compon
diseas
associ
behcet
diseas
egyptian
patient
healthi
egyptian
subject
control
group
hla
type
low
resolut
use
innolipa
fujirebio
sso
strip
assay
two
loci
hlaa
hlab
allel
level
resolut
loci
hlaa
b
c
use
ngsgo
workflow
gendx
illumina
miseq
platform
pairedend
sequenc
bp
hla
type
ngsengin
softwar
gendx
type
data
collect
ihiw
studi
result
present
studi
show
behcet
diseas
highli
associ
hla
class
allel
hlab
hlab
p
p
allel
highest
signific
compar
patient
genotyp
clinic
manifest
hlab
associ
sever
eye
diseas
p
blind
p
highli
recommend
patient
origin
link
histor
silk
road
perform
hlab
genotyp
risk
assess
blind
eye
diseas
attempt
guid
treatment
option
salvag
patient
eyesight
contribut
immun
system
pathogenesi
multipl
myeloma
mm
receiv
grow
attent
import
role
coinhibitori
receptor
process
consid
one
receptor
induc
costimulatori
molecul
ico
member
express
activ
cell
extend
previou
work
undertaken
evalu
associ
ico
gene
polymorph
suscept
mm
polish
popul
new
ico
gene
polymorph
c
genotyp
carri
use
allel
discrimin
method
taqman
snp
genotyp
assay
individu
includ
mm
patient
moreov
perform
haplotyp
estim
analysi
concern
previous
describ
polymorph
c
c
c
newli
investig
c
note
frequenc
c
g
allel
higher
mm
patient
healthi
control
differ
reach
statist
signific
grow
evid
endotheli
function
could
involv
pathogenesi
multipl
sclerosi
previou
report
shown
role
autoimmun
disord
like
rheumatoid
arthriti
induc
doubl
risk
multipl
sclerosi
furthermor
relapsingremit
multipl
sclerosi
sever
marker
inflamm
associ
sever
diseas
reason
investig
endotheli
damag
multipl
sclerosi
patient
measur
carotid
intimamedia
thick
correl
level
inflamm
biomark
patient
relapsingremit
multipl
sclerosi
age
median
edss
accord
mcdonald
criteria
without
known
vascular
risk
factor
recruit
carotid
intimamedia
thick
measur
patient
ultrasound
scan
dna
obtain
peripher
blood
use
semiautom
method
hla
antigen
identifi
polymeras
chain
reaction
sequencespecif
oligonucleotid
luminex
analysi
sever
biomark
inflamm
also
analyz
milliplex
system
luminex
platform
chi
method
student
test
use
statist
analysi
patient
antigen
carotid
intimamedia
thick
thicker
mean
mm
lack
antigen
mean
mm
correl
allel
sever
biomark
inflamm
reactiv
c
protein
erythrocyt
sediment
rate
fibrinogen
von
willebrand
factor
first
time
show
associ
endotheli
damag
measur
use
carotid
intimamedia
thick
patient
relapsingremit
multipl
sclerosi
hypothes
endotheli
damag
could
correl
inflamm
diseas
activ
larger
studi
requir
confirm
associ
katsushi
tokunaga
xiaoyuan
jia
tomoko
horinouchi
yuki
hitomi
akemi
shomo
seiksoon
khor
yosuk
oma
kanam
kojima
yosuk
kawai
masao
nagasaki
kandai
nozu
kazumoto
iijima
univers
tokyo
graduat
school
medicin
tokyo
japan
kobe
univers
graduat
school
medicin
kobe
japan
tohoku
medic
megabank
organ
sendai
japan
correspond
tokunaga
mutokyoacjp
nephrot
syndrom
common
caus
chronic
glomerular
diseas
children
genomewid
associ
studi
gwa
conduct
japanes
popul
total
patient
childhood
steroidsensit
nephrot
syndrom
ssn
adult
healthi
control
genotyp
use
affymetrix
japonica
array
discoveri
stage
imput
hlaa
c
b
genotyp
conduct
base
japanesespecif
refer
genotyp
perform
use
sequencespecif
oligonucleotid
probe
method
luminex
platform
wholegenom
snp
imput
conduct
use
phase
refer
panel
healthi
japanes
individu
replic
perform
independ
japanes
sampl
set
includ
case
healthi
control
candid
singl
nucleotid
polymorph
genotyp
use
assay
replic
stage
significantli
associ
snp
detect
hladrdq
region
success
replic
combin
p
hla
type
imput
identifi
strongli
associ
allel
diseas
moreov
identifi
signific
suscept
genet
factor
show
signific
stronger
associ
singl
allel
hirszfeld
institut
immunolog
experiment
therapi
polish
academi
scienc
poland
wroclaw
medic
univers
poland
hirszfeld
institut
immunolog
experiment
therapi
polish
academi
scienc
wroclaw
poland
correspond
bogunia
iitdpanwrocpl
rheumatoid
arthriti
ra
autoimmun
diseas
character
inflamm
joint
synovi
tissu
result
progress
cartilag
bone
tissu
damag
ultim
lead
disabl
previou
studi
show
tnfa
genet
variant
may
affect
ra
suscept
treatment
outcom
present
studi
aim
assess
relationship
serum
level
proinflammatori
cytokin
genet
variabl
progress
diseas
serum
level
select
cytokin
examin
use
monoplex
procartaplex
multiplex
srankl
tnfalpha
immunoassay
invitrogen
inc
luminex
system
measur
perform
ra
patient
three
time
point
three
six
month
antitnf
treatment
control
genotyp
perform
employ
either
taqman
lightsnip
assay
compar
control
patient
therapi
present
significantli
higher
serum
level
p
tnfalpha
p
presenc
cc
homozyg
genotyp
associ
highest
concentr
treatment
homozygos
also
frequent
detect
patient
activ
diseas
genotyp
found
significantli
associ
serum
level
cytokin
ra
patient
possess
c
allel
character
lower
crp
level
three
month
antitnf
therapi
tnfa
polymorph
studi
signific
relationship
identifi
tnfa
cc
homozygos
presenc
rheumatoid
factor
result
show
patient
control
differ
respect
tnfalfa
level
tnfa
cc
homozygos
seem
play
rather
unfavor
role
ra
recurr
implant
failur
rif
affect
approxim
women
undergon
sever
vitro
fertil
embryo
transfer
ivfet
kir
hlac
interact
nk
cell
trophoblast
propos
influenc
ivfet
outcom
aim
studi
evalu
associ
gene
encod
kir
ligand
hlac
suscept
rif
total
coupl
polish
popul
recruit
studi
among
coupl
suffer
recurr
implant
failur
ivfet
fertil
coupl
natur
concept
use
pcrssp
detect
kir
hlac
gene
statist
analysi
perform
use
twotail
fisher
exact
test
found
higher
frequenc
gene
femal
patient
rif
comparison
fertil
women
result
signific
p
p
respect
surprisingli
significantli
frequent
male
partner
rif
group
comparison
partner
control
group
p
p
p
p
respect
differ
frequenc
hlac
allel
genotyp
rif
patient
fertil
women
also
partner
observ
associ
combin
femal
kir
partner
hlac
genotyp
rif
conclus
polymorph
kir
gene
male
partner
could
associ
recurr
implant
failur
femal
celiac
diseas
one
preval
genet
determin
autoimmun
diseas
furthermor
one
diseas
strongest
associ
particular
hla
haplotyp
specif
demonstr
presenc
haplotyp
confer
risk
develop
diseas
ingest
gluten
would
lead
broad
rang
clinic
sign
symptom
histolog
alter
small
bowel
usual
diagnosi
celiac
diseas
includ
determin
iga
igg
antibodi
antitissu
transglutaminas
type
antiendomysi
antideamid
form
gliadin
peptid
case
definit
diagnosi
requir
jejun
biopsi
show
typic
histolog
abnorm
regard
risk
hla
haplotyp
sever
discrep
among
popul
found
mainli
due
take
account
differ
hla
molecul
reason
genotyp
celiac
diseas
patient
children
year
old
adult
fulfil
espghan
criteria
diseas
use
polymeras
chain
reaction
hybrid
sequenc
specif
oligoprob
luminex
platform
popul
analyz
children
adult
found
differ
frequenc
haplotyp
associ
increas
suscept
celiac
diseas
compar
previous
report
popul
risk
haplotyp
confer
diseas
mainli
distribut
either
homozyg
heterozyg
state
interestingli
half
genotyp
carri
tran
posit
differ
chang
substanti
analyz
separ
think
main
reason
differ
differ
preval
haplotyp
among
popul
b
lack
separ
analysi
hlag
gene
potenti
relat
decreas
hlag
express
level
associ
celiac
diseas
cd
hla
class
ii
gene
one
best
establish
document
diseas
associ
hla
system
aim
retrospect
studi
determin
whether
differ
hla
class
ii
allel
distribut
among
individu
higher
risk
develop
cd
famili
member
confirm
cd
patient
individu
unconfirm
diagnosi
refer
tissu
type
centr
hla
type
part
diagnost
procedur
healthi
control
histori
cd
famili
background
purpos
analyz
result
hladq
type
perform
use
pcrssp
high
resolut
method
olerup
gmbh
vienna
austria
carri
patient
cd
famili
member
cd
patient
subject
unconfirm
cd
healthi
control
hc
result
show
genotyp
ci
singl
doubl
dose
statist
frequent
among
group
compar
hc
p
also
frequent
among
patient
cd
famili
member
p
singl
doubl
dose
unconfirm
patient
respect
tran
configur
genotyp
also
show
significantli
higher
incid
among
patient
compar
hc
also
unconfirm
patient
famili
member
respect
differ
seen
unconfirm
patient
famili
member
compar
control
genotyp
show
specif
pattern
statist
signific
observ
group
singl
doubl
dose
result
show
highest
risk
cd
indic
presenc
heterodim
singl
doubl
dose
combin
cd
patient
underlin
import
type
assess
suscept
cd
manuela
testi
giulia
greco
maria
troiano
emanuel
rastelli
eugenio
pompeo
giovanni
antonini
marco
andreani
roberto
massa
san
camilloforlanini
hospit
rome
itali
neuromuscular
unit
rome
itali
laboratori
immunogenet
transplant
biolog
ime
foundat
polyclin
tor
vergata
rome
itali
thorac
surgeri
unit
rome
itali
depart
nesmo
rome
itali
correspond
mandreani
fondazioneimeit
assess
rel
preval
myasthenia
gravi
mg
subtyp
differenti
clinic
featur
associ
hla
class
ii
allel
within
larg
seri
unselect
italian
patient
consecut
patient
age
onset
presenceabs
serum
antiacetylcholin
receptor
achr
antimusclespecif
kinas
musk
antibodi
ab
presenc
thymoma
consid
stratif
mg
subgroup
moreov
perform
lr
l
hr
type
order
extend
preliminari
find
suggest
associ
particular
allel
mg
subtyp
mean
age
onset
lower
femal
thymomat
tmg
patient
comorbid
autoimmun
disord
frequent
thyroid
common
tmg
patient
often
associ
higher
mgfa
grade
show
significantli
higher
antiachr
ab
titer
nonthymomat
ntmg
patient
among
latter
late
onset
lontmg
show
significantli
higher
ab
titer
less
often
reach
high
myasthenia
gravi
foundat
america
mgfa
grade
earlyonset
eontmg
patient
signific
associ
found
hla
tmg
patient
allel
lontmg
therefor
lontmg
frequent
diseas
subtyp
increas
incid
itali
associ
high
antiachr
ab
titer
high
mgfa
grade
infer
prognost
valu
ab
serum
concentr
tmg
patient
tend
reach
higher
clinic
sever
well
higher
antibodi
titer
compar
ntmg
one
find
also
suggest
two
distinct
cutoff
year
onset
may
better
defin
mg
age
subgroup
differ
clinic
serolog
characterist
moreov
result
show
lontmg
tmg
differ
hladq
associ
ad
exist
evid
suggest
two
form
like
differ
pathogen
mechan
dentistri
palacki
univers
univers
hospit
olomouc
czech
republ
correspond
martinpetrek
fnolcz
sarcoidosi
multisystem
inflammatori
diseas
unknown
aetiolog
mostli
affect
lung
role
environment
genet
factor
polygen
natur
suggest
diseas
etiopathogenesi
studi
select
snp
locat
differ
gene
major
role
immun
system
inflamm
investig
associ
pulmonari
sarcoidosi
greek
popul
select
snp
investig
greek
sarcoidosi
patient
mean
age
year
standard
deviat
age
rang
male
femal
ratio
compar
healthi
control
subject
westslavon
czech
slovak
polish
origin
snp
genotyp
use
multiplex
massarray
iplex
assay
base
malditof
mass
spectrometri
agena
bioscienc
ca
usa
snp
test
hwe
use
pearson
chisquar
test
fisher
exact
test
applic
genet
associ
odd
ratio
confid
interv
ci
estim
use
allel
model
fisher
exact
test
analysi
reveal
associ
function
ci
pvalu
intron
variant
sarcoidosi
greek
patient
primari
level
preliminari
find
extend
previou
studi
perform
european
greek
popul
analysi
investig
gene
variant
extend
patient
cohort
importantli
inclus
greek
healthi
control
subject
result
verif
progress
laboratori
kalliroi
tsalimalma
kalliopi
adam
athanasio
konto
dimitri
malteza
nikolitsa
kafassi
gener
hospit
athen
laiko
athen
greec
nation
univers
athen
athen
greec
correspond
livecom
ratio
normal
emerg
strong
predictor
immun
reconstitut
virolog
suppress
patient
howev
hivinfect
individu
fail
normal
despit
recoveri
antiretrovir
treatment
art
although
characterist
phenotyp
extens
studi
still
elucid
hla
class
consist
link
outcom
hiv
infect
knowledg
data
report
hla
class
ii
allel
immun
recoveri
art
initi
present
studi
select
hiv
infect
patient
art
sustain
undetect
viral
load
copi
per
ml
classifi
two
group
accord
time
art
initi
till
normal
equal
one
least
three
consecut
valu
one
group
individu
reach
normal
rapidli
first
month
art
group
individu
b
patient
show
later
ratio
normal
month
art
rest
retain
last
follow
year
art
patient
type
hladr
low
resolut
pcrssp
patient
group
signific
differ
observ
frequenc
allel
individu
present
lower
higher
allel
vs
vs
kaplanmei
analysi
show
higher
probabl
achiev
normal
individu
without
lower
allel
result
ascrib
prognost
charact
type
individu
persist
suboptim
long
term
therapi
patient
neg
posit
allel
may
proven
appropri
candid
extend
therapeut
intervent
sinc
hlab
type
anyway
perform
begin
hiv
could
addit
includ
certainli
data
larger
sampl
size
need
valid
result
celiac
diseas
cd
preval
immunemedi
enteropathi
involv
perman
intoler
dietari
gluten
genet
suscept
individu
although
gluten
environment
driver
cd
sever
featur
strong
hla
class
ii
gene
associ
autoantibodi
presenc
cell
also
correl
diseas
thu
cd
provid
excel
exampl
like
benefit
incorpor
genet
test
patient
manag
cd
patient
carri
allel
encod
hladq
remaind
carri
allel
encod
dqb
present
evalu
summari
hladq
genotyp
observ
patient
refer
celiac
diseas
test
referr
hla
laboratori
patient
dna
sampl
type
gene
pcrssp
sequenc
specif
primer
andor
sso
sequenc
specif
oligonucleotid
method
patient
carri
haplotyp
consid
heterodim
posit
haplotyp
consid
heterodim
posit
consid
heterodim
posit
remain
haplotyp
consid
other
sampl
test
found
posit
posit
posit
six
posit
case
amongst
other
base
studi
observ
major
patient
refer
cd
test
carri
permiss
gene
pair
heterozyg
proport
patient
also
carri
haplotyp
impli
signific
hla
type
techniqu
molecular
method
includ
locu
accur
hla
genotyp
benefit
cd
patient
manag
hla
associ
diseas
analyz
kirsten
kronenberg
stela
radojska
melani
stoermer
birgit
gathof
univers
cologn
cologn
germani
correspond
kirstenkronenberg
ukkoelnd
immun
recognit
import
function
human
major
histocompat
complex
mhc
one
polymorph
genet
system
human
mani
hla
gene
report
associ
complex
autoimmun
infecti
diseas
aim
studi
reevalu
hla
type
diseas
associ
univers
hospit
intern
scientif
literatur
differ
medic
societi
guidelin
analyz
diagnost
relev
diseas
associ
request
diseas
associ
laboratori
analyz
rheumat
diseas
common
hla
associ
disord
hlab
request
declin
time
coeliac
diseas
associ
immunolog
mediat
diseas
small
intestin
mucosa
relat
ingest
gluten
recent
hla
associ
drug
intoler
hlab
abacavir
becom
diagnost
relev
prevent
seriou
hypersensit
reaction
strongest
associ
hla
class
ii
caucasian
patient
narcolepsi
relat
futur
predict
earli
diagnosi
diabet
type
allel
might
discuss
diseas
report
hla
associ
literatur
one
determin
clinic
prevent
context
project
next
year
develop
new
type
technolog
innov
bioinformat
lead
better
understand
structur
mhc
region
role
diseas
associ
genom
wide
larg
scale
multicent
studi
necessari
look
behind
mechan
relev
hla
associ
diseas
potenti
biomark
bipolar
disord
schizophrenia
romain
sayou
manier
nora
hamdani
alix
romier
aparna
sundaresh
christina
mariaselvam
gadel
hebbach
jeanromain
richard
marion
leboy
ryad
tamouza
inserm
franc
inserm
foundationaphp
franc
inserm
foundat
franc
correspond
r
sayousorg
bipolar
disord
bd
schizophrenia
sz
stage
disord
progress
cognit
function
declin
among
etiopathogen
hypothesi
immunoinflammatori
dysfunct
reemerg
recent
set
innov
field
immunopsychiatri
potenti
biomark
cognit
declin
part
mhci
molecul
cell
surfac
circul
concentr
reflect
cellular
immun
activ
ii
mhci
pivot
role
neurodevelopmentplast
implic
cognit
age
process
howev
relationship
psychiatr
condit
remain
unclear
hypothes
serum
level
may
reflect
acut
episod
function
impair
bd
sz
analyz
level
cohort
bd
sz
acut
episod
inpati
assess
twice
admiss
discharg
compar
bd
sz
stabil
outpati
healthi
control
subject
clinic
assess
standard
interview
madr
ymr
panss
symptom
dimens
gaf
cgi
fast
global
function
data
analysi
compar
serum
group
anova
groupbygroup
ttest
admiss
vs
discharg
pair
ttest
final
explor
correl
clinic
score
signific
level
differ
appear
group
p
remain
stabl
discharg
vs
admiss
bipolar
disord
level
higher
acut
episod
mgl
compar
euthymia
mgl
p
control
mgl
p
schizophrenia
patient
higher
level
mgl
p
compar
control
correl
panss
disorgan
subscor
item
p
preliminari
data
suggest
serum
state
biomark
acut
phase
bipolar
disord
disorgan
sever
biomark
schizophrenia
analysi
investig
stage
function
perspect
transfus
red
blood
cell
rbc
product
one
relev
caus
immun
rbc
alloantigen
associ
presenc
monospecif
rbc
alloantibodi
particular
variant
report
sever
studi
moreov
other
shown
rbc
multirespond
statu
gener
associ
allel
group
appar
minor
individu
prone
develop
rbc
alloantibodi
high
percentag
patient
form
alloantibodi
despit
repeat
transfus
therapi
aim
studi
investig
possibl
associ
unrespons
rbc
antigen
hla
class
ii
variant
total
czech
patient
without
rbc
alloantibodi
administ
least
rbc
unit
refer
nonrespond
enrol
studi
nonrespond
rhd
posit
rhd
neg
statu
variant
determin
pcrsso
method
frequenc
compar
group
nonrespond
ethnic
region
match
control
comparison
allel
group
nonrespond
healthi
control
group
statist
signific
differ
frequenc
investig
hla
class
ii
variant
reveal
conclus
find
associ
hla
class
ii
unrespons
rbc
antigen
work
need
analyz
hla
class
ii
variant
larger
nonrespond
subgroup
accord
rbc
antigen
statu
may
interfer
suscept
alloimmun
particular
rbc
antigen
publish
andor
access
genbank
embl
sequenc
databas
embl
dna
databank
japan
ddbj
provid
import
tool
investig
field
biomed
evolut
conserv
research
sfhi
propos
member
ept
program
hla
antibodi
ab
identif
sa
techniqu
total
sera
distribut
april
test
may
octob
six
per
class
time
point
origin
ept
analyz
result
three
level
classic
qualit
level
consensu
posit
neg
specif
quantit
studi
mean
fluoresc
intens
mfi
bead
serum
clinic
interpret
made
ab
profil
particip
affili
french
biomed
agenc
organ
alloc
agenc
de
la
biomedicin
list
antigen
would
declar
forbidden
permiss
grey
zone
accord
cristal
french
databas
kidney
transplant
alloc
particip
record
result
via
dedic
web
platform
cqxplore
tm
easili
allow
copi
mfi
data
fusion
one
lambda
matchit
immucor
softwar
well
input
positiveneg
forbiddenpermissiblegrey
zone
specif
three
level
analysi
allow
perform
laboratori
provid
anonym
compar
practic
discuss
sfhi
antibodi
organ
transplant
work
group
consequ
distinctli
report
antiallel
antidqalpha
antibodi
cristal
dramat
consequ
transplant
access
francophon
laboratori
franc
two
reagent
kit
provid
enrol
data
analysi
perform
certif
return
within
day
data
collect
deadlin
detail
result
access
member
sfhi
websit
ept
extend
antihla
ab
screen
chimer
hla
type
schedul
ept
regist
efi
open
european
laboratori
cytokin
constitut
express
influenc
develop
function
nervou
system
particular
recogn
play
import
role
normal
develop
brain
regul
synapt
function
neuron
plastic
underli
learn
memori
imbalanc
cytokin
product
signal
andor
regul
therefor
wide
rang
neurolog
consequ
cytokin
product
genet
control
polymorph
identifi
gene
intellectu
disabl
id
alreadi
demonstr
autism
cytokin
dysregul
could
contribut
neuron
dysfunct
influenc
cognit
develop
investig
polymorph
sever
cytokin
serum
level
id
patient
control
studi
demonstr
ct
ct
polymorph
involv
id
show
posit
associ
cc
genotyp
tt
genotyp
neg
associ
genderrel
differ
analysi
diseas
onset
confirm
result
polymorph
specif
predispos
associ
cc
genotyp
establish
femal
protect
one
tt
genotyp
male
gender
impact
still
evid
consid
polymorph
fact
predispos
cccc
combin
frequent
femal
analyz
serum
level
increas
level
seen
patient
group
predict
cc
genotyp
p
interest
note
highest
serum
level
found
femal
sever
id
overal
result
could
help
identifi
factor
caus
abnorm
cn
function
child
id
develop
correct
intervent
treatment
extract
blood
sampl
six
buccal
swab
sampl
perform
four
differ
method
qiasymphoni
sampl
manual
qiagen
column
sampl
ezi
tissu
kit
six
swab
sampl
quatrobrob
sampl
dna
concentr
use
carri
hla
hd
type
kit
data
sheet
elabor
fusion
histomatch
softwar
accord
ipdimgthla
databas
version
found
concord
final
identif
hlaa
b
commonwel
document
allel
kit
number
ambigu
differ
one
kit
regard
analyt
perform
luminex
session
hlaa
b
c
supplement
type
perform
allow
us
delet
great
number
null
allel
eg
b
bag
session
hlaa
b
extend
sampl
type
shorter
time
complet
autom
preliminari
data
suggest
bag
histo
spot
extend
use
method
hd
resolut
small
medium
size
h
laboratori
hand
high
resolut
type
differ
approach
need
sbt
plu
ssor
ng
technolog
